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Abstract
DNA gyrase is an essential bacterial topoisomerase with a central role in many
cellular processes. Its lack of homology to eukaryotic topoisomerases has been
the basis of its role as an important drug target. The quinolone antibacterials
have previously been shown to "poison" DNA gyrase of Escherichia coli, resulting
in rapid bacterial cell death by a pathway which has been a subject of
controversy. Following on from the finding that the complex of quinolone and
gyrase on DNA results in truncated mRNAs in vitro, the results presented in
this thesis show that in vivo, the addition of quinolone drugs results in the
production of truncated mRNAswhich are presumably translated into truncated
proteins. This is expected to cause total deregulation of cellular processes and
result in cell death.
It has also been shown that the newer more potent quinolone drugs such as
ciprofloxacin and ofloxacin have an additional effect on the bacterial cells in
that the chromosome is broken down into fragments of DNA, some of which
are estimated to be as small as 4kb in length. This process appears similar to
the degradation of chromosomal DNA that occurs during apoptosis of some
eukaryotic cells.
The acquisition of quinolone-resistance in E. coli and Salmonella has also been
investigated. Firstly, part of gyrA of S.typhimurium NCTC5710 was sequenced
and found to be 94% homologous at the nucleotide level to the corresponding
sequence of E.coli. Following on from this, clinical isolates were screened by
DNA sequencing and amino acid mutations in the "quinolone resistance
determining region" (QRDR) of gyrA identified. Mutations in gyrA such as
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serine-83 to leucine, serine-83 to phenylalanine, aspartate-87 to tyrosine,
aspartate-87 to asparagine and aspartate-87 to glycinewere found to have arisen
in the QRDR of gyrA in common with other quinolone resistance mutations
previously found.
It has been shown that high levels of gyrA are toxic to E. coli, probably as a
result of loss of homeostatis of the supercoiling of the bacterial chromosome
when large levels of DNA gyrase are present. This result was firstly inferred
by the ability to clone gyrA into a low copy number plasmid but not into a high
copy number plasmid. Cloning ofgyrA into a vector in which the copy number
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In 1963, with the advent of electron microscopy, Cairns (1963) showed that the
Escherichia coli chromosome is circular. From this microscopic data, it was
inferred that a DNA "swivelling" mechanism had to be present in bacterial
cells to separate the two strands ofDNAprior to replication. Since then enzymes
with this kind of activity, called topoisomerases, have been identified and
extensively studied and found to be essential components of all known cells.
BacterialDNA topoisomerases allow DNA replication to proceed by unwinding
the DNA double helix and also these enzymes have implicit roles in DNA
recombination, decatenation, unknotting, transposition and transcription and
hence gene expression (Reece and Maxwell, 1991b). Current interest in DNA
topoisomerases stems from the fact that they play a critical role in DNA
maintenance and are the primary cellular targets for some of the most widely
prescribed antibiotics and anticancer drugs used in the treatment of human
diseases (Bodley and Liu, 1988).
On studying the integrative recombination of bacteriophage X in an E.coli
derived cell free system, Gellert et al (1976) demonstrated that a negatively
supercoiled DNA substrate was required for phage integration. It was also
found that this negatively supercoiled DNA could only be exchanged for a
relaxed DNA substrate if an E.coli cell fraction was added along with ATP
(adenosine triphosphate) to the cell free system (Gellert et al, 1976). The energy
dependent enzyme present in this cell fraction with a negative supercoiling
activity was named DNA gyrase, and it became the prototype of a new class of
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topoisomerase enzymes that possessed the unique ability to catalyse the
introduction of negative supercoil turns into closed circular double stranded
DNA. Although all knownDNAtopoisomerases in eukaryotes and prokaryotes
are able to relax negatively supercoiled DNA, only bacterial DNA gyrase can
introduce negative supercoils into DNA by an energy dependent process.
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1.2 DNA Structure, Supercoiling, and Topology
To appreciate fully the roles of topoisomerases, it is necessary to understand
their mechanism of action at a molecular level (for a review see Wang, 1982).
Topoisomerases change the linking number between two intertwined single-
stranded DNA rings, that is, the number of times the two strands of a DNA
duplex circle are interwound.
The mechanism by which the linking number of a DNA duplex is changed is
illustrated in Figure 1.1,with the double-stranded DNA represented as a circular
ribbon and the two anti-parallel strands shown by the two edges of the ribbon.
In the first diagram 1.1.1, the two strands are unlinked, therefore the linking
number (Lk) is zero. The action of topoisomerases is demonstrated in 1.1.2
with the introduction of a temporary double-stranded break in the duplex which
is then resealed after the passage of another double-stranded segment through
it. In this nick-resealing mode of action, the linking number changes from 0 to
+2. The linking number of a duplex is a topological invariant up until the point
that the rings are no longer intact. The name given to identical rings differing
only in their linking numbers is topoisomers and these structures can be
distinguished by gel electrophoresis. The linking number of a DNA duplex at
its most stable conformation is known as Lk0, however unlike Lk, Lk0 is not a
topological invariant as its value is only fixed if the conditions specifying the
most stable state are unchanged.
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Figure 1.1: The mechanism by which the linking number of a DNA duplex is





If the linking number deviates increasingly from Lk0, the duplex becomesmore
strained, accumulating deformations and distortions of the DNA to create a
topological form ofDNA known as supercoiled DNA. Supercoiled DNAwith
a linking number greater than Lk0 is known as positively supercoiled whereas
supercoiled DNAwith a linking number less than Lk0 is negatively supercoiled.
Some of the ways that negatively supercoiled DNA can become distorted and
an electron micrograph of relaxed and supercoiled DNA are shown in Figure
1.2 and Figure 1.3 respectively.
Figure 1.2: Some of the ways that negatively supercoiled DNA can become







Figure 1.3: Electron micrograph of relaxed and supercoiled DNA (Taken from
Wang, 1982). Relaxed DNA Supercoiled DNA
1.3 Type II DNA topoisomerases
Type II DNA topoisomerases characteristically change the DNA topology by
introducing a break in both DNA strands and changing the linking number of
DNA in steps of two, thus differing from the action of type I topoisomerases
which change the linking number in steps of one. Type II topoisomerases are
essential cellular proteins and temperature-sensitive mutations in their genes
have been shown to result in cell death at the restrictive temperature (Kato et al,
1990; Kato et al, 1988) whereas type I topoisomerases are dispensable and their
loss is compensated for bymutations in the genes for the type II topoisomerases
causing a decrease in supercoiling efficiency (DiNardo et al, 1982). All
topoisomerases are by definition able to change the topology of DNA, through
breakage and reunion of DNA strands, however each enzyme has a different
activity. The two type I topoisomerases present in E.coli, topoisomerase I and
topoisomerase III relax and decatenateDNA respectively in the absence ofATP
(Wang, 1971; DiGate and Marians, 1988) whereas the two type II topoisomerases
in E.coli, gyrase and topoisomerase IV preferentially supercoil and decatenate
the DNA respectively (Adams et al, 1992) in an energy dependent fashion.
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Type II topoisomerases are ATP-dependent, and function as dyadicmolecules.
In bacteria, two or more polypeptide chains form each half of the topoisomerase
whereas in eukaryotes, identical polypeptide chains, ranging from 160 to 180kDa
form the two halves of the enzyme. In E.coli, two distinct type II topoisomerases
exist: DNA gyrase and DNA topoisomerase IV. These two enzymes have clear
and defined functions in the cell: whilst gyrase removes positive supercoils
and introduces negative ones, it can also unlink knots and catenanes generated
by recombination. However, gyrase does not play a major role in unlinking
catenanes formed during replication, and this function is predominantly the
responsibility of topoisomerase IV (Adams et al, 1992). Considering that there
is noticeable structural homology between gyrase and topoisomerase IV (see
1.3.4), it is interesting that the two enzymes have clearly defined roles in the
cell with minimal functional overlap.
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1.3.1 Biochemistry of DNA gyrase
Biochemical investigations have shown that DNA gyrase is formed from two
different subunits called GyrA and GyrB (Klevan and Wang, 1980). Sugino et
al (1977) demonstrated that the ratio of these two subunits was equimolar by
mixing different amounts of the two gyrase subunits with DNA before
separating the DNA-protein complex from free protein by gel filtration. These
gyrase-DNA complexes were found to consist of two homodimers of theA and
B proteins of size 97kDa and 90kDa respectively (Swanberg and Wang, 1987;
Yamagishi et al, 1986). A brief summary of some of the properties ofGyrA and
GyrB of E.coli is given in Table 1.1.
Table 1.1: Properties of E.coli GyrA and GyrB
GyrA GyrB
Gene gyrA gyrB
Length of gene 2625bp 2412bp
Molecular weight 96887 89893
Amino acids 875 804
Function Breakage and ATPase activity
reunion of DNA
Drug interactions Quinolone drugs Coumarin drugs
The GyrA subunit has been shown to comprise of two discrete domains with
different functional and structural features. Treatment of the A subunit of
E.coli DNA gyrase with trypsin yields two stable fragments, one of 64kDa and
one of 33kDa (Reece and Maxwell, 1989; Reece and Maxwell, 1991a; Reece and
Maxwell, 1991c) as shown in Figure 1.4. These two domains have been cloned
and their products investigated biochemically. The supercoiling reaction ofDNA
gyrase requires both subunits, studies of partial reactions, protein structure
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and the effects of inhibitors have shown that specific functions can be assigned
to the two subunits as shown below.
Figure 1.4: Domain model showing the two subunits of E.coli DNA gyrase.
Amino acid positions are numbered and the various domains represented.
Adapted from Reece and Maxwell, 1991b.
GyrA





N -• ; 43kL
Interaction with ATP Interaction with GyrA
and coumarins and DNA
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GyrA
The 64kDa N-terminal fragment of GyrA was found to be necessary for DNA
supercoiling, covalent attachment to DNA (Horowitz and Wang, 1987) and
interfacingwithGyrB and was thus concluded to be theDNA breakage-reunion
domain of the A subunit (Reece and Maxwell, 1989). The quinolone drugs
which interfere withDNA strand passage act upon this region ofGyrA (Yoshida
et al, 1988; Cullen et al, 1989; Hallett and Maxwell, 1991). In in vivo assays, the
64kDa N-terminal fragment was found to be able to carry out DNA cleavage
and religation (Reece and Maxwell, 1989), however DNA supercoiling was
found to proceed more efficiently in the presence of the 33kDa fragment (Reece
andMaxwell, 1991c). Truncated versions of this polypeptide were constructed
by introducing stop codons into the DNA sequence of the cloned fragment
(Reece and Maxwell, 1991a). It was thus found that the first six amino acids of
the N-terminal fragment, amino acids 1 to 6, can be deleted with no apparent
deleterious effect on the breakage-reunion reaction with DNA (Reece and
Maxwell, 1991a). However the breakage-reunion reaction is completely
abolished by removing the first 69 amino acids of the GyrA subunit (Reece and
Maxwell, 1991a). Experiments have shown that the smallest GyrA section
capable of breakage and reunion is the region encoded by amino acids 7 to 523
(Reece and Maxwell, 1991a). All the catalytic activity ofGyrA is believed to be
contained in this 64kDa fragment.
Investigations into the 33kDa C-terminal fragment indicated no enzymatic
activity (Reece and Maxwell, 1991c). Instead this region ofGyrA has been shown
to possess a DNA-binding activity and is thus thought to stabilise the gyrase-
DNA complex (Reece and Maxwell, 1989). By generating a clone which
overproduced the 33kDa subunit, itwas found that this polypeptide could form
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a complex with the 64kDa protein and also the GyrB subunit (Reece and
Maxwell, 1991c). It was also shown that the 33kDa protein is involved in the
wrapping of DNA around gyrase and this stabilises the complex by acting as a
non-specific DNA-binding protein (Reece and Maxwell, 1991c).
GyrB
On purification of GyrB, a truncated version of the protein named topoIF was
commonly found and further investigations identified it as the C-terminal half
of the GyrB subunit (from amino acid 394 to the end) which probably resulted
from proteolytic cleavage during cell lysis (Brown et al, 1979; Gellert et al, 1979;
Adachi et al, 1987). This fragment was found to be able to relax and cleave
DNA in conjunctionwith GyrAbut could not negatively supercoilDNA (Brown
et al, 1979; Gellert et al, 1979) and further studies showed that the C-terminal
GyrB fragment interactedwithGyrA (Brown et al, 1979). The rest of the subunit
(amino acids 1 to 393) was studied by inserting premature stop codons into the
middle of the gene resulting in a protein that had ATPase activity as well as
containing a binding site for ATP (Jackson et al, 1991; Ali et al, 1993). These
results confirmed the findings of Adachi et al (1987) who showed that the N-
terminal domain of GyrB included the site of ATP hydrolysis and is the region
where coumarin drugs such as novobiocin and coumermycin Al interact (Ali
et al, 1993). In conclusion, it is the GyrB N-terminal fragment that confers the
ability of the enzyme to negatively supercoil DNA.
A summary of reactions carried out by GyrA and GyrB is displayed in Table
1.2.
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Table 1.2: Reactions of DNA gyrase
Subunits ATP Inhibited by Inhibited
required required quinolones coumarii
Supercoiling A+B Yes Yes Yes
Relaxation of:
a)Negative supercoils A+B No Yes No
b)Positive supercoils A+B Yes Yes -
Catenation A+B Yes Yes Yes
Decatenation A+B Yes Yes -
Unknotting A+B Yes Yes Yes
DNA cleavage A+B No No No
ATPase B Yes No Yes
1.3.2 Crystallographic investigations into DNA gyrase
TheN-terminal domain ofGyrB has been co-crystallisedwith 5'ADPNP, (a non-
hydrolysable analogue ofATP) and its structure determined at 2.5A (Wigley et
al, 1991). The crystal structure information showed two distinct domains, both
with novel protein folds. Dimerisation of the fragment was also found to occur
in the presence of 5'ADPNP. Whilst theN-terminal domains bind and hydrolyse
ATP, the C-terminal domains form the sides of a 20A hole through the dimer.
It is this hole that is believed to be important in DNA strand passage during
the supercoiling reaction. The diameter of the hole is the same as the diameter
of the DNA helix, suggesting that this hole is the gateway through which the
DNA passes in the supercoiling reaction. This hole running through the protein
was also shown to be lined by positively charged arginine residues which is
thought to form some kind of DNA-binding surface .
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1.3.3 Molecular mechanism of DNA gyrase
The critical residue in the active site of the E.coli DNA gyrase enzyme responsible
forDNA cleavage has been mapped to tyrosine-122 on theA subunit (Horowitz
and Wang, 1987). This residue is believed to become covalently bound to a 5'
group ofDNA through anCT-phosphotyrosme bond (Horowitz andWang, 1987)
when the enzyme cleaves the phosphodiester bonds of DNA. The 5' O4-
phosphotyrosine bond formed conserves the energy of the broken
phosphodiester bond, allowing the DNA to be ligated without an additional
energy source.
DNA topoisomerases catalyse the interconversion of topological isomers of
DNA, for example the integration of X DNA into the bacterial chromosome.
This process involves the breakage of at least four strands of duplex DNA and
rejoining the ends to different partners without altering the linking number.
An outline of the mechanism by which this occurs is displayed in Figure 1.5.
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Figure 1.5: Molecular mechanism of DNA gyrase (Taken from Orp'hanides and
Maxwell, 1994).
DNA gyrase transports one double strandedDNA segment through an enzyme-
mediated double-stranded break in another (Roca, 1995). This is accomplished
by creating a temporary "gate" in one DNA helix which opens to let the other
helix be transported through. The break in the DNA is then resealed. A
nucleophilic transesterification reaction occurs between a pair of tyrosyl residues
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(located on each half of the gyrase holoenzyme) and two DNA phosphodiester
bonds four base pairs apart. Mechanistically this occurs by the covalent linkage
of the phenolic oxygens of the tyrosines to the phosphoryl groups at the 5' ends
of the transiently broken DNA. This leaves a pair of hydroxyl groups on the
recessed 3' ends. The DNA strands then separate around this area and the pair
of tyrosine-linked 5' ends move away from each other, opening a "gate" after
the binding ofATP. This enzyme-mediated gate is then closed once the second
DNA segment has been transported. The covalent bonds between gyrase and
DNA are broken by a transesterification reaction occurring between the pair of
3' hydroxyl groups and the phosphotyrosyl linkages. This causes the religation
of the two cleaved DNA strands into a continuous segment. Hydrolysis of
ATP resets the enzyme. The hole generated is believed to be as large as 35 to
40A.
1.3.4 DNA topoisomerase IV
In E.coli, DNA topoisomerase IV is encoded by the parC and parE genes (Kato et
al, 1990). This enzyme is essential for the partitioning of newly replicated
chromosomes and plasmids (Adams et al, 1992) and this has been shown by the
use of temperature-sensitive mutants of topoisomerase IV which accumulate
double-stranded nucleoids at the restrictive temperature (Kato et al, 1988).
Knocking out topoisomerase IV from cells results in a phenotype where
catenated plasmids fail to separate (Adams et al, 1992). It has also been shown
to have a relaxation activity (Peng and Marians, 1993) although in vivo, its
decatenating activity is more important than its relaxation activity (Kato et al,
1992). ParC and ParE have been found to have a high degree of similarity to
GyrA and GyrB, respectively. ParC is 730 amino acids long and 36% identical
toGyrA, whereas ParE is 601 amino acids long and 40% identical to GyrB (Kato
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et al, 1990). Although topoisomerase IV has no supercoiling activity, it has ATP-
dependent DNA relaxation and decatenation activities (Kato et al, 1992).
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1.4 Cellular Action of DNA gyrase
1.4.1 Intracellular localisation of GyrA and GyrB
Immunogold labelling of GyrA and GyrB showed that these two proteins were
found mainly in the cytoplasm and only less than 10% of the total GyrA and
GyrB content was located in the nucleoid (Thornton et al, 1994). It is estimated
that at least 1000 to 3000 molecules of each GyrA and GyrB is present in each
cell. Simultaneous labelling with both anti-GyrA and anti-GyrB revealed that
there was no obvious association between GyrA and GyrB in the cell, instead
the subunits seemed to exist as monomers instead of forming the DNA gyrase
tetramer. This study concluded that only a small fraction ofGyrA and GyrB is
actually associated with the nucleoid and loops of peripheral DNA with the
majority remaining free in the cytoplasm (Thornton et al, 1994).
1.4.2 The importance of supercoiling in bacterial cells
Bacterial DNA is negatively supercoiled as demonstrated by psoralen binding
studies (Sinden et al, 1980). Psoralen binds to negatively supercoiled DNA so
if bacteria are treated with coumermycin Al, psoralen is shown to bind with a
lower affinity since there is a decreased superhelical tension in the cell.
Supercoilrng ofDNA in bacterial cells has an implicit role in determining cellular
functions. The maintenance of the correct level of supercoiling on specific
sites of the bacterial chromosome dictates the probability of processes such as
DNA replication, transcription and recombination of occurring. In E.coli the
optimum range of supercoiling for a certain section of the chromosome is
maintained by a balance ofDNA gyrase and topoisomerase I activities, as well
as by the effects of transcription (see 1.4.6).
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1.4.3 The role of gyrase in the maintenance of fixed supercoiling
levels in E.coli
The levels of supercoiling on the bacterial chromosome are strictly regulated
by the action of the topoisomerases. It has been shown that gyrase inhibitors,
particularly the coumarin family of drugs, result in a decrease in the
superhelicity ofboth the bacterial chromosome and plasmids (Drlica and Snyder,
1978; Kano et al, 1981; Manes et al, 1983). It is thought that maintaining the
balance of supercoiling levels in the cell is the role of topoisomerase I and gyrase
with neither topoisomerase III nor topoisomerase IV having a significant role.
Gyrase and topoisomerase I have different substrate affinities: where gyrase is
more active on relaxed templates (Sugino and Cozzarelli, 1980), topoisomerase
I has a greater specificity for highly negatively supercoiled DNA in vitro (Wang,
1971). However, once DNA supercoiling drops below "normal" levels,
topoisomerase I is not found to be a major source of DNA relaxation in vivo.
Perturbations of supercoiling are also believed to be corrected by the changes
of gene expression in the genes encoding gyrase and topoisomerase I (see 1.4.5).
While gyrase increases the superhelical tension ofDNAby decreasing theDNA
linking number, topoisomerase I does the opposite. Cells that have mutations
in topA, the gene encoding topoisomerase I, commonly have compensatory
mutations in gyrA and gyrB, resulting in a decreased superhelical tension so
the supercoiling does not increase to excessively high levels (Pruss et al, 1982).
While higher than optimum levels of negative supercoiling resulting from an
absence of topoisomerase I is deleterious to the cell, a reduction in gyrase activity
is not (DiNardo et al, 1982). Sequence analysis has shown that in an E.coli topA
mutant, the gyrA gene is modified in such a way that Ala-569 and Thr-586 are
interchanged (Oram and Fisher, 1992). The apparent importance of these
changes is that they flank Arg-571, the site of trypsin cleavage that divides the
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GyrA subunit into two domains (see Figure 1.4). This suggests there is selective
pressure to maintain the net supercoiling activity within a certain range.
1.4.4 The effect of supercoiling on transcription
Many promoters are sensitive to supercoiling and the expression of certain
bacterial operons is sensitive to inhibitors of gyrase, presumably because of a
change in superhelicity of the template (reviewed by Drlica, 1984). Cloned
random fragments of E.coli DNA (Menzel and Gellert, 1987a) and randomly
insertedMudlac fusions in S.typhimurium (Jovanovich and Lebowitz, 1987) have
been used to demonstrate that up to 70% of promoters respond in a significant
manner to gyrase inhibition by coumermycin Al. This emphasises the
relationship between DNA supercoiling and transcription. For example,
negatively supercoiled cpX174 DNA has been found to be a better template for
transcription in vitro than relaxed DNA (Hayashi and Hayashi, 1971). The
binding of E.coli RNA polymerase to DNA causes the double helix to unwind
(Saucier and Wang, 1972), as a result, negative supercoiling should promote
RNA polymerase binding. Therefore an increased rate of initiation as a result
of facilitated RNA polymerase bindingwould be expected to result in an increase
in the overall transcription rate and number of transcription complexes
(Richardson, 1974; Richardson, 1975). However the situation is more complex
given that some promoters are stimulated by relaxation of DNA whilst some
are unaffected by either supercoiling or relaxation.
On examining a range of promoters it can be concluded that different promoters
require different amounts ofDNA supercoiling to facilitate structural transitions
needed for the initiation of transcription. The variation of the optimum levels
of supercoiling for the expression of different genes was demonstrated in vitro
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by the use of abortive initiation assays (Borowiec and Gralla, 1987). Results
showed that the rate of open complex formation in three lac promoter variants
peaked at different superhelical densities where these variants had single base
pair changes in the spacer and -35 regions as well as in the -10 region where
DNA unwinding occurs. From this it was concluded that supercoiling induced
deformation of the entire lac promoter region may be needed for proper
recognition by RNA polymerase. An alternative explanation is that changes in
the sequence in one section of the promoter may determine the ease of a
transition such as melting in another part through the topological coupling of
changes in the conformation of the supercoiled DNA. Therefore in some cases,
the supercoiling optimum is a characteristic of the interaction between RNA
polymerase and the promoter. Experiments carried out studying the gene
expression of X under different superhelical tensions in vitro showed that an
increase in supercoiling results in an increased amount of RNA synthesis but a
decreased amount of early gene transcription (Botchan et al, 1973) by raising
the transcriptional abilities of promoters not used on linear DNA (Botchan,
1976). Therefore different genes show different responses to changes in
supercoiling and in this way, differential effects on gene expression can be
achieved. Supercoiling can increase the amount of transcription of a particular
gene both by increasing the rate of transcription from existing initiation sites
andmaking new transcription sites available, this effect being promoter specific.
1.4.5 Relaxation-stimulated transcription
In contrast to the view that negatively supercoiledDNA stimulates transcription,
some promoters have been found to be stimulated when in a relaxed
conformation. Relaxation-stimulated transcription (RST) has been found to
occur in the promoters of gyrA and gyrB (Menzel and Gellert, 1983). On the
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addition of coumermycin or novobiocin, the rate of synthesis of the gyrA and
gyrB gene products increase 10 to 20 fold (Menzel and Gellert, 1983). Also in
experiments with a temperature-sensitive gyrase mutant strain, on raising the
temperature to the restrictive temperature, the rate of synthesis of GyrA and
GyrB was again shown to rise (Menzel and Gellert, 1983). Therefore in the
case of the promoters ofgyrA and gyrB, a decrease in DNAnegative supercoiling
increases promoter activity. Experiments using an in vitro transcription-
translation system showed that expression ofgyrA and gyrB increased 100-fold
if the template was relaxed and an inhibitor of gyrase, such as coumermycin,
was added to keep the template in a relaxed form (Menzel and Gellert, 1983).
However inhibiting gyrase by nalidixic acid has been shown to display a much
smaller increase in the expression of gyrase. Menzel and Gellert (1987b) went
on to show that this regulation of gyrase expression occurs at the level of
transcription since regions of gyrA and gyrB fused to galK makes galK activity
inducible in vivo, to coumermycin. On the other hand, the expression of
topoisomerase I responds to changes in supercoiling in the opposite way, that
is it is inhibited by treatments which relax DNA supercoils and it is stimulated
by treatments that increase the levels of negative supercoiling (Tse-Dinh and
Beran, 1988).
Since this response is analogous to feedback inhibition, it can be concluded
that supercoiling is likely to be a normal regulator of these genes. One can see
how RST has a homeostatic role in the cell so that a decrease inDNA supercoiling
stimulates the gyrA and gyrB promoters to synthesise DNA gyrase to increase
supercoiling to its normal level and an increase in negative supercoiling
stimulates the production of topoisomerase I.
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1.4.6 The effect of transcription on supercoiling
Transcription has a major effect on the local and global supercoiling state of
DNA. As transcription has been shown to have a profound effect on
supercoiling (Pruss and Drlica, 1986), localised variations in supercoiling can
be achieved. Supercoiling provides a way for the transcription of one gene to
affect adjacent genes via DNA topology. It can be imagined that depending on
local transcriptional activities in the bacterial chromosome, supercoiling in
localised regions of the chromosome could become quite different from the
global level. It has been found that different plasmids from the same strain can
have very different levels of supercoiling. Increased negative supercoiling results
from transcription from a strong promoter rather than a weak one. Both
divergent transcription and the membrane attachment of one of the transcription
units are required for transcription to profoundly alter DNA supercoiling. In
wild type bacteria, gyrase and topoisomerase I have the capacity to keep pace
with transcription-generated topological problems and are therefore major
determinants of DNA supercoiling in cells (Cook et al, 1992).
1.4.7 Function of DNA gyrase in the replication of the E.coli
chromosome
DNA gyrase is involved in the initiation, chain elongation and termination of
DNA replication (Baker and Kornberg, 1988; Baker et al, 1986). At the origin of
replication, gyrase is required for the unwinding of the double helix (Baker
and Kornberg, 1988). DNA gyrase is one of five essential proteins involved in
the elongation stage of replication of the E.coli chromosome. Unwinding the
DNA duplex causes a "strain" to build up in front of the replication machinery
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as a result of the generation of positive supercoils as displayed in Figure 1.6.
The function of gyrase is to remove this topological strain. DNA gyrase reduces
the linking number of the parental strands prior to them becoming unwound
by the DnaB helicase (Baker et al, 1986). The remaining proteins required for
elongation of the nascentDNA strand are DnaB helicase which generates single-
stranded DNA by unwinding theDNA duplex, DnaG primase which is needed
to "prime" DNA synthesis by forming oligonucleotide primers, DNA
polymerase III holoenzymewhich replicates the single-stranded DNA templates
by extending the primers formed by primase and the single-stranded DNA
binding protein (SSB) which binds to the unwound DNA strands and melts
any secondary structure so the replication machinery can run smoothly.
Unsurprisingly, this elongation stage ofDNA replication is inhibited by gyrase
inhibitors such as novobiocin and nalidixic acid (Drlica, 1984). Once the bacterial
chromosome has been completely replicated, the two catenanes must be
unlinked and moved to opposite ends of the cell before cell division. This
process, as mentioned before, is principally carried out by topoisomerase IV.
Figure 1.6: Generation of positive supercoils during DNA replication.
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1.4.8 Segregation of bacterial chromosomes
Catenanes are the structures in which bacterial chromosome are found during
the later stages of DNA replication when the replication forks approach the
terminus region. The two linked daughter chromosomes must be unlinked
before partitioning occurs into daughter cells. Although both gyrase and
topoisomerase IV can decatenate in vitro, topoisomerase IV is the principle
decatenating enzyme in bacterial cells. Gyrase can however substitute in some
ways for topoisomerase IV, however it has to be present at high concentrations
to do this (Kato et al, 1992). It has been suggested that the specificity of
topoisomerase IV rather than gyrase for the terminus region may result from
topoisomerase IV and the other terminus-acting proteins being sequestered in
a "termisome complex" (Rothfield, 1994). One of the two subunits of
topoisomerase IV, ParC has been found by Kato et al (1992) to be attached to the
cytoplasmic membrane. Of further interest is the fact that ParC can be released
from the membrane subsequent to DNase I treatment. Therefore it seems that
the segregation machinery is likely to be located at the inner face of the
membrane (Kato et al, 1992).
1.4.9 The role of DNA gyrase in recombination
In recombination, the supercoiling induced by gyrase is essential. Some types
of general recombination are sensitive to inhibition of gyrase in vivo (Hays and
Boehmer, 1978) and transpositional recombination ofMu needs a supercoiled
DNA substrate (Mizuuchi and Craigie, 1986). The involvement of gyrase in
illegitimate recombination has also been demonstrated at least in vitro, possibly
with the interchange between gyrase molecules bound to different sites on the
DNA fragment (Naito et al, 1984).
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1.5 DNA gyrase as a drug target
As DNA gyrase is unique to prokaryotes, it is an ideal target for antibiotics.
Antibacterial drugs which specifically target DNA gyrase will damage the
bacterial pathogens in a way that will be described later while leaving the host
unaffected. There are twomain classes of antibacterial drugs which specifically
target DNA gyrase: the quinolones and the coumarins. DNA topoisomerase-
targeting drugs can be divided into these two classes based on their mode of
action:
Class I includes the quinolones which target DNA gyrase. Drugs in class I are
"topoisomerase poisons", which act by stabilising the covalent topoisomerase-
DNA complex as will be described in section 1.6.2. Two naturally occurring
polypeptides target DNA gyrase with a similar mode of action. These are
microcin B17 (Vizan et al, 1991) and the CcdB gene encoded toxin carried on the
F plasmid (Miki et al, 1992), both of which will be discussed in 1.5.6-1.5.7.
Class II includes the coumarin family of antibiotics which interact with the
DNA gyrase ATPase domain (Contreras and Maxwell, 1992). Drugs in class II
are distinguished from those in class I in that they interfere with the catalytic
functions of DNA topoisomerases without trapping the covalent intermediate
and are thus "topoisomerase inhibitors" rather than "topoisomerase poisons".
1.5.1. Quinolone antibacterial agents: an overview
The quinolone drugs are synthetic compounds which do not resemble any
compounds found in living organisms. The first quinolone to be synthesised
was nalidixic acid which was introduced into the field of antimicrobial
24
chemotherapy in 1962 (Lesher et al, 1962). This antibacterial agent was used
extensively for the treatment of urinary tract and enteric infections, particularly
against members of the Enterobacteriaceae, towhich it has a high efficacy. Despite
extensive clinical use, resistance to nalidixic acid was found to remain relatively
low. A few years later in the 1970s, several other antibacterial agents that were
chemically related to nalidixic acid, oxolinic acid and cinoxacin, were introduced.
However, the most significant discovery in the development of quinolone
antibacterial agents came later when it was discovered that the insertion of a
fluorine at position 6 in the basic nucleus enhanced and broadened the
antimicrobial activity. This resulted in the development of newer quinolone
drugs with antibacterial activities approximately a thousand times that of
nalidixic acid (Smith and Lewin, 1988). Newer quinolones such as norfloxacin,
enoxacin, ofloxacin and ciprofloxacin are active against both Gram positive
and Gram negative bacteria (Wolfson and Hooper, 1985).
The quinolone antibacterial agents can be divided into four general groups:
naphthyridines, cinnolines, pyridopyrimidines and quinolones. The chemical
structure of the basic nucleus and its derivatives are shown in Figure 1.7. The
common 4-quinolone skeleton (4-oxo-l,4-dihydroquinolone) is produced by
inserting an oxygen at position 4 in the basic nucleus. Nalidixic acid and
enoxacin are naphthyridines and have an additional nitrogen atom at position
8, thus they are 8-aza-4-quinolones. Quinolone antibacterial agents that derive
from the quinolone nucleus are simply known as 4-quinolones or quinolones.
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Figure 1.7: The 4-quinolone skeleton and structures of drugs derived from it
O
norfloxacin ciprofloxacin
It has been shown that for greatest activities, quinolone drugs have a carboxyl
group at position 3, a keto group at position 4 and a fluorine at position 6 and
a piperazinyl group or a methyl-substituted piperazinyl group at position 7
(Chu and Fernandes, 1989).
1.5.2 Binding of quinolones to DNA gyrase/ DNA
Before binding studies had been carried out, it was believed that quinolone
drugs bound directly to GyrA (Gellert et al, 1977; Sugino et al, 1977), since
quinolone resistance mutations occurred in the gyrA gene. However, the
occurrence of quinolone resistance mutations in gyrB suggested that the
quinolone binding site might encompass both subunits (Yamagishi et al, 1986).
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Binding studies carried out by Shen and Pernet (1985) suggested that quinolones
bound to DNA but not to gyrase, nor its individual subunits and it was
separately observed that the binding of quinolones to DNA causes the DNA to
unwind to a small extent (Tornaletti and Pedrini, 1988). It has been suggested
that quinolone drugs bind preferentially and cooperatively to single-stranded
DNA (Shen and Pernet, 1985; Shen et al, 1989a) which led to the idea that drugs
interact with a single stranded pocket ofDNA formed during the strand passage
reaction catalysed by gyrase. This hypothesis was modified slightly when it
became apparent that DNA gyrase was able to stimulate the binding of
quinolones to double stranded DNA (Shen et al, 1989b). Shen et al (1989c) later
proposed a cooperative drug-DNAbindingmodel for the binding of quinolones
to the gyrase-DNA complex. It was suggested that the enzyme cuts double-
stranded DNA, producing a four base pair stagger and the resulting exposed
single stranded regions form the quinolone binding site. The quinolone drugs
are thought to interact with the bases through hydrogen bonds which occur
between the 3-carboxy and 4-oxo groups which almost all quinolones possess.
At least four molecules are believed to bind per binding site and ring stacking
and hydrophobic interactions contribute to this co-operativity. Shen et al (1989c)
postulated that gyrase interacts via the group at the C7 position of the drug
(Figure 1.7), however Maxwell later pointed out that the C7 group is rather
variable (Maxwell, 1992). However, a new angle has recently been added to
this drug binding hypothesis with the discovery that mutations in gyrA which
have tyrosine-122 replacedwith either phenylalanine or serine (and thus cannot
cleave DNA) still can bind quinolone drugs (Critchlow and Maxwell, 1996)
suggesting that DNA cleavage by gyrase is not a prerequisite for drug binding.
Critchlow and Maxwell (1996) proposed that a pre-cleavage complex between
gyrase, quinolone and DNA exists which is converted to a, perhapsmore stable,
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complex following cleavage. This could occur if quinolones interact with a
gyrase-DNA complex in a similar way to the interaction of eukaryotic
topoisomerase II inhibitors with topoisomerase and DNA (Freudenreich and
Kreuzer, 1993). Intercalation of the planar ring of the quinolone drug into the
internucleotide space next to the cleaved phosphodiester bond could occur
where it can interact with residues of gyrase. This would occur either in the
presence or absence ofDNA cleavage but in the presence of quinolones would
likely favour DNA cleavage (Critchlow and Maxwell, 1996).
1.5.3 Resistance to the quinolone drugs
Increasingly, the occurrence of E.coli and S.typhimurium isolates highly resistant
to fluoroquinolones has been reported recently (Heisig et al, 1993; Heisig, 1993;
Heisig et al, 1994; Griggs et al, 1994; Heisig et al, 1995). Bacterial resistance to
the quinolone drugs has been frequently shown to occur concurrently with a
mutation in either gyrA, gyrB or both (Reece and Maxwell, 1991b).
1.5.4 The Quinolone Resistance Determining Region of gyrA
It appears that themajor target of quinolone drugs isGyrA (Yoshida et al, 1988).
Pointmutations arising in theDNA sequence ofgyrA associated with quinolone
resistance seem to map in a specific region of the protein called the quinolone
resistance determining region (QRDR) (Yoshida et al, 1990). The QRDR spans
the area of the protein between alanine-67 and glutamine-106 as shown
previously in Figure 1.4. Structurally, the importance of the region is believed
to result from its proximity to tyrosine-122. Residues which have been found
to change correlating with an increase in theminimum inhibitory concentration
(MIC ) of quinolone drug are as follows: alanine-67, glycine-81, serine-83,
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alanine-84, aspartate-87 and glutamine-106 (Reece and Maxwell, 1991b),
however serine-83 and aspartate-87 are thought to be the most critical (Yoshida
et al, 1990; Oram and Fisher, 1991; Hallett and Maxwell, 1991).
Table 1.3:Mutations in the quinolone resistance determining region of the gyrA
gene of E.coli
Position Amino acid Change in MIC of Reference
in GyrA change ciprofloxacin (mg/L)a
67 Ala—>Ser 4 Yoshida et al, 1990
81 Gly—>Cys 8 Yoshida et al, 1990
81 Gly—->Asp ND Cambau et al, 1993
83 Ser—>Ala 4 Hallett and Maxwell, 1991
83 Ser—>Leu 32 Yoshida et al, 1990
83 Ser—>Trp 32 Yoshida et al, 1990
84 Ala—>Pro 8 Yoshida et al, 1990
87 Asp—>Asn 16 Yoshida et al, 1990
87 Asp—>Val 5 Yoshida et al, 1990
87 Asp—>Tyr 8 Heisig et al, 1993
106 Gin—>Arg 4 Hallett and Maxwell, 1991
106 Gin—»His 4 Yoshida et al, 1990
a The change in MIC is given as the factor by which the MIC has changed
compared to the original parent strain
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Given that the amino acid changes leading to the highest levels of ciprofloxacin
resistance are serine-83 to leucine and serine-83 to tryptophan as highlighted
in Table 1.3, it was suggested that only such bulky hydrophobic residues at this
positionwould be able to confer the quinolone resistant phenotype (Yoshida et
al, 1990). However, site-directed mutagenesis (SDM) carried out by Hallett
and Maxwell (1991) showed that changing serine-83 to alanine in the GyrA
subunit ofE.coli resulted in a gyrase protein conferring resistance to ciprofloxacin
in an in vitro assay, suggesting that it is the loss of the hydroxyl group that is
responsible for the resistance phenotype. Interestingly, theMICS) of ciprofloxacin
of strains carrying the serine-83 to alanine mutation is lower than that seen
with strains with serine-83 to leucine and serine-83 to tryptophan mutations
(Cullen et al, 1989; Yoshida et al, 1990; Yoshida et al, 1988). It has been speculated
that the bulkiness of the leucine and tryptophan residues contributes further to
the level of quinolone resistance, presumably by destabilising the gyrase-
quinolone interaction more, perhaps by preventing quinolone entry into the
"quinolone pocket", the region of the complex in which the drug is thought to
bind.
SDMwas also carried out on glutamine-106 ofGyrA. Glutamine-106 to histidine
is the only quinolone resistance mutation reported to occur naturally at this
position (Yoshida et al, 1988; Yoshida et al, 1990). The MIC of ciprofloxacin for
glutamine-106 to histidine was only found to be four timesmore than the wild
type value, consistentwith the proposal by Yoshida et al (1990) that this change
leads to low level resistance (Yoshida et al, 1990). HoweverHallett andMaxwell
(1991) found that changing glutamine-106 to arginine resulted in a level of
quinolone resistance comparable to that induced by the mutation serine-83 to
alanine, suggesting that the level of resistance is determined by the specific
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amino acid that is substituted. Interestingly, both histidine and arginine are
positively charged residues whereas glutamine is polar so both these changes
could cause destabilisation of the gyrase-quinolone interaction. It has also
been proposed that residues serine-83, aspartate-87 and glutamine-106, being
hydrophilic, may participate in hydrogen-binding interactions with the drug
molecules (Hallett and Maxwell, 1991). However, in the model of quinolone
binding postulated by Shen et al (1989c), the hydrogen-bonding interactions
are thought to occur between the drug and hydrogen-bond donors on the DNA
while enzyme-drug interactions are believed to occur between the C7 group of
the quinolone and DNA gyrase. The mutations serine-83 to alanine and
glutamine-106 to arginine do not affect the cleavage reaction per se but instead
cause the interaction of the quinolonewith the enzyme to become destabilised.
Extensive site-directedmutagenesis has been carried out on serine-83 (Yonezawa
et al, 1995a). Artificial mutants of E.coli GyrA were generated and the effect of
the mutations on the level of quinolone resistance studied. It was found that
converting serine-83 to tryptophan, leucine, phenylalanine, tyrosine, alanine,
valine and isoleucine resulted in bacterial resistance to the quinolones.
Changing serine-83 to glycine, asparagine, lysine, arginine and aspartate was
found not to confer resistance. Table 1.4 describes the measured MIC of nalidixic
acid after changing serine-83 by SDM to an amino acid of different chemical
structure.
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Table 1.4: The MIC of nalidixic acid after changing serine-83 of GyrA of E.coli
to an amino acid of a different chemical structure.
83rd amino acid MIC of nalidixic acid (mg/L) Amino acid side-group
Serine 6.25 -ch2-oh
Glycine 6.25 —h
































On interpreting these results, it was concluded that, for quinolone resistance to
occur, the amino acid at position 83 has to be hydrophobic and the hydroxyl
group of serine was not important in the quinolone-gyrase interaction. It was
also concluded that serine-83 did not directly interact with other amino acids.
These findings modify the previous ideas of Hallett and Maxwell (1991) as
Yonezawa et al (1995a) found that replacing serine-83 with tyrosine confers
quinolone resistance, thus it cannot be the loss of the hydroxyl group that results
in quinolone resistance, since tyrosine also has a hydroxyl group although the
latter amino acid has a farmore bulky structure than does serine (see Table 1.4).
Another group have proposed that the hydroxyl group of serine might be part
of an important hydrogen bonding or metal-liganding interaction essential for
the action of quinolones (Oram and Fisher, 1991). The results of the work
carried out by Yonezawa et al (1995a) dispute the theory that the hydroxyl group
plays an important role in the quinolone-gyrase interaction and strengthen the
hypothesis that the 83rd amino acid must be hydrophobic to express the
quinolone resistant phenotype. It was further proposed that serine-83 is at the
entrance to the quinolone pocket.
1.5.5 The Quinolone Resistance Determining Region of gyrB
The gyrB gene has also been described as having a quinolone resistance
determining region (Yoshida et al, 1991) however mutations in gyrB seem to be
of minor importance compared to mutations in gyrA. This region is around
the centre of the gene and the important residues seem to be aspartate-426 and
lysine-447 (Yoshida et al, 1991). Changing aspartate-426 to asparagine and
lysine-447 to glutamate has the effect of raising the MICs of some quinolone
drugs (Yamagishi et al, 1986). A small increase in the MICs of acidic quinolones
such as nalidixic acid, oxolinic acid and cinoxacin is detectable for both
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mutations, however only the change aspartate-426 to asparagine conferred
resistance to fluorinated quinolones also. It was also found that changing
lysine-447 to glutamate results in an increased sensitivity to fluoroquinolones
(Yamagishi et al, 1986). It has been postulated that either nalidixic acid could
become adjacent to the quinolone resistance determining region of gyrB when
bound or that the mutations in the quinolone resistance determining region of
gyrB may result in changed resistance levels as a result of different contacts
withGyrA being formed whichmay then change the ease of binding of nalidixic
acid to the GyrA protein (Yamagishi et al, 1986).
1.5.6 The CcdB/ CcdA system of E.coli
The ccdA and ccdB genes of E.coli are present on the F plasmid and function to
preserve stable maintenance of the plasmid by forming a poison-antidote
mechanism (Bernard and Couturier, 1992). Production of CcdB results in an
inhibition of DNA partitioning and cell division which is lethal to the cell,
however under normal circumstances, it is neutralised by CcdA (Miki et al,
1992). The half life of CcdA is shorter than that of CcdB so if the F plasmid is
lost, decay of CcdA leads to activation of CcdB and subsequent cell death by
filamentation (Miki et al, 1992). It has been shown that CcdB forms a complex
with GyrA in a manner very similar to that of the quinolone drugs (Bernard et
al, 1993) whilst E.coli mutants with resistance to the cytotoxic activity of CcdB
have been shown to have amutation ingyrA converting arginine-462 to cysteine
(Bernard and Couturier, 1992). The CcdB protein has been shown to be
responsible for gyrase-mediated double-stranded DNA breakage (Bernard et
al, 1993), resulting in the stimulation of the SOS response (Bernard and Couturier,
1992). However in the gyrA462 mutant, the SOS response is not activated
indicating that the gyrA462 mutant protein does not damage the DNA, unlike
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thewild-type (Bernard and Couturier, 1992). This evidence suggests that CcdB,
like the quinolone drugs is a DNA gyrase poison (Bernard and Couturier, 1992).
CcdB has indeed been found to trap gyrase into a cleavable complex and this
reaction can be reversed by adding CcdA (Bernard et al, 1993). The mechanism
of DNA strand cleavage by CcdB shows close parallels to the action of the
quinolones. However unlike the quinolones, which carry out theDNA cleavage
reaction in the presence or absence of ATP, CcdB cleavage of DNA requires
ATP (Bernard et al, 1993). It is interesting that quinolone resistant bacteria are
sensitive to CcdB, thus possibilities are open for the development of new gyrase-
targeting drugs based on CcdB (Bernard et al, 1993).
1.5.7 Microcin B17
Microcin B17 is a low molecular weight peptide antibiotic produced by certain
E.coli strains (Herrero andMoreno, 1986). The mechanism of action ofmicrocin
B17 has been shown to involve DNA replication arrest and a consequent
induction of the SOS response through inhibition ofDNA gyrase (Herrero and
Moreno, 1986). Cells treated with microcin B17 have been found to induce
production of SOS-induced proteins such as RecA, SulA and UmuC, indeed
recA' and recBC strains are hypersensitive to this antibiotic. Microcin B17 is
mutagenic, however this effect is either thought to be a result of poorly repaired
DNA lesions or an increase in UmuCD expression (Herrero and Moreno, 1986)
whilst induction of the SOS response is RecBCD dependent as with the
quinolones (see 1.6.8). E.colimutants resistant tomicrocin B17 have been isolated
and shown to map in gyrB (Vizan et al, 1991) resulting from a tryptophan-751
to arginine conversion in the GyrB protein. The mode of action of the antibiotic
is to cause double-stranded cleavage of chromosomal DNA so that its
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mechanism is similar to that of the quinolones.
1.5.8 DNA topoisomerase IV as a drug target
The two proteins constitutingDNA topoisomerase IV, ParC and ParE have been
purified and studied in respect to them forming a putative antimicrobial target
(Hoshino et al, 1994). The specific activity of topoisomerase IV decatenation
was found to be five times greater than topoisomerase IV relaxation suggesting
that the decatenation activity of topoisomerase IV seems the most relevant for
the study of drug inhibition. Topoisomerase IV was found to be less sensitive
to quinolones than was gyrase and the 50% inhibitory concentrations for
decatenation were found to be significantly lower than this for type I
topoisomerases. A positive correlation was found between the inhibitory
activity against topoisomerase IV decatenation and that for gyrase thus
topoisomerase IV certainly is a candidate target for quinolone drugs in intact
bacteria. It is imagined that when quinolone drugs are present in the cell in
high concentrations, these drugs would be likely to inhibit the decatenation
activities of topoisomerase IV as well as the supercoiling activities of gyrase.
In vitro, only gyrase and topoisomerase IV segregate intact catenated DNA in
the presence of ATP (Adams et al, 1992) but recent work has suggested that
DNA gyrase may not decatenate DNA in bacterial cells (Adams et al, 1992;
Hiasa et al, 1994). Formation of catenanes byDNA gyrase tends only to happen
under conditions of aggregated DNA, for example in the presence of high
spermidine concentrations (Kreuzer and Cozzarelli,1980; Mizuuchi et al, 1980).
The IC50 for nalidixic acid against the decatenation reaction of topoisomerase
IV was found to be eight times higher than the IC^ for the supercoiling reaction
of gyrase (Hoshino et al, 1994).
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Residues corresponding to the quinolone resistance determining region and
coumarin resistance region are conserved in topoisomerase IV, suggesting that
quinolone and coumarin drugs may also inactivate topoisomerase IV. It has
been found that although topoisomerase IV is inhibited by quinolone and
coumarin drugs, it is not as sensitive to these drugs as is gyrase (Peng and
Marians, 1993). Sensitivity to novobiocin and oxolinic acid has been observed
for the E.coli DNA topoisomerase IV relaxation reaction (Kato et al, 1992) but
the decatenation reaction seems to be much less sensitive. If topoisomerase IV
is indeed membrane bound, it is possible that in vivo the enzyme does not
come into contact with drugs such as novobiocin and oxolinic acid.
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1.6 Effect of DNA gyrase inhibition at a cellular
level
1.6.1 Effect of quinolones on the bacterial chromosome
Experiments carried out investigating the effect of quinolones on the bacterial
chromosome were undertaken in the late 1970s and used oxolinic acid as a
representative quinolone (Snyder and Drlica, 1979). It was found that the
incubation of E.coli cells with oxolinic acid resulted in the cleavage of DNA
after addition of sodium dodecyl sulphate (SDS). It was estimated that there
are about 45 breaks in the chromosome, a value similar to the number of domains
of supercoiling found in the isolated chromosome. Since the E.coli chromosome
is about 4700kb, this corresponds to approximately one gyrase site per lOOkbp
(Drlica et al, 1980). This information is interesting given that the number of
activeDNA gyrase sites has been estimated as approximately 50 per cell (Snyder
and Drlica, 1979). The number of supercoiled domains per cell has also been
estimated as being 50 (Worcel and Burgi, 1972), suggesting that one gyrase
complex may be associated with each domain of supercoiling (Snyder and
Drlica, 1979). By using low oxolinic acid concentrations, it was realised that
each gyrase cleavage site consists of two independent drug targets, one on each
strand (Snyder and Drlica, 1979). This conclusion was drawn since single-
stranded sites were found to predominate at low oxolinic acid concentrations
and the number of cleaved single stranded sites were found to parallel the
inhibition ofDNA synthesis. A further conclusion of Snyder and Drlica (1979)
was that each gyrase site was contacted by two nicking-sealing subunits, one
on each strand, and for DNA synthesis to continue, both subunits would have
to be functional. The effect of oxolinic acid on the cell is rapid, with DNA
synthesis decreasing rapidly within a few minutes, even when low drug
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concentrations are used and few cleavable complexes are formed (Snyder and
Drlica, 1979).
Drlica et al (1980) postulated that this rapid inhibition ofDNA synthesis resulted
from oxolinic acid combining with gyrase and forming a barrier to themovement
of replication forks. Inactivation of gyrase in replicating regions of the
chromosome would understandably inhibit DNA synthesis quickly. Kinetic
measurements carried out by Drlica et al (1980) showed that inactivating gyrase
at the replication forks was the major cause of inhibition ofDNA synthesis and
gyrase sites elsewhere on the chromosome did not contribute to this inhibition
to any major extent.
1.6.2 Implications of "Cleavable Complex" Formation
The bactericidal effect of quinolones is complex and presently poorly
understood. Quinolone-mediated cell death does not occur by the inhibition
of DNA supercoiling which is demonstrated by the fact that the IC50 value (the
concentration of drug at which 50% inhibition of supercoiling occurs) for a
particular quinolone drug exceeds the MIC by a factor of 10 to 100 (Domagala
et al, 1986; Gellert et al, 1977; Zweerink and Edison, 1986). It was postulated by
Kreuzer and Cozzarelli (1979) that quinolone drugs act as "topoisomerase
poisons" by blocking all activities of DNA gyrase, with these drugs trapping
the gyrase enzyme at a certain stage in the reaction cycle, thus inhibiting the
supercoiling of DNA and arresting the movement of polymerases. Cell death
would be expected to occur when only a small fraction of intracellular gyrase
molecules had quinolone bound to them, that is at a concentration of drug that
would not affect supercoiling appreciably. On the addition of SDS to a reaction
mixture of chromosomal DNA, gyrase and oxolinic acid, the DNA is found to
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be cleaved on both strands with a 4bp stagger and protruding 3' ends (Gellert
et al, 1977; Sugino et al, 1977; Morrison and Cozzarelli, 1979). These 3' ends
provide a template primer forDNA polymerase (Morrison and Cozzarelli, 1979),
however the cleaved DNA is resistant to labelling with T4 polynucleotide kinase
even after treatment with proteinase K suggesting that the denatured enzyme
remains attached to the cleaved DNA and is covalently bonded to both 5'
terminal extensions as illustrated in Figure 1.8.
Figure 1.8: Diagrammatic representation of the gyrase-DNA "cleavable
complex" (represented by the yellow circle) on double stranded DNA.
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1.6.3 The effect of quinolone drugs on transcription
Experiments carried out by Willmott et al (1994) have shed some light on the
mode of action of quinolone drugs. By the use of an in vitro transcription
system, the effect of quinolones on transcription was studied. It was found
that the complexes of gyrase and quinolone with DNA result in transcriptional
arrest by both E.coli and T7 RNA polymerases, seen by the production of short
transcripts. However, whenDNA gyrase carrying a pointmutation conferring
resistance to quinolones was introduced into the system, it was found that
transcriptional arrest only occurred at much higher concentrations of the
quinolone drug. Itwas therefore found that the amount of ciprofloxacin needed
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to stall transcription significantly is of a comparable level with the amount
required to promote DNA cleavage by gyrase (Hallett and Maxwell, 1991).
Changing the active site tyrosine-122 to serine results in the lifting of this
transcriptional block in vitro, suggesting that DNA cleavage is required for
polymerase blocking (Critchlow and Maxwell, 1996). Interestingly, DNA
synthesis by DNA polymerase I is inhibited by gyrase and quinolone drug
together but not by either component alone Willmott et al (1994). These
observations confirm those of Chow et al (1988) who showed that the addition
of ciprofloxacin, norfloxacin and difloxacin to a logarithmic culture of E.coli
resulted in a rapid decrease in DNA synthesis. Even low levels of oxolinic acid
have been found to form cleavable complexes on DNA, thus inhibiting DNA
synthesis and RNA synthesis in proportion to the number of complexes formed
(Snyder and Drlica, 1979). Manes et al (1983) found that oxolinic acid inhibits
RNA synthesis at concentrations at which DNA supercoiling is unimpeded.
Therefore, DNA synthesis and transcription are much more sensitive to
quinolone action than is DNA supercoiling and it is probably the inhibition of
the former that is the lethal event. Camptothecin, a eukaryotic type I
topoisomerase inhibitorwhich is also a "topoisomerase poison" has been shown
to cause replication fork and transcriptional arrest (Bendixen et al, 1990; Hsiang
et al, 1989). Formation of the cleavable complex consisting of quinolone-gyrase
and DNA seems to stimulate various activities as described in Figure 1.9. Briefly,
the SOS response can be induced by either the formation of free ends after
collision of the cleavable complex with the transcriptional machinery
(Possibility!) or the induction of DNA repair (Possibility 2).
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Figure 1.9: Diagrammatic representation of quinolone-mediated transcription
arrest and its implications.
SOS
Possibility 1: The cleavable complex is broken by the movement of
the transcriptional machinery for example
Possibility 2: The distortions in the DNA duplex are detected by
repair enzymes, for example, Uvr endonuclease, which sets off the
SOS response
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1.6.4 Formation of Double-Stranded Breaks (DSBs) by the
Quinolones
After the formation of the cleavable complex, two potential double-stranded
DNAbreak (DSB)-forming scenarios can be imagined (Figure 1.9). It is probably
the case that when the replication or transcription machinery collides with the
"cleavable complex" on the DNA, it stops and reinitiates some distance away,
leaving a gap in the DNA to which RecA can bind. Another possibility is that
the impact of the replication or transcription complex on the "cleavable
complex" rips it apart, resulting in a double-stranded break possibly with the
5' end attached to theGyrAsubunit and the 3' end free (Morrison and Cozzarelli,
1979). Also distortions in the DNA helix are detected by repair enzymes such
asUvr endonuclease which initiatesDNA repairmechanisms (Kuemmerle and
Masker, 1980; Sancar and Rupp, 1983). Whether or not the action of quinolones
results in free DNA ends in bacterial cells has been a debatable point. Work
carried out by Snyder and Drlica(1979) showed that treating E.coli cells with
oxolinic acid at concentrations sufficient to completely block the synthesis of
DNA did not result in much DNA fragmentation as mostly intact nucleoids
containing negative supercoiled DNA were isolated after sedimentation into
ethidium-containing sucrose gradients (Snyder and Drlica, 1979). However if
the isolated nucleoids were then treated with SDS to denature the proteins,
fragments of DNA were detected. Therefore the gyrase enzyme holds the
DNA together in bacterial cells and the lesion can be thought of as a complex of
quinolone-gyrase-DNA containing a double-stranded break. These lesions
would act as barriers to the passage of the replication fork and transcriptional
machinery and would be prone to breakage in an actively replicating/
transcribing cell. The formation of DSBs in cells is potentially lethal and to
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protect itself, the cell mounts a DNA repair response. Single-stranded DNA
ends produced by DSB formation are bound by RecA which protects them
against further damage and induces binding of RecBCD. It is not surprising
that lack of these important recombination and repair enzymes in recA', recB'
and / or recC cells causes hypersensitivity to quinolone drugs (Lewin et al,
1989a). The hypersensitivity of recA13 and recBll mutants is thought to be as
a result of their lack of recombinational repair (Lewin et al, 1989a). A major
determinant of the cytotoxicity of Class I drugs seems to be the interconversion
of dormant single or double stranded breaks in a inhibitor-topoisomerase-DNA
ternary complex into an irreversible double-stranded DNA break. The fact
that yeast RAD52 mutants (RAD52 is a repair enzyme which reseals DNA
double stranded breaks) are very sensitive to Class I drugs (Nitiss and Wang,
1988) gives weight to this hypothesis.
1.6.5 Repair of quinolone-induced DNA lesions
Genetic studies which made use of cells with mutations in several of the DNA
recombination and repair genes showed that it is mainly such genes that affect
the survival of the bacterial cell after treatment with quinolones (Lewin et al,
1989a). RecA has a central role in the protection of free DNA ends before they
are repaired, ensuring that DNA is sufficiently intact before cell division can
proceed. Another important enzyme is RecBCD (Exonuclease V) which is
comprised of three subunits encoded by the recB, recC and recD genes (Smith,
1988). RecBCD has DNA helicase, single-strand DNA nuclease and double-
strand DNA nuclease activitieswhich combine to expose single-stranded DNA
with a free end which acts as a substrate for RecA. RecBCD can only unwind
DNA which has a free duplex end so once it has attached itself to the DNA it
moves along, unwinding and rewinding DNA. The recombination activity of
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RecBCD is stimulated by a sequence in DNA called Chi (5' GCTGGTGG 3').
When RecBCD encounters a Chi sequence, the nucleolytic activity of RecBCD
causes cleavage of the exposed single-stranded region near Chi so rewinding
of the DNA cannot occur. As a result, a gap in the DNA and a single-stranded
tail are produced, both ofwhich RecA can bind. This structure is thus competent
for DNA strand exchange with a homologous sequence.
1.6.6 The endo-exonuclease activity of RecBCD
Endo-exonucleases are thought to be present in all living organisms enhancing
the survival of organisms by promoting recombination and repair of DNA.
This leads to diversification of the genome, an advantageous ability in a
changing environment. However if genomic DNA becomes damaged to such
an extent that it cannot be repaired, it is the function of the endo-exonucleases
to degrade it thus, in this way the population is relieved of cells containing
detrimental mutations. Endo-exonucleases have both endonuclease and
exonuclease activities. RecBCD in E.coli is an endo-exonuclease, possessing
single-strand specific endonuclease and single-strand and double-strand
exonuclease activities (Fraser, 1994). The breaks generated by the endonuclease
activity have 3' OH and 5' P termini and the exonuclease activity on either
linear single-stranded or double-stranded DNA results in the generation of
small oligonucleotides with 5' P ends. RecBCD is highly processive on double-
stranded linear DNA, yielding single strands of DNA which are thousands of
nucleotides long (Fraser, 1994).
1.6.7 Induction of the SOS response by the quinolones
The quinolone drugs have been shown to induce the SOS response in E.coli
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(Phillips et al, 1987). The maximal induction of the SOS response was found to
occur at the OBC, suggesting that maximal induction of the SOS response might
be lethal (Phillips et al, 1987). Concentrations of nalidixic acid greater than the
OBC have been found to result in less DNA damage and less bactericidal activity
(Crumplin and Smith, 1975). Also, agents that induce the SOS response are
known to increase the mutation rate in E.coli (Quillardet et al 1985). This
mutagenic effect can only occur in cells that are sensitive to quinolones and
can mount an SOS response. Interestingly, the SOS response is also switched
on in response to gyrase inhibition by coumermycin, albeit slowly at over two
hours after addition of the drug (Menzel and Gellert, 1983). This in itself
emphasises the essential nature of correct supercoiling levels in bacterial cells.
1.6.8 Induction of the SOS response is mediated by RecA
DNA damage in bacterial cells is detected by RecA, a protein central to
recombination (Smith, 1988). As previously mentioned, RecA binds to single-
stranded regions of DNA, coating it so it is protected from nuclease action
(Smith, 1988). Binding to DNA in such a manner stimulates a catalytic ability
ofRecA to be able to cleave certain cellular repressors. This protease activity of
RecA specifically cleaves the LexA repressor into two fragments. This results
in the induction of the "SOS response", a response which is stimulated after
treatment with DNA damaging agents which give rise to regions of single-
stranded DNA, either by excision damage or because the damage is encountered
by a replication complex (Goss et al, 1965; Crumplin et al, 1984; Benbrook and
Miller, 1986). The action of RecBCD on DNA damaged by nalidixic acid is
perhaps the signal for induction of the SOS response (Walker, 1984; Bailone et
al, 1985). Each genewhich is part of the SOS response has an operator recognised
by the LexA repressor (Gottesman, 1984). Once RecA has cleaved the LexA
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repressor, transcription of the SOS genes proceeds. The recA and lexA genes
are also repressed by LexA. When DNA is damaged, the rate of synthesis of
both RecA and LexA increases. More RecA is required for the high rate of
DNA repair by recombination whereas more LexA is needed for the time that
the DNA is repaired and repression of the SOS genes can again occur. Until
this time, LexA is destroyed at a steady rate by RecA (Gottesman, 1984).
Meanwhile, production of the SOS-induced SulA protein results in inhibition
of septation. SulA binds to FtsZ and thereby prevents its action in the initiation
of cell division. As long as SulA is produced, the cell cannot divide and instead
is seen to form long filaments. This allows the cell to be able to recover from
DNA damage before division resumes when SulA is degraded by the Lon
protease. The stimulation of the SOS response by DNA damage is illustrated
in Figure 1.10.
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1.6.9 The Involvement of the SOS Response in Repairing
Quinolone-damaged DNA
It has been suggested previously that either the SOS response or recombinational
repair systems of E.coli are responsible for repairing DNA damage caused by
quinolone drugs (Drlica, 1984). The effect of quinolones on the bacterial cell
does not seem to bemediated only through the SOS response (Lewin et al, 1989a).
Lewin et al (1989a) used a cellwith a lexA3mutation, the LexA protein of which
was resistant to proteolytic cleavage by RecA and the SOS response was not
induced. However this strain was as sensitive to nalidixic acid as the wild
type, at a number of concentrations (Lewin et al, 1989a). It would be expected
that either a decreased or increased sensitivity to nalidixic acid would result
depending on the action of the SOS response to either repair the damaged DNA
or to kill the cell. It is also interesting that a recA13recB21 double mutant was
found to have an increased sensitivity to nalidixic acid than either singlemutant
(Lewin et al, 1989a). The fact that two mutations blocking the same pathway
have an additive effect in this situation, disputes that the induction of the SOS
response is solely responsible for repair. It therefore seems that it is the
recombination activities of RecA and RecBCD that seem to be important in
repair of quinolone-induced DNA lesions and the SOS response only seems to
have a minor role.
1.6.10 Quinolone Cell Death Mechanisms
There are obviously many unanswered questions as far as cell death goes.
Another confusing issue is the fact that the newer quinolones have been reported
not to need protein synthesis to die but the older quinolones such as nalidixic
acid do (Lewin et al, 1991). Experiments carried out have shown that the newer
quinolones can kill nongrowing cells, cells in stationary phase and cells treated
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with protein- and RNA-synthesis inhibitors (Zeiler, 1985; Lewin et al, 1990; Eng
et al, 1991). Conclusions drawn separately by Diver and Wise (1986) and Smith
(1984) suggested that in ciprofloxacin-challenged E.coli, there are at least two
modes of cell death. Firstly, more than 90% of cell death is thought to occur by
a mechanism not involving additional protein synthesis. This is the mechanism
that Smith (1984) referred to as Mechanism B and was found only to occur
with potent fluorinated quinolones such as ciprofloxacin or ofloxacin. Secondly,
a minor cell death mechanism exists which does require protein synthesis and
leads to cell filamentation and vacuolation. This mechanism was named
Mechanism A by Smith (1984) and was found to occur with all quinolones. A
third mechanism, Mechanism C, has also been identified which apparently
workswith ciprofloxacin, ofloxacin and norfloxacin (Ratcliffe and Smith, 1985).
RNA and protein synthesis but not cell division are thought to be required.
Howard et al (1993) proposed that Mechanism C is mediated via a drug
interaction with the GyrB subunit. Experiments carried out by Crumplin and
Smith (1976) demonstrated that single-stranded DNA precursors accumulated
in nalidixic acid challenged cells. Smith(1984) proposed that this nicked DNA
would form a substrate for cellular exonucleases which would cause a certain
amount of DNA degradation and would then induce the SOS response.
Whether or not the SOS response would be able to rescue the cell to any extent
would presumably depend on the extent of gyrase inhibition and therefore
inhibition of proteins needed to repair the DNA. Evidence for the SOS response
would be observed by signs of filamentation and /or vacuolation of the cell
which would themselves contribute as a secondary mechanism of cell death.
1.6.11 Topoisomerase IV and cytotoxicity
The inhibition of topoisomerase IV does not seem to lead to cytotoxicity when
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inhibited by quinolones thus differing from the inhibition of gyrase. Since the
cytotoxic effect of quinolones on gyrase is believed to result from cellular
enzymes, for example the DNA replication complex, tracking along the
chromosome and colliding with the cleavable complex, splitting it and leaving
double strand breaks which then cannot be resealed, it can be concluded that
for the inhibition of topoisomerase IV to be cytotoxic, this enzyme would also
have to be present in front of the replication complex. As discussed in 1.5.8,
the roles of gyrase and topoisomerase IV seem to be specific and it is likely that
topoisomerase IV is localised to the terminus region of the chromosome and
could even be membrane-bound (Rothfield, 1994). The fact that topoisomerase
IV is unlikely to be present in front of the replication complexes on the
chromosome explains the lack of cleavable complexes formed between
topoisomerase IV, quinolone and DNA. Even though quinolones have been
shown to inhibit topoisomerase IV, cytotoxicity will not result because of the
lack of cleavable complex formation by the enzyme. Levels of quinolones
completely inhibiting topoisomerase IV have been shown to be over one
hundred times the normal MICs of potent quinolones (Nitiss, 1994). Although
some quinolone-resistant E.coli have been found to have mutations in
topoisomerase IVwhich results in an increased resistance to quinolones (Heisig,
1996; Vila et al, 1996), topoisomerase IV is only a minor target of quinolones in
E.coli compared to gyrase and a decreased susceptibility to quinolones cannot
occur without a mutation in DNA gyrase. Therefore while gyrase inhibition is
potentially bactericidal, topoisomerase IV inhibition is largely bacteriostatic.
This is thought to be as a result of its location in the cell membrane and/or
behind the replication fork (Khodursky et al, 1995).
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1.7 Aims of this thesis
1. To sequence the QRDR of gyrA of S.typhimurium and S. typhi.
2. To identify mutations arising in the QRDR of gyrA of S.typhimurium and
S.typhi in response to a decreased susceptibility of quinolone drugs.
3. To study the difference in amino acid substitutions in the QRDR of gyrA
between E.coli and Salmonella and to relate them to differential codon usage.
4. To clone gyrA from E.coli into a suitable cloning vector and study its effect on
the cell when expressed at high levels.
5. To investigate the molecular mechanisms of quinolone-mediated cell death
by attempting to correlate viability of the bacterial culture to integrity of the
chromosomal DNA when electrophoresed on both pulsed field and
conventional agarose gels.
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2 Materials and Methods
2.1 Reagents
Chemicals and reagents were all supplied by Sigma Chemicals (Poole, Dorset)
unless otherwise indicated. All antimicrobial agents were freshly prepared
with sterile distilled water. Manufacturers of the antibiotics along with the
solvents used to dissolve the powders are listed in Table 2.1.
Table 2.1 Antimicrobial Agents
Antimicrobial Agent Abbreviation Solvent Manufacturer
Ampicillin Amp Water Sigma
Chloramphenicol Cm Ethanol Sigma
Ciprofloxacin Cip Water Bayer
Nalidixic acid Nal Water Sigma
Norfloxacin Nfx 0.5M NaOH Mercke, Sharp and Dohme
Ofloxacin Ofx 0.5MNaOH Roussel Laboratories Ltd
Oxolinic acid Oxl 0.5M NaOH Sigma
Rifampicin Rif Water Ciba Laboratories
Streptomycin Sm Water Sigma
Tetracyclin Tet Water Sigma
Trimethoprim Trim Lactic acid Wellcome Foundation
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2.2 Bacterial and Phage Maintenance
Bacterial strains used in this study are listed in Table 2.2. Bacteria were either
maintained on Luria-Bertani (LB) agar plates at room temperature or in Frozen
Storage Buffer at -70°C for longer term storage. To prepare bacteria for frozen
storage, a fresh 5ml overnight culture was prepared with antibiotic selection if
required. A volume of 0.9ml of this culture was added to 0.1ml Frozen Storage
Buffer [50% (v/v) glycerol] in sterile cryovials (Alpha Laboratories, Eastleigh,
Hants), briefly vortexed and stored at -70°C. Strains were sub-cultured directly
from stock onto solid media, for verification of phenotype and purity prior to
use but were never passaged. Phage lysates were stored at 4°C as suspensions
to which a few drops of chloroform were added to prevent microbial growth.
Table 2.2 Bacterial Strains
Strain Genotype Reference
E.coli K12 TGI thi, A(lac-proAB), F'[lacIqlacZAM15]
E.coli DH5a thi, AlacU169 (O80/acZAM15)
E.coli KNK453 gyrAts
E.coli XL-1 A(mcrA)183, D(mcrCB-hsdSMR-mrr)
BLUE MRF' endAl, supE44, thiOl, recAl, gyrA96,
relAl, lac[F'proAB, lac!qZDM15, TnlO (tetR]
E.coli SOLR el4~(mcrA), A{mcrCB-hsdSMR-mrr)17\,
sbcC, recB, recj, umuC::Tn5(kanR), uvrC,
lac, gyrA96, relAl, thi-1, endAl, IR,







The clinical strains which were investigated in Chapter 3 were received as
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follows. The S.typhimurium isolates from Vellore, India were collected by Dr
Hilary-Kay Young (University of Dundee) in 1984. The S.typhi isolates from
Vellore, India were collected by DrMary Jesudason (Christian Medical College
and Hospital, Vellore, India) between 1992 and 1994. The clinical isolates of
E.coli and S.typhimurium collected from a variety of British hospitals were
received from a culture collection documented by Dr Robert Paton (University
of Edinburgh).
Plasmids used and constructed in the course of this study are listed in Table
2.3.
Table 2.3 Plasmids
Plasmid Size Markers Description Reference
pBR322 4.3kb AmpR TetR Cloning vector Balbas et al, 1986
pUC18 2.7kb AmpR/flcZ Cloning vector Norrander et al, 1983
pKIL119 3kb KanR Encodes ccdB Bernard, 1995
pNotl - AmpR Encodes Notl New England Biolabs
pOU61 9kb AmpR Cloning vector Larsen et al, 1984
pBluescript 2.9kb AmpR lacZ Cloning vector Stratagene
pPH3 8kb AmpR Encodes gyrA Hallett et al, 1990
pNJR3-2 28kb TetR Encodes gyrA Robillard, 1990
pBRgyrA 6.8kb AmpR Encodes gyrA This work
pOUgyrA 11.8kb AmpR Encodes gyrA This work
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2.3 Growth Media and Buffers
Luria-Bertani (LB) broth [l%w/v Bactotryptone (Difco), 0.5% (w/v) Bacto yeast
extract (Difco), 1% (w/v) sodium chloride] and Luria-Bertani (LB) agar [Luria-
Bertani broth +1.5% bacteriological agar number 1 (Oxoid)] were used routinely
for all bacterial manipulations exceptwhere stated. For work with phage X, the
media were supplemented with lOmM MgS04 and 0.2% maltose to maximise
expression of the X receptor protein.
2.4 Growth of Bacteria
Bacteria were routinely grown as liquid overnight cultures at 37°C. A single
colony from a freshly streaked out strain was inoculated aseptically into broth
and shaken overnight in a temperature-controlled orbital shaker (Gallenkamp).
If the strain, or a plasmid harboured by it, contained antibiotic resistance
markers, the appropriate antibiotic was added to the culture for selection
purposes.
2.5 Determination of the Minimum Inhibitory Concentration of
a particular antibiotic
Minimum Inhibitory Concentrations (MICs) were performed on Isosensitest
(1ST) agar following the British Society for Antimicrobial Chemotherapy (BSAC)
guidelines for susceptibility testingwhere applicable (Phillips et al, 1991). MICs
were determined by agar double dilution of the antimicrobial agent. Agar,
containing the appropriate concentrations of antimicrobial agent,was inoculated
with a 2pl spot of each organism, delivered from amultipoint inoculator (Denley,
Billinghurst, Surrey). Bacterial strains to be tested were inoculated into Luria
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Bertani broth and incubated for 16 hours at 37°C before dilution in 0.7% sterile
saline to give an inoculum of 104 colony forming units (cfu/spot) in each case.
Inoculated agar plates were incubated overnight at 37°C.
2.6 Determination of the Optimum Bactericidal Concentration of
a particular antibiotic
Determination of the optimum bactericidal concentration (OBC) of a particular
antibiotic was performed on a log phase culture of the bacteria to be tested.
Various concentrations of antibiotics were added to a specified volume of culture
and allowed to grow for a specified length of time. Aliquots of culture (neat)
and 10 "and 10~4 dilutions (in 0.7% sterile saline) of the aliquots were plated out
on McConkey agar (Oxoid), incubated overnight and the viable counts
determined. The concentration of antibiotic corresponding to the most cell
death was termed the OBC.
2.7 Preparation of Plugs for Pulsed Field Electrophoresis
Pulsed field electrophoresis of chromosomal DNA was carried out by
embedding a specified number of cells in low melting point agarose (Biorad)
tominimise shearing ofDNA. The bacterial culture was centrifuged (at 3000rpm
for 15 minutes) in a bench top centrifuge, drained and the pellet resuspended
in lOOpil SE buffer [lOmM NaCl, 25mM EDTApH7.5] and the OD590 adjusted to
1. An equal amount of bacterial culture in SE buffer was added to 1% low
melting point agarose (Biorad) in a sterile Eppendorf tube and mixed thoroughly.
A 80|il volume of thismixture was inserted into awell of the plug mould (Biorad)
and allowed to set at 4°C. The set plugs were transferred to a 2ml sterile bijoux
containing 2ml lysis buffer [l%w/v N-lauroylsarcosine, 50mM EDTA pH9.5
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with 0.5mg/ml proteinase K freshly prepared]. The plugs were deproteinised
overnight and the following day, washed three times thoroughly with 2ml TE
buffer [lOmM Tris, ImM EDTA pH8], A 1% agarose gel was prepared by the
addition of lg Pulsed Field grade agarose (Biorad) to 100ml 0.5xTBE [lOxTBE
is 0.89M Tris-borate pH8.3,20mM EDTA]. The plugs were inserted into the gel
and sealed by pipetting 5ml of molten agarose over them.
2.8 Pulsed Field Electrophoresis
A pulsed field gel electrophoresis tank (Chef DR-II, Biorad, UK ) was used to
separate the DNA fragments. The initial pulse time was 1 second, the final
pulse time was 60 seconds, the voltage was 200V and the temperature kept
constant at 14°C for 16 hours. To size the DNA fragments, X concatemermarkers
(Biorad,UK) were used. After 16 hours, the gel was stained in 50jag/l ethidium
bromide and photographed overUV light from a transilluminator (UV Products,
Cambridge).
2.9 Preparation of Competent Cells
To prepare competent E.coli cells, the method of Chung and Miller (1988) was
used. A single colony of the appropriate strain of bacteria was inoculated into
5ml of LB broth containing a suitable antibiotic and shaken overnight at 37°C.
This was then diluted 1 in 100 into a flask containing LB broth and grown until
an OD600 of between 0.3 and 0.4. The cells were subsequently placed on ice and
transferred to a sterile thick-walled glass universal bottle and pelleted at
3000rpm in a benchtop centrifuge for 10 minutes. The broth was poured off
and after allowing the pellet to drain briefly by inversion, the cells were again
placed on ice. Ice-cold TSS buffer [1% (w/v) Bactotryptone (Difco), 0.5% (w/v)
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Yeast extract (Difco), 1% (w/v) NaCl, 10% (w/v) PEG3350,20mM MgS04, lOmM
PIPES pH6.5] was added in a volume equivalent to O.lx original volume of
cells and the cells resuspended by vortexing. A volume of DMSO equivalent to
0.05X original volume of cells was added after which the cells were ready for
transformation.
2.10 Transformation of competent cells with plasmid DNA
Transformation of competent cells (prepared as described in Section 2.9), was
carried out by adding l-100ng of plasmid DNA (in a volume of <10pl) to 100(il
of cells. The tubes were left on ice for a period of 30 minutes, after which 400|iil
of LBG (LB broth + 20mM glucose) was added to each, mixed and the cells
incubated at 37°C for one hour to allow expression of plasmid antibiotic
resistance genes. Aliquots of 200|il of the incubated cells were then spread on
appropriate antibiotic-containing plates and incubated overnight at the
appropriate temperature. During the cloning experiments, inserts that had been
ligated into lacZ of the cloning vector could be identified by plating the
transformants out on agar plates which contained 20(ig/ml X-gal and O.lmM
IPTG. Plasmids which carried inserts which interrupted expression of lacZ
appeared white, whereas those which had no insert remained blue.
2.11 Small Scale Plasmid Preparation
Routine preparations of plasmid DNA were performed by a modification of
the alkaline lysis method of Birnboim and Doly (1979). A 5ml volume of LB
broth (plus suitable antibiotic selection) was inoculated with a single colony of
the plasmid bearing strain, and incubated with continuous shaking at the
appropriate temperature (typically 37°C) overnight. The culture was then
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centrifuged at 3000rpm in a benchtop centrifuge. The supernatant was
discarded, and the bacterial pellet resuspended in 0.1ml of Solution I [1%
glucose, lOmM EDTAand 25mM Tris-HCl (pH8)]. To this cell suspension, 0.2ml
of Solution II [0.2M NaOH, 1% SDS] was added, mixed by gentle inversion of
the tube and incubated on ice for 5 minutes to allow lysis to proceed. A volume
of 0.15ml of Solution III [3M sodium acetate (pH5.0)] was then added and the
contents of the tube mixed vigorously by extensive vortexing (vortexing was
only carried out when the plasmids to be extracted were less than lOkb, plasmids
larger than this would be likely to shear by this step). After leaving the prep on
ice for 10 minutes to allow precipitation of chromosomal DNA and insoluble
cellular debris, the mixture was then spun in a microfuge for 10 minutes. The
resulting supernatant (about 0.5ml) was transferred to a fresh Eppendorf tube
and 0.5ml of phenol/ chloroform/ isoamyl alcohol (ratio 25:24:1) was added,
mixed by vortexing and centrifuged in a microfuge for 2 minutes. The upper
aqueous phase was transferred to a fresh tube and the plasmid DNA could
then be recovered from solution by ethanol or isopropanol precipitation.
Typically, the final pellet of nucleic acid was resuspended in TE buffer (lOmM
Tris, ImM EDTA pH8) containing RNase A (20|ig/ml). It was usually observed
that 5ml of overnight culture yielded approximately 3-5|ig of plasmid DNA.
2.12 Large Scale Plasmid Preparation
To prepare large scale quantities of plasmid DNA, a Qiagen midiprep kit
(Qiagen, Chatsworth, California) was used. A 25ml volume of culture (high
copy number plasmids) or 100ml volume of culture (low copy number plasmids)
routinely yielded 50pg to 100gg DNA.
2.13 Preparation of chromosomal DNA
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Chromosomal DNA was prepared by a slight modification of the protocol of
Zyskind and Bernstein (Zyskind & Bernstein, 1992). A single colony was
inoculated into 5ml of nutrient broth and grown overnight in a 37°C incubator.
A 1.2ml volume of this culture was spun in a microcentrifuge (Microcentaur
MSE) for a period of 15 seconds. The broth was discarded and the cell pellet
resuspended in a volume of 0.31ml HTE buffer [50mM Tris-HCl, pH 8.0,20mM
EDTA] by briefly vortexing to which 0.35ml of a 2% solution sarcosyl in HTE
was added with brief inversion of the tube, followed by 5jli1 RNase [lOmg/ml
in TE buffer]. A volume of 35)0.1 of pronase [lOmg/ml in lOmM Tris-HCl pH8.0,
lOmM NaCl, O.lmM EDTA buffer] was added and the tubes incubated in a
50°C waterbath until lysis had occurred. Three rounds of phenol/chloroform
extraction were carried out and the resulting lysate treated with a 10% volume
of 3M sodium acetate and a 100% volume of isopropanol at -20°C. DNA
precipitation was achieved after placing the tubes at -70°C for 15 minutes
followed by centrifugation at 13,000rpm in a microcentrifuge for 20 minutes.
The resulting pellet was briefly washed by the addition of 70% ethanol and
then dried in a vacuum desiccator. Resuspension of the pellet in lOOjil of TE
gave a solution of DNA suitable for amplification by the Polymerase Chain
Reaction.
2.14 Amplification of DNA by the Polymerase Chain Reaction
(PCR)
Polymerase chain reaction (PCR) amplification of a specified fragment ofDNA
was carried out in a total volume of 100|il prepared in a 0.5ml polypropylene
microcentrifuge tube (Alpha Laboratories) with a Techne PHC-2 Dri-Block
Cycler (Cambridge, Cambs.). PCR amplifications consisted of lxPCR buffer
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(Gibco, BRL), 2.5mM MgCl2 (Gibco, BRL), 200-400|iM each dNTP (Boehringer
Mannheim), lOpmoles of each primer (Oswel, Department of Oswel,
Department of Chemistry, University of Edinburgh), lOng DNA template and
1 unit of Taq polymerase (Gibco, BRL). Reaction mixtures were overlaid with
one or two drops of mineral oil to reduce evaporation, and the tips of the tubes
were smeared with a thin film of silicone grease to improve thermal contact
with the heating block. After completion of the PCR reaction, samples were
placed on ice to quench any further reaction.
Two sets of primers, designed on inspection of the gyrA sequence of Escherichia
coli (Yoshida et al, 1988), were used during the course of this work, one set
amplified the first 620bps of gyrA including the QRDR and the other set
amplified the whole gene including promoter and terminator sequences.
Primer sequence Amplification Conditions
Region amplified: +1 to +620bps
51 ATGAGCGACCTTGCGAGAGAAATTACACCG 3 1 96°C for 15s
5' TTCCATCAGCCCTTCAATGCTGATGTCTTC 3 11 * 96°C for 15s
* indicates that a biotin tag was added to the end 50°C for 30s
UoO for 90s
U0O for 5 mins
Region amplified: -70 to +2840bp
5' CCGCGGATCCGAATAAAGCGTATAGGTTTA 3 ' 94°C for 3 mins
5' TCGAATTCGCCCAGACTTTGCAGCCTGG 31i vO 4^ 0n for 3 mins
56°C for 3 mins
74°C for 3 mins
74°C for 5 mins
62
2.15 Restriction of DNA
Endonuclease cutting of DNA was typically performed in volumes of between
20 and 100|il. These contained the requisite amount of DNA (usually 1-lOgg)
and the appropriate Promega restriction buffer (Promega, Madison, WI, USA)
at lx concentration. The restriction enzyme (Promega, Madison,WI, USA) was
usually present in a 2-5 fold excess, i.e. 2-5 units per microgram of DNA. The
digests were made up to their final volume with distilled water. The complete
restriction digests were incubated at the recommended temperature (usually
37°C) for 1-3 hours. The products of the reaction were either directly analysed
by agarose gel electrophoresis, or phenol extracted, ethanol precipitated and
dissolved in a suitable volume of TE buffer [lOmM Tris, ImM EDTA pH8] for
future manipulations.
2.16 Conventional Agarose Gel Electrophoresis
Agarose gel electrophoretic analysis of DNA was either performed with TAE
[10X TAE is 40mM Tris-acetate pH7.6, ImM EDTA] or TBE [10X TBE is 0.89M
Tris-borate pH8.3, 20mM EDTA] buffer. The gels were made up by melting the
appropriate amount of agarose (Gibco BRL) in either lx TAE or lx TBE in a
microwave oven. Gels were cast in an appropriate casting tray and once set,
placed in a gel electrophoresis tank (Bethesda Research Laboratories Horizon
20.25 gel tank, Life Technologies, Petersburg, Florida or a Pharmacia GNA-100
minitank) and immersed in the same buffer (either lxTAE or lxTBE) used in
the preparation of the gel. TheDNA samples containing lx tracking dye [30%w /
v glycerol, 0.25%w/v bromophenol blue, 0.25%w/v xylene cyanol] were loaded
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into the wells at one end of the tray and then electrophoresed at between 50V
and 100V for a time, the length of which depended on the size of the DNA
fragments concerned. After completion of electrophoresis, gels were stained in
water containing 50|ig/l ethidium bromide for about an hour. The gels could
be photographed with Polaroid film and UV transillumination (UV Products,
Cambridge).
For RFLP analysis, Metaphor agarose (FMC Bioproducts, supplied by Flowgen,
UK) was used on its merits of discriminating between small fragments ofDNA.
2.17 Size Fractionation of DNA
DNA of a certain size (or range of sizes) was isolated from agarose gels by a
Geneclean kit (Bio 101 Inc, La Jolla, California, USA). The appropriate DNA
band (or range of bands) was located in an ethidium bromide stained gel under
UV transillumination and cut outwith a clean razor blade in as small a volume
of agarose as possible. Gel slices were transferred to Eppendorf tubes, the weight
of the slice determined and 3 volumes of saturated sodium iodide solution
added. These were incubated at 50°C until the gel slice had dissolved. A 5|il
volume of glassmilk was then added and the suspension mixed well and left
on ice for 5 minutes. Tubes were spun in a microfuge for 5 seconds and the
supernatant poured off. The pellets were washed three times in 0.5ml of
Geneclean New Wash Solution (supplied with the kit), centrifuging and
resuspending the pellets each time. After the final washing, all traces of the
wash solution were removed with a Pasteur pipette and the pellets were then
suspended in 5pl distilled water. These were incubated at 50°C for 2-3 minutes,
centrifuged for 30 seconds and the DNA containing supernatant transferred to
a fresh tube. A further 5|il of distilled water was added to the glassmilk pellets
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and the procedure was repeated to give a final DNA containing solution with a
volume of lOgl. This DNA solution could be directly used for further
manipulations.
2.18 Ligation of DNA
Ligations of DNA were typically performed in a final volume of lOgil, or 5|il
when ligating into XZAPII (Stratagene, La Jolla, California). The constituents
of the ligation reactions were an appropriate amount of vector and insert (both
extracted with phenol/ chloroform and ethanol precipitated), ligation buffer
and 0.1 unit of T4 DNA ligase (Gibco BRL) made up to the correct volume with
distilled water. The ligation reactions were incubated for 16 hours at 12°C.
2.19 Creation of a chromosomal library in the vector /CZAPII
The vector, A.ZAPII pre-digested with EcoRl and calf intestinal alkaline
phosphatase (Stratagene, La Jolla, California, USA) in a volume of lpl (lgg)
was added to 3pl EcoRl -digested E.coli chromosomal DNA, 0.5|il 10X T4 DNA
ligase buffer (Gibco,BRL) and 0.5(il T4 DNA ligase (Gibco, BRL). This ligation
mixture was incubated at 12°C overnight.
2.20 Packaging of XZAPII
After ligation of DNA into this vector, packaging of the phage was necessary
prior to infection into the plating cells. To the 5(il ligation mixture (see above),
the two components of the Gigapack II Gold Packaging extract (Stratagene, La
Jolla, California, USA) were added, following the manufacturer's protocol.
Incubation at room temperature for 2 hours proceeded, after which 500|il of
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SM buffer [0.5% (w/v) NaCl, 0.2% (w/v) MgSO^ 5% 1M Tris-HCl pH7.5,
0.01% gelatin] was added alongwith 20|il chloroform. This aliquot of packaged
phage was stored at 4°C until it was used to infect the prepared plating cells
(see section 2.21).
2.21 Preparation of X Plate Lysates
A single colony of E.coli XL-1 BLUE MRF' was inoculated into 50ml LB broth
supplemented with 20mM MgS04 and 20% maltose for 4-6 hours at 37°C. The
culture was then spun down in a benchtop centrifuge at 3000rpm for 10minutes,
after which the brothwas discarded and the pellet resuspended in lOmMMgS04.
The OD600 of the cells was measured and the cells titered with lOmM MgS04 to
an OD600 value of 0.5. These plating cells in a volume of 200gl were added to l(il
of packaged phage particles (see section 2.20). This was allowed to incubate at
37°C for 15 minutes, after which 3ml of Top Agar [LB broth + 0.7% agarose] at
55°C was added and themixture immediately poured onto fresh LB agar plates.
After 10 minutes, the plates were transferred to a 37°C incubator overnight or
until visible lysis had occurred. Since the LZAPII vector contains lacZ, estimation
of the proportion of plaques formed from phages containing inserts to those
which did not, could be accomplished by the addition of 50gl 250mg/l X-gal
and 15jil lOmM IPTG to the top agar. After lysis had occurred, those plaques
formed from phage containing inserts appeared clear, whereas those which
had formed by the re-ligation of the two arms of the vector, appeared blue.
2.22 Titering the phage library
A single colony of E.coli XL-1 BLUE MRF' was inoculated into 50ml LB broth
supplemented with 20mM MgS04 and 20% maltose for 4-6 hours at 37°C. The
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culture was then spun down in a benchtop centrifuge at 3000rpm for 10 minutes,
after which the broth was discarded and the pellet resuspended in lOmMMgSOr
The ODh00 of the cells was measured and the cells titered with lOmM MgS04 to
an ODft00 value of 0.5. These plating cells in a volume of 200pl were added to
various dilutions of packaged phage particles (see 2.20). This was allowed to
incubate at 37°C for 15 minutes, after which 3ml of Top Agar [LB broth + 0.7%
agarose] at 55°C was added and themixture immediately poured onto fresh LB
agar plates. After 10 minutes, the plates were transferred to a 37°C incubator
overnight or until visible lysis had occurred. The number of plaques were
counted and the pfu/ml of the library was determined.
2.23 Preparation of Single Stranded DNA prior to DNA
Sequencing
Sequencing was carried out directly from the PCR fragment with Dynabeads
M-280 (Dynal A.S., N-0212, Oslo, Norway) to separate the strands.A40jil volume
of PCR-amplified DNA was added to 40|il of washed Dynabeads according to
the manufacturer's protocol and the strands subsequently separated.
2.24 DNA Sequencing
A 5gl volume of the single-stranded DNA template attached to the Dynabeads
prepared as above was used routinely in the sequencing reaction which was
carried out with a Sequenase 2.0 kit according to the manufacturer's protocol
with [35S]-dATP (Amersham Life Sciences, UK) radiolabel.
2.25 DNA Sequencing Gel Electrophoresis
DNA sequencing was performed with a Nucleic Acid Sequencing Cell (Bio-
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Rad,Watford, Herts). The glass sequencing gel plates were thoroughly cleaned
with ethanol and distilled water and assembled together with 0.2mm spacers
separating the two plates. The top plate was siliconized with Gel Slick (AT
Biochem, Malvern, Pennsylvania), in order to prevent the gel sticking to both
the plates when the apparatus was disassembled. The gel was prepared as
described by Ausubel et al (1995). For the plug, 20ml of the gel solution was
polymerised by the addition of a lOOjul of a 25% ammonium persulphate solution
and lOOpl TEMED. Immediately, this was poured into the gel casting tray to
form a plug. For each ml of remaining gel solution, lpl of 25% ammonium
persulphate solution and lpl of TEMED was added and the solution poured
carefully between the two plates of the gel apparatus. The flat edge of a shark
toothed comb was pushed between the plates to layer the top of the gel. The gel
was set aside for at least one hour to allow polymerisation. Once set, the comb
was removed and the top of the gel was thoroughly flushed with distilled water.
The sharktooth comb was then replaced with the points downwards just
touching the surface of the gel. The gel was clamped into the sequencing
apparatus and 0.6x TBE solution poured into the top and bottom reservoirs.
The gel was then pre-run at 50W for 1 hour. The gel was ready to be loaded
with the sequencing reactions. The samples were loaded in the order G, A, T
and C immediately after denaturing the DNA by heating the samples to 80°C
for 2 minutes to denature the DNA. Immediately after this incubation, 2-3|il of
each sample were loaded onto the gel. The gel was then electrophoresed at
50W for 2-6 hours, depending on which part of the sequence was to be read.
Once electrophoresis was complete, the glass plates were removed from the
apparatus and the top plate very carefully removed. The bottom platewith the
gel attached was then placed in a fixing bath containing 15% methanol and 5%
acetic acid in water for 30 minutes. The plate and gel were then removed and a
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sheet ofWhatman 3MM paper placed on top of the gel. Even pressure was then
applied and the paper peeled off taking the gel with it. The gel attached to the
paper was covered in SaranWrap and dried in a vacuum gel drier for 1-2 hours
at 80°C. When dry, the gel was placed in an autoradiography cassette
(Amersham Life Sciences, UK) and exposed to Kodak Biomax MR-1 film at
room temperature for 24 hours after which the film was developed at the X-ray
department, Royal Infirmary of Edinburgh.
2.26 Extraction of RNA
Total RNA was extracted by the use of a RNeasy kit (Qiagen, Chatsworth,
California). Potentially contaminating RNases were removed from theworking
area by applying RNase ZAP (Ambion, Austin, Texas, USA) to pipettes and
bench surfaces.
2.27 Electrophoresis of RNA
RNA was electrophoresed in a formaldehyde containing gel. The gel was
prepared by melting an appropriate amount of agarose in water, cooling to
60°C and adding 5x gel buffer [0.2M morpholinopropane sulfonic acid pEI7,
50mM sodium acetate and 5mM EDTApH8) and formaldehyde to give IX and
2.2M final concentrations respectively. The RNA sample in a volume of 9gl
was added to 4pl 5x gel buffer, 7jil formaldehyde and 20|il formamide and
incubated at 65°C for 15 minutes. After chilling on ice and briefly pulsing in a
microcentrifuge, 4pl of sterile-DEPC-treated formaldehyde gel loading buffer
[50% glycerol, ImM EDTApH8,0.25% bromophenol blue, 0.25% xylene cyanol
FF] was added. Each mixture was divided between two wells on opposite
halves of the gel, as by loading in duplicate, one half of the gel could be blotted
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(see 2.28) and the other half could be stained with ethidium bromide. The
samples were electrophoresed in lx formaldehyde gel running buffer for 3 to 4
hours at 100V. After electrophoresis, half of the RNA gel was soaked in 0.5M
ammonium acetate for 20 minutes in a RNase-free glass dish. This solution
was then poured off and replaced with 0.5pg/ml ethidium bromide in 0.5M
ammonium acetate and stained for 40 minutes. The gel was destained in 0.5M
ammonium acetate for one hour and the RNA fragments visualised on a UV
transilluminator.
2.28 Preparation of Northern Blots
The half the gel that was not stained with ethidium bromide was thoroughly
washed in DEPC-treated water before soaking in 5mM sodium hydroxide for
30 minutes. This solution was replaced with 20xSSC [3M sodium chloride,
0.3M trisodium citrate adjusted to pH7with 1M HC1] and soaked for 45 minutes.
The gel was then transferred to a RNase free glass baking dish and any unused
areas of the gel trimmed away with a razor blade. The procedure then that
followed that described in Ausubel et al, (1995).
2.29 Plaque Lifts
The E.coli genomic library prepared in ^.ZAP was screened by carrying out
plaque lifts. Plating cells were prepared as described before and infected with
an appropriate volume of phage. The phage lysates were plated out on 24.3cm
by 24.3cm Petri dishes and incubated overnight. The plates were then chilled
for two hours at 4°C to prevent top agar from sticking to Hybond N+ filter
(Amersham Life Sciences, USA). The filter was applied to the surface of the
Petri dish and the transfer allowed to proceed for two minutes. The filter was
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then denatured after lifting by submerging in denaturing solution [1.5M NaCl,
0.5M NaOH] for 2 minutes, neutralised for 5 minutes in neutralising solution
[1.5M NaCl, 0.5M Tris-HCl pH8], rinsed for 30 seconds in rinsing solution [0.2M
Tris-HCl pH7.5,2X SSC] before blotting briefly onWhatman 3MM filter paper.
After baking the filter for 2 hours at 80°C, it was hybridised as explained in
2.30.
2.30 Hybridisation of Plaque Lift Filters
Hybridisation was carried out by the use of a ECL 3' oligo labelling kit
(Amersham, Bucks) following the manufacturer's protocol. The probe used
was a oligonucleotide specific to gyrA (described in Table 2.4) that had been
previously labelled with fluorescein.
2.31 Hybridisation of Northern blot filters
Hybridisation of Northern blot filters was carried out following the protocol
detailed inAusubel et al, (1995). The probe used was either a fluorescein-labelled
oligonucleotide specific to gyrA (as described in 2.30) or a 620bp PCR-amplified
fragment ofgyrA (described in Table 2.4) into which 32P-dCTP (Amersham Life
Sciences, UK) had been incorporated by random prime labelling. 20ng of
purified DNA was made up to 24|ll1 in distilled water and boiled for 3 minutes.
Themixture was placed at 37°C and added to 10pl OLB buffer [OLB buffer was
made from the following components: Solution O (1.25M Tris-HCl pH7.5,
0.125MMgCl), SolutionA (1ml Solution 0,18pl (3-mercaptoethanol), Solution
B (2M Hepes, pH 6.6) and Solution C (Hexadeoxyribonucleotides (Pharmacia)
at 4.5mg/ml). Solutions A, B and C were mixed at a ratio of 100: 250:150 and
the OLB mix was stored at -20°C]. To this, 2|il BSA (lOmg/ml), lpl of each of
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dATP, dGTP and dTTP (stock solutions of lOmM), lOgl ?2P-dCTP and 1ml
Klenow polymerase (Gibco BRL) was added. The reaction was placed at 19°C
for 30 minutes then at 30°C for 30 minutes before termination by the addition
of 150pl OLB stop buffer [25mM NaCl, 25mM Tris-HCl pH7.5, 5mM EDTA, 1%
SDS). The DNAwas purified through a Sephadex G-50 spun column, the 200gl
solution collected being immediately useable as a probe. The blot was pre-
hybridised in 25ml of pre-hybridisation buffer [5XSSC, 0.5% SDS, lOOmg/ml
denatured, fragmented salmon sperm DNA (Genebloc, MBI Fermantas), 50X
Denhardt's reagent (5g Ficoll, 5g polyvinylpyrrolidone, 5g BSA and water to
500ml)] for 2 hours at 68°C after which this solution was replaced with 25ml
hybridisation buffer [pre-hybridisation buffer + 9% dextran sulphate]. The32P-
labelled probe (prepared as described in 2.31) was denatured by heating the
probe at 96°C for 5 minutes before rapidly chilling on ice and adding to the
hybridisation mix. This was incubated overnight at 68°C. The filter was washed
of excess probe and non-specific hybrids by 3 washes of 30 minutes at 55°C in
RNA wash buffer [0.1% SDS, 5mM Tris-HCl pH7.5, 25mM NaCl and ImM
EDTA]. The filter was then air dried for 3 minutes and sealed into a thin plastic
bag ready for autoradiography. Filters were placed between two Ilford "plus-
X" intensifying screens in an autoradiographic cassette with a sheet of X-ray
film and stored at -70°C until development.
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3 Detection of mutations in the QRDR of
gyrA in quinolone-resistant bacteria
3.1 Introduction
Since the introduction of quinolone drugs such as ciprofloxacin, ofloxacin and
nalidixic acid for the treatment of Enterobacteriaceae infections, there have been
numerous reports of clinical isolates showing a reduced susceptibility to these
drugs (Wiedemann and Heisig, 1994). By far themost heavily reported type of
mutation causing this decreased susceptibility is a change in the gyrA gene
(Reece and Maxwell, 1991b), occurring in the quinolone-resistance determining
region (QRDR). Such mutations can be identified by various molecular
techniques and subsequently correlated to a change in theminimum inhibitory
concentration (MIC) of the cell for a particular drug compared to a sensitive
isolate.
73
Mini-surveys were carried out on four separate groups of clinical
Enterobacteriaceae isolates and DNA sequencing was performed to detect
mutations that had arisen in response to challenge with the quinolone drugs.
The sequencing results were confirmed by showing that a change in the
restriction pattern of this region of the QRDRhad also occurred. The four groups
of clinical isolates studied were as follows:
4 Salmonella typhimurium isolates from Vellore, India, collected in 1984
4 Salmonella typhi isolates from Vellore, India, collected during the period
1992 to 1994
4 Salmonella species (various) from a variety of British hospitals collected
during the period 1989 to 1992
4 Escherichia coli isolates from a variety of British hospitals collected during
the period 1989 to 1992
3.2 DNA Sequencing of the QRDR of gyrA of
S.typhimurium NCTC 5710
At the onset of this work, a published DNA sequence of any part of the gyrA
gene of S.typhimurium was unavailable. Consequently, part of the gyrA gene of
the standard sensitive isolate S.typhimurium NCTC5710 was sequenced so that
any point mutations found in theDNAof the clinical isolates could be compared
to the sensitive NCTC isolate. This NCTC strain was sensitive to ciprofloxacin,
ofloxacin and nalidixic acid; the MICs of each of these antibioticswere 0.008mg/
1,0.064mg/l and 2mg/l respectively. A620bp fragment incorporating the QRDR
of the enzyme was amplified by the polymerase chain reaction from
chromosomal DNA and both DNA strands consequently sequenced. A DNA
sequence 486 base pairs long was achieved and is shown in Figure 3.1 along
with the predicted amino acid sequence.
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Figure 3.1: The DNA and predicted amino acid sequence of S. typhimurium
gyrA (nucleotides 72 to 557, amino acids 24 to 185). The nucleotide sequence of
the gyrA gene is presented from the 5' (left) to 3' (right) end. The deduced amino
acid sequence is given below the DNA sequence. Amino acid positions are
numbered, starting at codon 24. Deviations from the nucleotide sequence of
E.coli (Yoshida et al, 1988) are highlighted in bold.
TAT GCG ATG TCG GTC ATT GTT GGC CGT GCG CTG CCA GAT GTC CGA GAT GGC CTG
Tyr Ala Met Ser Val lie Val Gly Arg Ala Leu Pro Asp Val Arg Asp Gly Leu
25 30 35 40
AAG CCG GTA CAC CGT CGC GTA CTT TAC GCC ATG AAC GTA TTG GGC AAT GAC TGG
Lys Pro Val His Arg Arg Val Leu Tyr Ala Met Asn Val Leu Gly Asn Asp Trp
45 50 55
AAC AAA GCC TAT AAA AAA TCT GCC CGT GTC GTT GGT GAC GTA ATC GGT AAA TAC
Asn Lys Ala Tyr Lys Lys Ser Ala Arg Val Val Gly Asp Val lie Gly Lys Tyr
60 65 70 75
CAT CCC CAC GGC GAT TCC GCA GTG TAT GAC ACC ATC GTT CGT ATG GCG CAG CCA
His Pro His Gly Asp Ser Ala Val Tyr Asp Thr lie Val Arg Met Ala Gin Pro
80 85 90 95
TTC TCG CTG CGT TAC ATG CTG GTG GAT GGT CAG GGT AAC TTC GGT TCT ATT GAC
Phe Ser Leu Arg Tyr Met Leu Val Asp Gly Gin Gly Asn Phe Gly Ser lie Asp
100 105 110
GGC GAC TCC GCG GCA GCA ATG CGT TAT ACG GAG ATC CGT CTT GCG AAA ATC GCC
Gly Asp Ser Ala Ala Ala Met Arg Tyr Thr Glu lie Arg Leu Ala Lys lie Ala
115 120 125 130
CAC GAA CTG ATG GCC GAT CTC GAA AAA GAG ACG GTC GAT TTC GTG GAT AAC TAT
His Glu Leu Met Ala Asp Leu Glu Lys Glu Thr Val Asp Phe Val Asp Asn Tyr
135 140 145
GAC GGT ACG GAA AAA ATT CCG GAC GTC ATG CCG ACC AAA ATT CCG AAT CTG CTG
Asp Gly Thr Glu Lys lie Pro Asp Val Met Pro Thr Lys lie Pro Asn Leu Leu
150 155 160 165
GTG AAC GGT TCT TCC GGT ATC GCA GTA GGT ATG GCA ACG AAT ATC CCG CCG CAC
Val Asn Gly Ser Ser Gly lie Ala Val Gly Met Ala Thr Asn lie Pro Pro His
170 175 180 185
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The nucleotide sequence of this region was found to bear an overall amino acid
identity of 100% with the corresponding region of E. coli GyrA (Yoshida et al,
1988). The homology of S. typhimurium with E. coli at the nucleotide level was
found to be 94%. In this region of 486 nucleotides, 27 changes were found
compared to E.coli, all of which occur in the third position of the codon and are
synonymous. The amino acid sequence of this region ofgyrA ofS. typhimurium
was compared to that of E. coli, Staphylococcus aureus and Bacillus subtilus as
shown in Figure 3.2.
Figure 3.2: Alignment of the amino acid sequences derived from the region of
the nucleotide sequence between bases 72 and 557 of the gyrA genes (amino
acids 24 to 185) of Salmonella typhimurium, Escherichia coli (Yoshida et al, 1988),
Staphylococcus aureus (Sreedharan et al, 1990) and Bacillus subtilis (Moriya,


















3.3 The Effect of Mutating S.typhimurium
NCTC5710 to a Higher Level of Ciprofloxacin
Resistance on the Sequence of gyrA
This ciprofloxacin-sensitive strainwas then selected for ciprofloxacin resistance
by daily inoculation into broth containing a sub-inhibitory concentration of
ciprofloxacin until the MIC reached 0.512mg/l/ a 64-fold increase. Although
ofloxacin and nalidixic acid were not used in this selection process, the MICs of
these antibiotics increased to 2mg/l and 256mg/l respectively.
S. typhimurium NCTC5710, mutated to a 64-fold higher level of ciprofloxacin
resistance was found to have undergone a G to T transition at the first position
of codon number 87, resulting in the substitution of a tyrosine residue for the
original aspartic acid. This is in keeping with the recent proposal of Yonezawa
et al (1995b) that a quinolone resistant phenotype is exhibited on the conversion
of aspartate at position 87 to a non-acidic amino acid such as tyrosine. This is
only the second report of the substitution of aspartate-87by tyrosine in response
to a higher level of ciprofloxacin resistance, the first was been reported in a
ciprofloxacin resistant clinical isolate of Pseudomonas aeruginosa (Kureishi et al,
1994). Similar changes of aspartate-88 to tyrosine in Haemophilus influenzae
(Georgiou et al, 1996)and aspartate-91 to tyrosine in Helicobacter pylori (Moore
et al, 1996) have also been reported.
In the same way, the gyrA DNA sequences of ten of the Indian S. typhimurium
isolates were investigated.
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3.4 Investigating the QRDR of gyrA of the Multi-
Resistant Clinical Isolates of S. typhimurium from
Vellore, India
One hundred and one clinical isolates of S. typhimurium were collected from
Vellore, India in 1987. TheMICs of these strains were measured and a number
of those showing either a relatively higher resistance or in one case, a higher
sensitivity to ciprofloxacin, were investigated further. The average MIC of
ciprofloxacin, ofloxacin and nalidixic acid for these 101 strains were 0.016mgl,
0.064mg/l and 4.0mg/l respectively. Ten strains were investigated further as
described in sections 3.4.1 -3.4.2.
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3.4.1 DNA Sequencing of the QRDR of the gyrA gene of the S.
typhimurium strains isolated from Vellore, India
A 620bp fragment incorporating the QRDR of the enzyme was amplified by
the polymerase chain reaction from chromosomalDNA and both DNA strands
consequently sequenced. The nucleotide changes in the QRDR of gyrA found
as a consequence of DNA sequencing are shown in Table 3.1.
Table 3.1: Minimum Inhibitory Concentrations (MIC) of the investigated
Salmonella typhimurium strains from Vellore, India along with any base pair
changes found as a consequence ofDNA sequencing. The base change resulting
in an amino acid substitution is highlighted in bold and underlined.
STRAIN MICs (mg/L) Nucleotide Amino acid
Ciprofloxacin Ofloxacin Nalidixic acid change* change
VI13 0.128 0.512 256 GAC—>GGC Asp-87—>Gly
VII6 0.128 0.512 128 GAC—>AAC Asp-87—>Asn
VI253 0.256 0.512 256 TCC—>TTC Ser-83 —>Phe
GAC->AAC Asp-87—»Asn
VI258 0.064 0.064 2 NO CHANGE NO CHANGE
VI264 0.128 0.512 256 GAC—>GGC Asp-87—>Gly
VI325 0.128 0.512 128 GAC—>GGC Asp-87—>Gly
VI343 0.128 0.512 128 GAC—>AAC Asp-87—>Asn
VI358 0.008 0.064 4 NO CHANGE NO CHANGE
VI367 0.128 0.256 128 GAC—>GGC Asp-87—>Gly
VI385 0.064 0.256 128 GAC—>GGC Asp-87—>Gly
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* Note that the first codon for each pair is the codon sequence of the NCTC and
clinical sensitive isolates and not the sequence of the codon before mutation to
quinolone resistance. It is possible that the pre-mutation sequence of codon 83
of the parent strain is different to that above.
Various mutations were found in the QRDR of those strains possessing higher
MICs. Mutations such as aspartate-87 to glycine, aspartate-87 to asparagine
and serine-83 to phenylalanine in the QRDR seemed to be, at least, partly
responsible for the decreased susceptibilities for ciprofloxacin, ofloxacin and
nalidixic acid. In strains VI13, VT264, VT325, VI367 and VI385, the acidic aspartate
residue was substituted by a neutral non-polar glycine residue and in strains
VI16, VI253 and VI343 the same aspartate residue became asparagine, a neutral
polar amino acid. Again, this correlates with the hypothesis proposed by
Yonezawa et al (1995b) that the substitution of an acidic amino acid at position
87with a non-acidic amino acid results in a decreased susceptibility to quinolone
drugs. In strain VI253, serine-83, a neutral polar amino acid was substituted by
phenylalanine, a neutral non-polar hydrophobic amino acid. Again this agrees
with the hypothesis ofYonezawa et al (1995a) that the 83rd amino acid has to be
hydrophobic to express the quinolone-resistance phenotype. The fact that strain
VI258 (MIC of ciprofloxacin 0.064mg/l) has no change in its nucleotide sequence
despite requiring eight times as much ciprofloxacin to inhibit its growth
compared to the NCTC strain (MIC of ciprofloxacin 0.008mg/l) suggests that
the decreased susceptibility of VI258 must be as a result of a change occurring
somewhere other than in gyrA. This could possibly be a change in outer
membrane proteins, efflux mechanisms or in gyrB or parC (see later). It is
interesting that strain VI385 (MIC of ciprofloxacin 0.064mg/l) was found to
have a change in the nucleotide sequence ofgyrA resulting in aspartate-87 being
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replaced with glycine. Although VI258 and VI385 have similar susceptibility
levels to ciprofloxacin, it is apparent that their resistancemechanismmust differ
since the measured MICs of ofloxacin and nalidixic acid are very different
between the two strains. It is possible that the level of resistance conferred
upon the S. typhimurium strains by a change in gyrAmodifying aspartate-87 to
glycine is very similar to that resulting from a change in gyrA modifying
aspartate-87 to asparagine. This conclusion was reached on the basis that all
the strains but one that had either a mutation in gyrA consistently had aMIC of
ciprofloxacin of 0.128mg/l. The one strain that had a MIC above 0.128mg/l,
strain VI253, was found to have not one but two mutations: aspartate-87 to
asparagine and serine-83 to phenylalanine. Therefore the combination of a
mutation at serine-83 and aspartate-87 results in the MIC of the cell raising
above 0.128mg/l.
3.4.2 Restriction Fragment Length Polymorphisms (RFLPS) of the
QRDR of gyrA of the Salmonella typhimurium Clinical Isolates
Restriction Fragment Length Polymorphisms (RFLPS) were carried out on the
QRDR of the Salmonella typhimurium clinical isolates with the restriction
endonucleaseHinfl. As a result of certain common gyrAmutations, for example
some found in E. coli (Fisher et al, 1989), often causing the abolition of a Hinfl
restriction site in gyrA occurringwithin a region of the enzyme centred around
serine-83, Hinfl restriction was used as a screen for amino acid substitutions in
the QRDR. The sequence recognised and cleaved by this enzyme is G/ANTC,
thus a gyrA PCR fragment of S. typhimurium amplified from a strain with no
amino acid substitution at serine-83 (nucleotide sequence encoding amino acids
82 and 83 being GATTCC) would be cleaved by the enzyme whereas a gyrA
PCR fragment amplified from a quinolone-resistant strain with a mutation at
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serine-83 (replaced by, for example, phenylalanine) would not be cut since this
would change the nucleotide sequence at this area to GATTTC. In quinolone-
sensitive S. typhimurium, the DNA sequence encoding these two amino acids is
GATTCC.
As can be seen in Figure 3.3, the gyrA PCR fragment amplified from strain
VI253 shows a different restriction pattern from all the other strains by virtue
of its point mutation at serine-83 which abolishes the Hinfl site. The enzyme
Hinfl cuts the amplified 620bp fragment of the wild-type S. typhimnrium gyrA
three times as shown in Figure 3.4. This results in the digestion of the fragment
into four sections of lengths 246bp, 99bp, 149bp and 126bp. Since the PCR
fragments from VI13, VI16, VI258, VI264, VI325, VI343, VI358, VI367 and VI385
do not have a mutation at serine-83, they followed the pattern of the restriction
of thewild-type fragment. However, the presence of a serine-83 to phenylalanine
substitution in the gyrA gene of S. typhimurium VI253 removed theHinfl site in
the codons for amino acids 82 and 83, resulting in the generation of only three
fragments of lengths 345bp, 149bp and 126bp.
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Figure 3.3: Restriction fragment length polymorphisms in the amplified 620bp
section of gyrA in S. typhimurium strains sensitive or with a decreased
susceptibility to ciprofloxacin. Lanes 1 to 12 inclusive: PCR fragments have
been restricted with Hinfl.
1 23 45 6 78 9 10 11 12 M
Lanes: 1, VI13; 2, VI16; 3, VI253; 4, VI258; 5, VI264; 6, VI325; 7, VI343; 8, VI358;
9, VI367; 10, VI385; 11, S. typhimurium NCTC5710 (ciprofloxacin sensitive); 12,
S. typhimurium NCTC5710 (mutated to MIC of 0.512mg/l, see section 3.3); M,
Molecular weight markers of sizes 251bp, 114bp and 69bp as shown to the
right of the gel. Fragment sizes of the restricted DNA are indicated in base
pairs to the left of the gel.
Figure 3.4: Diagrammatic representation of the Hinfl restriction sites in the
sequenced region of gyrA of S. typhimurium. The restriction map is the same
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3.5 Investigating the QRDR of gyrA of the Multi-
Resistant Clinical Isolates of S. typhi from
Vellore, India
3.5.1 Levels of Resistance to the Quinolone Drugs
Fifteen S. typhi strains isolated in the Christian Medical Centre, Vellore, India
were examined and compared throughout with sensitive Salmonella spp. control
strains. TheMICs of ciprofloxacin, ofloxacin and nalidixic acid were determined
as shown in Table 3.2. Twelve out of 15 of the Indian isolates were found to
have MICs of ciprofloxacin of 0.256mg/l, a level considerably higher than
expected. The three S. typhi strains which were relatively sensitive to
ciprofloxacin were also sensitive to ofloxacin and nalidixic acid. Similarly the
isolates showing decreased susceptibilities to ciprofloxacin had high levels of
resistance to these two other drugs. It is interesting that the three remaining S.
typhi strains sensitive to ciprofloxacin were isolated from patients in 1992 and
1993 whereas 11 of the 12 isolates which were markedly more resistant to this
drug were isolated in 1994. Only one of the isolates (ST5), which was isolated
in 1992 had a decreased susceptibility to quinolone drugs and investigating the
cause of this revealed that the acquisition of quinolone resistance must result
from a totally different mutation compared to the other resistant isolates (see
later).
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3.5.2 DNA Sequencing of the QRDR of the gyrA gene of S. typhi
strains isolated from Vellore, India
A 620 bp fragment was amplified from the gyrA gene of each of the S. typhi
strains as before and the double-stranded DNA separated into single strands
by the use of Dynabeads. The nucleotide sequences of the three ciprofloxacin-
sensitive S. typhi strains (ST3, ST7 and ST12) and ciprofloxacin-sensitive S.
typhimurium were found to be identical. A ciprofloxacin-sensitive strain of S.
arizoniae was also used as a sensitive control strain for sequence comparisons
since a NCTC S. typhi could not be obtained. The nucleotide sequence of
ciprofloxacin-sensitive S. typhi along with the predicted amino acid sequence
is identical to that of S. typhimurium as shown in Figure 3.1. Deviations from
the amino acid sequence of both ciprofloxacin-sensitive S. typhi and S.
typhimurium were found in all of the twelve isolates with decreased
susceptibilities to ciprofloxacin as shown in Table 3.2.
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Table 3.2: Minimum Inhibitory Concentrations (MIC) of the investigated S.typhi
strains from Vellore, India along with any base pair changes found as a
consequence of DNA sequencing. The base change resulting in an amino acid
substitution is highlighted in bold and underlined.
ISOLATE MICs(mg/L) Nucleotide"" Amino acid
Ciprofloxacin Ofloxacin Nalidixic acid changes change
ST1 0.256 0.512 256 TCC —>TTC Ser-83—> Phe
ST2 0.256 0.512 256 TCC ->TTC Ser-83-^ Phe
ST3 0.016 0.064 4 NO CHANGE NO CHANGE
ST4 0.256 0.512 256 TCC —>TTC Ser-83 —>Phe
ST5 0.256 0.512 256 NO CHANGE NO CHANGE
ST6 0.256 0.512 256 TCC —>TTC Ser-83 —>Phe
GAC-> TAC Asp-87 —>Tyr
ST7 0.016 0.032 4 NO CHANGE NO CHANGE
ST8 0.256 0.512 256 TCC —>TTC Ser-83 —>Phe
ST9 0.256 0.512 256 TCC —>TTC Ser-83 —>Phe
ST10 0.256 0.512 256 GAC —>TAC Asp-87 -^Tyr
ST11 0.256 0.512 256 TCC —>TTC Ser-83—>Phe
ST12 0.016 0.032 4 NO CHANGE NO CHANGE
ST13 0.256 0.512 >256 TCC -»TTC Ser-83 —»Phe
ST14 0.256 0.512 >256 TCC —>TTC Ser-83 ^Phe
ST15 0.256 0.512 >256 TCC -^TTC Ser-83 —>Phe
* Note that the first codon for each pair is the codon sequence of the NCTC and
clinical sensitive isolates and not the sequence of the codon before mutation to
quinolone resistance. It is possible that the pre-mutation sequence of codon 83
of the parent strain is different to that above.
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In strains ST1, ST2, ST4, ST8, ST9, ST11, ST13, ST14, ST15 a single substitution
of serine at position 83 to phenylalanine was found to have occurred. Again
this correlates with the hypothesis that changing serine-83 to a hydrophobic
amino acid results in the expression of a quinolone-resistant phenotype
(Yonezawa et al, 1995a). Strains ST6 and ST10 were found to carry different
mutations, namely a double mutation of serine-83 to phenylalanine and
aspartate-87 to tyrosine in ST6while ST10 showed a singlemutation of aspartate-
87 to tyrosine. However a different type of quinolone-resistancemutation was
concluded to be the cause of the high quinolone MICs in strain ST5. On
sequencing the QRDR of this strain, no amino acid substitutions were found.
Quinolone-resistance in ST5 is thus likely to be attributed to either an outer
membrane protein mutation or amutation affecting efflux or perhaps amutation
in gyrB or parC. It is interesting that ST5 was isolated in 1992 whereas all the
other quinolone-resistant isolates with mutations in gyrA were isolated two
years later in 1994.
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3.5.3 Restriction Fragment Length Polymorphisms (RFLPS) of the
QRDR of gyrA of the Salmonella typhi Clinical Isolates
The amplified PCR-products were restricted withHinfl as described in 3.4.2 in
order to confirm the point mutations around serine-83. As can be seen in Figure
3.5, the gyrA PCR fragments amplified from strains ST3, ST5, ST7, ST10, ST12
and ST16 show a different restriction pattern from all the other strains since
there is no pointmutation at serine-83 which leaves the Hinfl site. The enzyme
Hinfl cuts the amplified 620bp fragment of the wild-type S. typhi gyrA three
times as shown in Figure 3.4. This results in the digestion of the fragment into
four sections of lengths 246bp, 99bp, 149bp and 126bp. Since the PCR fragments
from ST1, ST2, ST4, ST6, ST8, ST9, ST11, ST 13, ST14 and ST15 do have amutation
at serine-83, thus abolishing the Hinfl site, the PCR product is only cut into
three fragments of lengths 345bp, 149bp and 126bp.
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Figure 3.5: Restriction fragment length polymorphisms in the amplified 620bp
section of gyrA in S. typhi strains sensitive or with a decreased susceptibility to
ciprofloxacin. Lanes 1 to 17 inclusive: PCR fragments have been restricted with
Hinfl.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Lanes: 1, ST1;2, ST2;3, ST3;4, ST4;5, ST5; 6, ST6;7, ST7;8, ST8;9, ST9; 10,
ST10; 11, ST11; 12, ST12; 13, ST13; 14, ST14; 15, ST15; 16, Ciprofloxacin-
sensitive Salmonella typhimurium NCTC5710;. 17, Molecular weight markers of
sizes 251bp, 114bp and 69bp as shown to the right of the gel. Fragment sizes of
the restricted DNA are indicated in base pairs to the left of the gel.
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3.6 Investigating the QRDR-containing region of
gyrA of multi-resistant clinical isolates of
Salmonella from British hospitals
Ten clinical isolates of various Salmonella species were received from a variety
of British hospitals during the period 1989 to 1992. The MICs of ciprofloxacin,
ofloxacin and nalidixic acid for the strains weremeasured and are displayed in
Table 3.3.
The strains were investigated further by sequencing the QRDR of the gyrA gene
and confirming these results by Hinfi digestion as before as described in sections
3.6.1 -3.6.2.
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3.6.1 DNA Sequencing of theQRDR of thegyrA gene of Salmonella
strains isolated from British hospitals
Part of the gyrA gene of each was sequenced as before and any point mutations
that were detected in the QRDR are shown alongside the MIC results in Table
3.3.
Table 3.3: Minimum Inhibitory Concentrations (MIC) of the investigated
Salmonella strains along with any base pair changes found as a consequence of
DNA sequencing. The base change resulting in an amino acid substitution is
highlighted in bold and underlined.
STRAIN MICs mg/1 Nucleotide5'' Amino Acid
Ciprofloxacin Ofloxacin Nalidixic Acid Change Change
CIP179 0.064 0.512 4 NOCHANGE NO CHANGE
CIP182 0.004 0.032 4 NO CHANGE NO CHANGE
CIP184 1 2 >256 TCC—»TTC Ser-83—>Phe
CIP185 1 2 >256 TCC—>TTC Ser-83-oPhe
CIP247 0.064 0.128 8 NO CHANGE NO CHANGE
CIP248 0.256 0.512 >256 TCC—»TTC Ser-83^Phe
* Note that the first codon for each pair is the codon sequence of the NCTC and
clinical sensitive isolates and not the sequence of the codon before mutation to
quinolone resistance. It is possible that the pre-mutation sequence of codon 83
of the parent strain is different to that above.
Isolates CIP179 and CIP184, CIP182 and CIP185, CIP247 and CIP248 are paired
strainswith CIP179, CIP182 and CIP247 being isolated pre-therapy and CIP184,
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CIP185 and CIP248 being isolated post-therapy. It is interesting that during
therapy each of the three isolates became less susceptible to the action of
ciprofloxacin, ofloxacin and nalidixic acid which could be correlated to a
mutation at serine-83 of gyrA changing serine-83 to phenylalanine.
3.6.2 Restriction Fragment Length Polymorphisms (RFLPS) of the
QRDR of gyrA of the Salmonella Clinical Isolates
The amplified PCR-products were restricted with Hinfl as before in order to
confirm the detected changes around serine-83. As can be seen in Figure 3.6,
the gyrA PCR fragments amplified from strains CIP179, CIP182 and CIP247
show a different restriction pattern from all their post-therapy partners since
there is no point mutation at serine-83 which leaves the Hinfl site. As a result
the PCR fragment is digested into four sections of lengths 246bp, 99bp, 149bp
and 126bp. Since the PCR fragments from the post-therapy isolates CIP184,
CIP185 and CIP248 do have a mutation at serine-83, thus abolishing the Hinfl
site, the PCR product is only cut into three fragments of lengths 345bp, 149bp
and 126bp.
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Figure 3.6: Restriction fragment length polymorphisms in the amplified 620bp
section of gyrA in the clinical Salmonella strains sensitive or with a decreased
susceptibility to ciprofloxacin. Lanes 2 to 7 inclusive: PCR fragments have been
restricted with HinfL.
Lanes: 1, pUC18 plasmidDNA digested with EcoRl and Hinfl (sizes of fragments
1419bp, 517bp, 396bp, 214bp, 75bp and 65bp as shown to the left of the gel); 2,
CIP179; 3, CIP182; 4, CIP184; 5, CIP185; 6, CIP247; 7, CIP248. Fragment
sizes of the restricted DNA are indicated in base pairs to the right of the gel.
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3.7 Investigating the QRDR-containing region of
gyrA of multi-resistant clinical isolates of E. coli
Ten clinical isolates of Escherichia coli were received from a variety of British
hospitals during the period 1989 to 1992. The MICs of ciprofloxacin, ofloxacin
and nalidixic acid for the E. coli isolates were measured and are displayed in
Table 3.4. Part of the gyrA gene of each was sequenced as before and any point
mutations that were detected in theQRDR are shown alongside the MIC results
in Table 3.4.
The strains were investigated further by sequencing the QRDR of gyrA and
confirming the results by digestion of the PCR product as described in sections
3.7.1 -3.7.2.
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3.7.1 DNA Sequencing of the QRDR of the clinical isolates of E.
coli
Table 3.4: Minimum Inhibitory Concentrations (MIC) of the investigated E.
coli strains along with any base pair changes found as a consequence of DNA
sequencing. The base change resulting in an amino acid substitution is
highlighted in bold and underlined.
STRAIN MICs (mg/1) Nucleotide* Amino acid
Ciprofloxacin Ofloxacin Nalidixic acid Change Change
256 TCG —>T!G Ser83 -ALeu
GAC—> 1AC Asp87 -ATyr
TCG —>TTG Ser83 —>Leu
GAC —>AAC Asp87—>Asn
CIP108 4 8
CIP109 8 8 256
CIP262 0.256 0.512 256
CIP65 1 1 256
CIP113 2 4 256
CIP223 2 4 256
CIP218 4 4 256
CIP261 16 16 256
CIP66 0.008 0.032 2









TCG —>TTC Ser83 ->Phe
NO CHANGE NO CHANGE
NO CHANGE NO CHANGE
* Note that the first codon for each pair is the codon sequence of the NCTC and
clinical sensitive isolates and not the sequence of the codon before mutation to
quinolone resistance. It is possible that the pre-mutation sequence of codon 83
of the parent strain is different to that above.
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Compared to the quinolone-sensitive isolates CIP66 and CIP110, the quinolone-
resistant isolates showed a variety ofmutations in the gyrA gene such as serine-
83 to leucine in isolates CIP262, CIP65, CIP113, CIP223 and CIP218, and serine-
83 to phenylalanine in isolate CIP261. High level quinolone resistance in isolates
CIP108 and CIP109 (MICs of ciprofloxacin 4mg/l and 8mg/l respectively) was
found to be as a result of two mutations in gyrA as shown in Table 3.4 although
there is the possibility that additional mutations could also be present.
3.7.2 Restriction Fragment Length Polymorphisms (RFLPS) of the
QRDR of gyrA of the E. coli Clinical Isolates
The amplified PCR products were restricted with Hinfl as before to confirm the
sequencing results.
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Figure 3.7: Restriction fragment length polymorphisms in the amplified 620bp
section of gyrA in the clinical E.coli strains sensitive or with a decreased
susceptibility to ciprofloxacin. Lanes 1 to 10 inclusive: PCR fragments have
been restricted with Hinfl.
Lanes: 1, CIP65; 2, CIP66; 3, CIP109; 4, CIP110; 5, CIP108; 6, CIP113; 7, CIP218;
8, CIP223; 9, CIP261; 10,CIP262; 11, pUC18 plasmid DNA restricted with EcoRl
and Hinfl (sizes of fragments 1419bp, 517bp, 396bp, 214bp, 75bp and 65bp as
shown to the left of the gel). Fragment sizes of the restricted DNA are indicated
in base pairs to the right of the gel.
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A Hinfl restriction map of this amplified region is shown in Figure 3.8.
Correlating with the fact that isolates CIP108, CIP109, CIP262, CIP65, CIP113,
CIP223, CIP218 and CIP261 showed a change from serine-83 at the QRDR of
gyrA, the PCR products amplified from these strains were cut by Hinfl once
resulting in the production of two fragments of lengths 345bp and 275bp as
shown in Figure 3.7. Likewise the fact that strains 66 and 110 showed no change
at serine-83 was confirmed by the generation of three fragments on Hinfl
digestion.
Figure 3.8: Diagrammatic representation of the Hinfl restriction sites in the
amplified region of gyrA of E.coli
54 Sac I 307 Acc I
54 HgiA I 237 Sty I
54 Ecl136 I 237 Nco I 494 BspM I
54 Bsp1286 I 173 Bsr I 263 Pvu I 469 Aha II
54 Ban II 163 Rma I 244 Hinfl' 469 Aat II
40 Mnl I 139 BstU I 237 Dsa I 465 BspE I 601 Bbs I
31 Hindi 120 BsiY I 237 BsaJ I 421 BsmA I 561 PshA I
27 Age I 117 Hae I 231 BstX I 343 Hinfl' 457 Xmn I 546 Fau I
ILLJ U I U LU I I I I LU I II 1—.
E coli GyrA l-620bp 620 base pairs Unique Sites
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3.8 Discussion
All the strains investigated, except one, which showed a decreased
susceptibility to quinolone drugs was shown to have incorporated an amino
acid mutation at either serine-83 and/or aspartate-87 of the QRDR of gyrA.
The importance of these two amino acids of the QRDR has been investigated
previously. The conversion of serine-83 to a hydrophobic amino acid has the
effect of making the cell less susceptible to the action of quinolone drugs
(Yonezawa et al, 1995a), presumably byweakening the interactionbetween DNA
gyrase and the quinolone-DNA complex (Oram and Fisher, 1991). Likewise,
changing aspartate-87 to a non-negatively charged amino acid results in a
decreased susceptibility to quinolone drugs. Therefore, serine-83 and aspartate-
87must be key residues involved in the interaction betweenDNA gyrase, DNA
and the quinolone drug . Indeed, this has been speculated previously (Hallett
and Maxwell, 1991). It has been postulated that this region of the protein is
involved in the action of quinolone drugs with its close contact to the site of
DNA attachment at tyrosine-122. All of the changes above could modify the
strength ofbinding between the quinolone and gyrase either by the presence of
differently charged and sized residues making this site of DNA breakage and
reunion less accessible, or through loss of the hydrogen bonding capabilities of
serine-83. Clinical resistance to the quinolone drugs resulting from a mutated
GyrA protein seems to almost universally arise from a mutation in this stretch
of the enzyme known as the quinolone resistance determining region (QRDR)
(Yoshida et al, 1990).
Quinolone-resistant clinical isolates of E. coli and S. typhimurium with similar
mutations in theQRDR have been recentlywidely reported (Heisig, 1994; Heisig
et al, 1995; Ruiz et al, 1995; Truong et al, 1995; Griggs et al, 1996; Bazile-Pham-
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Khac et al, 1996). While quinolone resistant E. coli isolates commonly show a
serine-83 to leucine (Heisig et al, 1993; Yoshida et al, 1988; Oram and Fisher,
1991) or serine-83 to tryptophan (Cullen et al, 1989; Yoshida et al, 1988; Oram
and Fisher, 1991) change, quinolone-resistant Salmonella seem to bemore inclined
to a serine-83 to phenylalanine change (this work, also Griggs et al, 1996; Reyna
et al, 1995). The triplet encoding serine-83 of GyrA in Salmonella was found to
be TCC compared to TCG in E. coli. Therefore a change from TCC (serine) to
TTC (phenylalanine) which only involves one nucleotide change is
understandable. However, in E. coli, the triplet encoding serine-83 is TCG which
has been previously found to change to TGG (tryptophan) (Oram and Fisher,
1991), or TTG (leucine) (this work) in response to quinolone challenge. A
mutation in the triplet involving two nucleotide changes was found to occur in
this study. A clinical isolate of E. coli, CIP261, was found to have a serine-83 to
phenylalaninemutation as a result of a change in the DNA sequence from TCG
to TTC. This change is novel in E. coli and possibly results from the differential
codon usage within E. coli species. Since E. coli and S. typhimurium can be
considered to be diverging from a common ancestral genome, it would be
expected that somewhere between the classic "definition" of a E. coli bacterium
and a S. typhimurium bacterium, there is some "middle ground", where the codon
usage is perhaps different. Itwould have been interesting to examine the parent
strain of CIP261, in order to ascertain what the nucleotide of codon 83 was
before the isolate had mutated to quinolone resistance. As the occurrence of
two mutations adjacent to each other is probably quite a rare event, it is possible
that the original codon sequence was TCC as in Salmonella species. To reconfirm
the clinical records that it was E.coli rather than Salmonella, features of the DNA
sequence were examined further, revealing that the gyrA sequence of CIP261
was more similar to E.coli than Salmonella.
100
Although the patterns of codon usage in E. coli and S. typhimurium are similar
(Sharp and Li, 1986; Ikemura, 1985), there are certainly some differences in silent-
base composition, occurring as the result of a mutation-selection balance. The
average divergence of E. coli genes compared to S. typhimurium has been shown
to be 15.6% (Sharp, 1991), however since proteins mutate at different rates, this
is only a very average value and for highly evolved proteins such as DNA
gyrase, the degree of change of the amino acid sequence would be expected to
be minimal. However, since codon preferences vary from one organism to
another depending on the abundance and anticodon sequence of the various
tRNAs in the cell (Ikemura, 1981), a mutation occurring in one position of the
triplet could easily change the same amino acid in two species to two different
amino acids, as shown to happen with the isolates investigated in this chapter.
As the GC contents of E.coli and S.typhimurium are vary slightly, it is
understandable that the two species are predisposed to different amino acid
substitutions at the same codon.
From a more clinical perspective, the results show the occurrence of a decreased
susceptibility to quinolone drugs in the isolated bacteria. The ease with which
mutations in gyrA are acquired has been demonstrated in 3.3 where a NCTC
strain of S.typhimurium was inoculated daily into broth containing increasing
levels of ciprofloxacin. Amutation in gyrA converting aspartate-87 to tyrosine
was readily acquired and resulted in the MIC of ciprofloxacin of the cell
increasing 64-fold from 0.008mg/l to 0.512mg/l. At this point, the experiment
was stopped, however, furthermutation of the strain by increasing amounts of
ciprofloxacinmay have resulted in the occurrence of furthermutations, perhaps
changing serine-83 to a hydrophobic amino acid. It is significant that of the
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twelve isolates of S. typhi with decreased susceptibility to quinolone drugs (see
3.5), only ST10 did not respond to ciprofloxacin therapy when this drug was
administered to a patient (M. Jesudason, personal communication). The eleven
other isolates examined had the same MIC for ciprofloxacin (0.256mg/l), thus
there is a possibility that these isolates could also become more resistant to
quinolone drugs actually during the course of therapy, if, for example, a sub¬
therapeutic dose of the drug was given. However, for the purpose of this study,
the amount of quinolone drug administered to patients on a clinical basis was
found to be sufficient to inhibit the growth of these isolates.
Clinical isolates which did not respond to quinolone therapy have previously
been described and shown to have much greater MICs of quinolone drugs
(Piddock et al, 1993). However, even although the isolates examined in this
study still have MICs below the recommended breakpoint concentration for
the quinolone drugs, it is possible that under conditions of prolonged quinolone
therapy, further mutations in gyrA, gyrB or another locus may arise, resulting
in a highly quinolone-resistant isolate not amenable to quinolone therapy, such
as that described by Heisig (1993).
Although it is well-accepted that the occurrence ofmutations at serine-83 and/
or aspartate-87 of gyrA of the Enterobacteriaceae contribute to quinolone
resistance, the lack of correlation betweenMIC and point mutation in gyrA for
the above isolates can possibly be attributed to the occurrence of additional
mutations in other loci. Changes in outermembrane proteinmutations, changes
affecting efflux mutations in gyrB, changes in parC and/or parE have all been
shown previously to contribute to quinolone resistance. For example, two
isolates of Salmonella, CIP185 and CIP248 with the same amino acid mutation
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at serine-83 resulting in the replacement of serine-83 by phenylalanine were
shown to have MICs of ciprofloxacin of lmg/1 and 0.256mg/l respectively. This
is in keepingwith the ideas discussed before that high level quinolone resistance
in clinical bacteria is rarely the result of a single mutation, instead it arises from
a sequential build-up of alterations in permeability and in the structural genes
mainly of gyrA and parC.
Recent evidence has demonstrated the contribution ofmutations in parC in the
development of high-level quinolone resistance in E.coli (Heisig, 1996). This
underlines the role of topoisomerase IV as a secondary, less sensitive target for
quinolone action in E.coli. Despite parCmutations being detected in quinolone
resistant E.coli with mutations in the QRDR of gyrA, bacteria harbouring
mutations in parC alone have not been identified. It is likely that on further
investigation of the clinical isolates examined in this chapter, furthermutations
in the outer membrane proteins, genes affecting the efflux mechanisms, parC
and parE would be revealed. Armed with all this information, it would then be
possible to assign different numerical levels of quinolone resistance to different
resistance mechanisms. Genetic strain construction experiments in vivo could
then be used to confirm such results.
Therefore, in conclusion, the quinolone resistant clinical isolates examined in
this study were all found to possess mutations in the QRDR of gyrA at amino
acid positions that had been previously proposed to be critical for the affinity
of binding to the DNA-quinolone complex (Hallett and Maxwell, 1991). Only
one isolate, S.typhi ST5, was found not to have a changed DNA sequence of
gyrA despite showing a decreased susceptibility to the quinolone drugs. This
and the fact that there is only a vague correlation between MIC and mutations
in gyrA points towards the presence of mutations in other loci.
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4 Cloning of gyrA and investigating
its high copy expression
4.1 Introduction
At the onset of this work, itwas aimed to examine the effect ofmutations arising
in the QRDR of gyrA in a neutral genetic background where any contribution
to the quinolone-resistance phenotype by other mutations such as outer
membrane protein mutations and mutations affecting efflux which were
probably present in the previously investigated clinical strains could be
eliminated. It was planned to clone gyrA with its promoter into a high copy
number plasmid from which single-stranded DNA could be extracted, then
engineering point mutations in the DNA of the QRDR of gyrA artificially by
site-directed mutagenesis, so the effect of the changed amino acid on the MIC
of the cell could easily be ascertained. The gyrA temperature-sensitive (gi/rA*5)
strain E.coli KNK453 (Kreuzer and Cozzarelli, 1979) was to be used as the host
for the various manipulations by virtue of its ability to grow at 30°C but not at
42°C. The vector pBluescript was favoured for the cloning ofgyrA since, being
a phagemid vector, single-stranded DNA could easily be obtained on infection
with helper phage. Figure 4.1 shows the various stages that had to be carried
out in this investigation.
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Figure 4.1: Plan of action to investigate changing serine-83 and aspartate-87 of
GyrA of E.coli on the Minimum Inhibitory Concentration of ciprofloxacin the
cell by inserting point mutations in these positions to create amino acid changes





However, during the course of the initial stages of this work, these results were
published by another group (Yonezawa et al, 1995a, 1995b). Therefore the aim
was altered to study the effect of changing the important tyrosine-122 residue
inGyrA again by site-directedmutagenesis to chemically similar and dissimilar
amino acids and assess how this affected the efficiency of the supercoiling
reaction. A scheme for this is presented below (Figure 4.2).
Figure 4.2: Plan of action to investigate changing tyrosine-122 ofGyrA of E.coli
on the supercoiling reaction by inserting point mutations in this position to








Cut out appropriate fragment
and ligate into suitably restricted
pPI-^i (expression vector induced by 1PTG)
Induce,
Purify protein- -►Supercoiling assays
During the initial course of this work, these results were published by Critchlow
andMaxwell, (1996). The highly competitive nature of these studies confirmed
their importance and indeed, the construction of gyM-containing plasmids
generated some interesting results which will be discussed below.
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4.2 Construction of pBluescript carrying gyrA
4.2.1 Strategy 1: Cloning of gyrA from a genomic library of E.coli
Cloning
Chromosomal DNA extracted from E.coli TGI was fully digested with the
restriction enzyme EcoRl and the restriction product run out on a 1% agarose
gel. DNA fragments in the size range 4kb to llkb were cut out, purified and
ligated into the vector XZAPII which had been predigested with EcoRl and
dephosphorylated with calf intestinal alkaline phosphatase (CIAP). The
products of the ligation were packaged into Gigapack IIGold packaging extract
and the efficiency of the packaging verified by titering the phage library in
E.coli XL-1 BLUE and plating out on LB agar overlaying with top agar containing
IPTG and X-gal. The number of clones containing inserts was found to be
approximately 100 times greater than those not containing inserts.
Screening
The phage library was plated out on large Petri dishes and plaque lifts
performed. After baking the membrane, hybridisation was carried out by the
use of the plasmid pPH3 which contains a copy of the E. coligyrA gene (excluding
the upstream promoter sequences). After developing the film corresponding
to the blot, 3 putative positively hybridising plaques were revealed. The
corresponding plaques were cored out of the master plate and stored in SM
buffer at 4°C with a few drops of chloroform. On carrying out a secondary
screen, itwas found that the three putative plaques were actually false positives.
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Conclusions
It was decided to discontinue with this strategy since a restriction map of this
region of E.coli chromosomal DNA downloaded from Genbank showed that
gyrA was present on a EcoRl-EcoRl fragment which was at least 8810bp long. It
was therefore speculated that the presence of excessive upstream and
downstream regions also present in the potential construct was deemed
unnecessary and it was feared that the overproduction by pBluescript of other
genes present in the constructmight lead tomisleading results. Itwas thereafter
aimed to achieve a much neater construct, only containing gyrA to eliminate
this possibility.
Figure 4.3: A simplified restriction map of the area surrounding and including
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17270 Bsm I •
16810 BsmI'
15055 Bsm 18984 BsmO
_L 11
EC049-72 21119 base pairs
ThegyrA gene is present on the 3250bp Bsml-Bsml fragment between nucleotides
415 and 3665 on this contig.
4.2.2 Strategy 2: Cloning of gyrA from a cosmid
Cloning
The gyrA gene of E. coli was excised from the cosmid vector pNJR3-2 on a 3.3kb
fragment, by the restriction enzyme Bsml. This BsmI fragment had 3' overhangs
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on each side, therefore the enzyme T4 DNA polymerase was used to produce
blunt-ended fragments. ThisDNA fragmentwas ligated into pBluescriptwhich
had been digested with Smal to create blunt ends.
Figure 4.4: Diagram of pBluescript showing the relevant restriction sites
The ligationmixture was transformed into E.coli XL1-BLUE and the cells plated
out onto LB agar plates containing ampicillin, IPTG and X-gal. After overnight
incubation at 37°C, three white colonies resulted which were subsequently
analysed.
Screening
Plasmid preps of the three white colonies were separately restricted with EcoRl
and BamHl and compared to pBluescript with no insert. It was expected that
the presence of the 3.3kb inserted fragment containing gyrA would generate an
extra band compared to pBluescript alone. Instead, anomalous restriction














out by the use of the gyrAts strain E.coli KNK453. The three putative positive
colonies were transformed into E.coli KNK453 and the cells plated out on LB
agar plates containing ampicillin and incubated at either 30°C or 42°C. However
it was found that none of the putative plasmids was able to complement E.coli
KNK453, thus none carried a functional gyrA gene.
Conclusions
It was thus concluded that the insert present in the three clones was not the
required one. There is a possibility that during the gel extraction of the Bsral-
Bsml 3.3kb fragment, the DNA became sheared and smaller fragments carrying
the incomplete gyrA gene were ligated into pBluescript instead. It was decided
that this strategy should be discontinued since extraction of sufficient quantities
of DNA from pNJR3-2 was difficult. The cosmid pNJR3-2 is present in a low
copy number in the cell and the fact that only a 3.3kb fragment of the total 28kb
cosmid is useful, makes the whole extraction procedure very inefficient.
Therefore a more specific strategy was adopted.
4.2.3 Strategy 3: Cloning of gyrA from a PCR product
Cloning
The gyrA gene of E.coli was PCR-amplified from a chromosomal prep of E.coli
TGI. The primers used were as follows:
CCGCGGATCCGAATAAAGCGTATAGCTTTA
TCGAATTCGCCCAGACTTTGCAGCCTGG
As shown by underlining, a BamHl restriction site was introduced into the
upstream primer and a EcoRl restriction site introduced into the downstream
primer to facilitate subsequent cloning steps.
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The resulting 2910bp PCR fragment was digested with the restriction enzymes
BamHl and EcoRl and the product of restriction run out on a 1% agarose gel.
The DNA fragment was cut out, purified and ligated into pBluescript that had
been digested alsowith BamHl and EcoRl. The ligationmixturewas transformed
into £. coli XL1-BLUE and the cells plated out on LB agar plates containing
ampicillin, IPTG and X-gal. Forty-eight white colonieswere picked and plasmid
DNA extracted. The plasmid DNA from the putative recombinants was
restricted with an appropriate restriction enzyme. However, unexpected
restriction patterns were again observed.
Screening
To investigate whether the putative plasmids constructed did contain gyrA,
genetic complementation studies were again carried out. The 48 putative
positive colonies were transformed into E.coli KNK453 and the cells plated out
on LB agar plates containing 50mg/l ampicillin and incubated at either 30°C
or 42°C. The results of the complementation experiments revealed that none of
the recombinants actually carried a functional gyrA gene.
Conclusions
As a result of the inability to clone gyrA into pBluescript, it was decided to
attempt to clone gyrA into a lower copy number plasmid such as pBR322. It
was thought that the overexpression of gyrA may be deleterious to the cell
through imbalancing the homeostatis of supercoiling in the cell. If there was
such a deleterious effect on the cell, cloning ofgyrA into pBR322 (copy number
15 to 20 compared to a copy number of 200 to 1000 with pBluescript), would
have the advantage that less GyrA molecules would be produced.
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4.3 Construction of pBR322 carrying gyrA
4.3.1 Strategy 4: Cloning of gyrA from a PCR product into pBR322
The gyrA gene of E.coli was PCR-amplified from a chromosomal preparation of
E.coli TGI as before and the resulting PCR fragment digested with EcoRl and
BamHl. The product on the restriction was run out on an agarose gel, purified
and ligated into pBR322 that had also been digested with EcoRl and BamHl.




































The ligationmixture was transformed into E.coli XL1-BLUE and the cells plated
out on LB agar plates containing ampicillin. Eighteen putative positives were
picked and plasmid DNA extracted. The resulting plasmids were digested
with an appropriate restriction enzyme to confirm the presence of the insert.
Again, spurious results were achieved and none of the putatives complemented
the gyrAts strain E.coli KNK453 at 42°C.
Conclusions
The inability to be able to clone gyrA into pBR322 was unexpected, since the
cloning of a similar construct had been published before (Swanberg andWang,
1987). However, it seemed that the exact positioning of gyrA in pBR322 was
crucial since the tet gene of pBR322 is supercoiling sensitive (Jaworski et al,
1989). Bearing this in mind, the cloning procedure was slightly modified as
described below.
Strategy 4b: Cloning of gyrA from a PCR-amplified PCR product
into pBR322
Instead of cloning the PCR-amplified gyrA EcoRl-BamHl fragment into the EcoRl
and BamHl sites of pBR322 as before, the fragment was cloned into BamHl-
digested pBR322, the ends ofwhich had been filled inwith T4DNA polymerase.
The ligationmixture was transformed into E.coli XL1-BLUE and the cells plated
out on LB agar plates containing ampicillin. Many putative positives were
generated, twelve were picked from which plasmid DNA was extracted. The
resulting plasmids were digestedwith Smal to confirm the presence of the insert.
All of the twelve putatives were shown to produce a 6810bp fragment on
digestion with Smal, which was the size of fragment expected from Smal
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digestion of the desired construct. To confirm that this was indeed the correct
construct, the plasmid was transformed into gyrAts E.coli KNK453 and grown
at 42°C. The plasmid was found to complement E.coli KNK453 at 42°C, therefore
a suitable yyrA-containing clone had finally been achieved. After re-confirming
the status of the plasmid by various restriction enzyme digests (data not shown),
this plasmid was named pBRgyrA. A diagram of pBRgyrAwith some restriction
sites is shown in Figure 4.6.
Figure 4.6: Diagram of pBRgyrA
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4.4 Is high-level expression oigyrA toxic to E.coli?
The inability to clone gyrA into a high copy number plasmid prompted the
relationship between the level of expression of gyrA and cell viability to be
investigated. It seemed possible that high level expression of gyrA affected the
levels of supercoiling in the cell and thus affected cell viability. The fact that
gyrA was cloned without problem into pBR322 suggested that levels of up to
15 to 20 plasmid-encoded copies per cell of gyrA could be tolerated.
In order to investigate this further, the PCR-fragment carrying gyrA was
amplified as before, restricted with EcoRl and BamHl and ligated into the EcoRl
and BamHl sites ofplasmid pOU61 to form construct pOUgyrA. Plasmid pOU61
is a temperature-dependent cloning vector which is present in one copy per
chromosome at temperatures below 37°C but at 42°C, shows uncontrolled
replication (Larsen et al, 1984). By growing E.coli TGI transformed with
pOUgyrA at temperatures at and above 37°C and correlating the proportion of
gyrA mRNA transcripts and amounts of GyrA with cell viability, the possible
high level toxicity of GyrA was investigated.
A log culture of E.coli TGI containing pOUgyrA was grown at temperatures
30°C, 35°C, 37°C and 42°C for two hours. RNA was extracted from each
culture, electrophoresed, blotted and hybridised to a gyrA probe. The results
of this Northern blot are displayed in Figure 4.7.
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Figure 4.7: Northern blot showing the increase in gyrA transcripts produced
by strain E.coli TGlpOUgyrA at increasing temperatures. Runaway replication
of plasmid pOUgyrA is achieved by increasing the incubation temperature (see
text for details).
A log culture of E.coli TGI containing pOUgyrA was grown at temperatures
30°C, 35°C, 37°C and 42°C for two hours. RNA was extracted from each
culture, electrophoresed, blotted and hybridised to a gyrA probe. Lane 1: E. coli
TGI pOUgyrA grown for 2 hours at 30°C; Lane 2: E. coli TGI pOUgyrA grown
for 2 hours at 35°C; Lane 3: E. coli TGI pOUgyrA grown for 2 hours at 37°C;
Lane 4: E. coli TGI pOUgyrA grown for 2 hours at 42°C.
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The results of the Northern blot show that between 30°C and 35°C/ the levels of
gyrA mRNA in E.coli TGI pOUgyrA increases (Figure 4.7, Lanes 1 and 2).
However, the E.coli TGI pOUgyrA cultures grown at 37°C and 42°C show less
gyrA transcripts (Figure 4.7, Lanes 3 and 4). This can be explained by the fact
that incubation of the cultures at the higher temperatures for 2 hours results in
cell death by overexpression ofgyrA and subsequently less gyrA transcripts are
detected. It was apparent that more than one band of RNA hybridising to the
gyrA probe was present at the higher temperatures (Figure 4.7, Lanes 3 and 4).
The reason for this higher molecular weight band is unknown.
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A 100|il volume of each culture was also removed after one hour to measure
the cell viability. The cell viability at each temperature measured is plotted in
Figure 4.8.
The graphs add weight to the proposal that GyrA is toxic when expressed at
high levels in E.coli. The percentage viability of four cultures derived from the
same parent but grown at different temperatures was calculated at two time
points: one hour and two hours. The E.coli TGI pOUgyrA culture that was
grown at 30°C shows normal growth kinetics with the culture doubling in size
every hour. The pattern of growth of E.coli TGI pOUgyrAgrown at 35°C almost
is identical to that of the previous culture grown at 30°C, however, the viable
count was actually found to be lower. The fact that pOU61 shows partial
runaway replication is reflected by the results of the E.coli TGI pOUgyrA culture
grown at 37°C which decreases in cell viability with time. After one hour, 40%
of the original population were found to be viable and after 2 hours 10% were
viable. Flowever, at 42°C, a rapid loss of cell viabilitywas observed (10% of the
original population after one hour and 4% of the original population after two
hours) suggesting even more so that over-expression of GyrA may be
detrimental to the cell.
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By attempting to clone gyrA into a high copy number plasmid, it was found
that expression of this gene may be toxic at high levels. This theory was
strengthened by cloning gyrA into pOU61, a runaway replication vector which
is present in one copy per cell at 30°C but shows uncontrollable replication at
42°C (Larsen et al, 1984). When gyrA was expressed at a high level (confirmed
by Northern blotting, Figure 4.7), the viability of the culture was observed to
decrease dramatically (Figure 4.8). The fact that more gyrA transcripts were
detected at 35°C than at 30°C (Figure 4.7, compare Lane 2 to Lane 1) and the
viable count of the culture at 35°C was lower confirms this. Although it is
likely that the overexpression of GyrA in the cell affects the viability of the
culture, it is possible, however, that the sheer density of plasmid DNA has the
same effect. On exploring the possibility that gyrA was toxic to the cell at high
levels (thiswork; A.Maxwell, personal communication), a search of the literature
was carried out to investigate what cloning vectors had been previously used
by other groups to clone gyrA (Table 4.1)
Table 4.1: Descriptions of plasmids into which gyrA has been cloned.
Plasmid Backbone Uninduced copy number Reference
pMK90 pBR322 15 to 20 Mizuuchi et al, 1984
pTS7 pACYC184 5 to 6 Saiki et al, 1994
pPH3 pUC18 Zero Hallett et al, 1990
pBP515 pRSFK low Heisig and Wiedemann, 1991
pAW012 pBR322 15 to 20 Nakamura et al, 1989
pAWOll pBR322 15 to 20 Yoshida et al, 1988
pNJR322 pLA2917 low Robillard, 1990
pJSWIOl pUC19 200 Soussy et al, 1993
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pSLS447 pBR322 15 to 20 Swanberg and Wang, 1987
All the gyrA-encoding vectors but one previously made had been based on low
copy numbers such as pBR322. The oneyi/M-encoding vector thatwas expressed
in high copy number was pJSWIOl (Soussy et al, 1993). By cloning and
expressing gyrA in pUC19, GyrA would be expected to be present in at least
200 to 1000 extra copies per cell, more if the gene was readily transcribed.
Plasmid pJSWIOl is described as a pUC19-based plasmid with a BamHl-Sall
fragment from E.coli KL16 containing gyrA cloned into the BamHl and Sail sites
(Soussy et al, 1993). However when a restriction map of this area was
constructed, the nearest BamHl site was found to be at least 6891bp from the
end of gyrA and a Sail site on the other side of the gene could not be found.
Therefore the accuracy of the construction of this plasmid may be dubious.
Figure 4.9: Simplified restrictionmap of the region surroundinggyrA showing
BamHl and Sail sites.
The inability to clone gyrA into the EcoRl and BamHl sites of pBR322 possibly
was a result of the insert affecting the negative supercoiling of the plasmid. It
has been observed previously that some inserts cloned into the BamHl site of
pBR322 result in the occurrence of deletions (Jaworski et al, 1989). These authors
suggested that the deletions resulted from genetic recombination because of a
change in the negative supercoiling that occurred when transcription of the tet
gene was disrupted. Although it was concluded that cloning some inserts in
10556 BamHI* 20248 Sail'
EC049-72 21119 base pairs
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the BamHl sitewould lead to deletions whereas cloning into the EcoRl sitewould
not (Jaworski et al, 1989), the fact that gyrA itself is a supercoiling-specific gene
may affect the negative supercoiling of the plasmid in such a way such that
inserting the gene into the EcoRl and BamHl sites is impossible.
The high copy number toxicity of gyrA in E.coli almost definitely will result
from a loss of control of supercoiling levels. Maintaining the correct supercoiling
levels in E.coli is of upmost importance as transcription of many genes is
supercoiling sensitive (see 1.4.2-1.4.3). There also seems to be a mechanism to
keep the amounts of cellularGyrA andGyrB at similar levels. However, studies
have shown that overproduction of gyrA has no effect on supercoiling,
suggesting thatGyrA is in excess compared to GyrB, consistentwith the results
of extraction studies (Staudenbauer and Orr 1981). It has been suggested that
it might be the concentration of GyrB rather than that of GyrA which controls
the levels of supercoiling. It is possible that very high level expression ofGyrA
in E.coli may affect the cell somehow either by GyrA binding and interfering
with a different target other than GyrB. Another explanation is that high level
expression ofgyrA results in the production of inclusion bodies. Overexpression
of proteins commonly results inmisfolding of the polypeptide so it cannot take
up its native aggregated state and instead remains as an aggregated inclusion
body (Wetzel, 1994).
In conclusion, overexpression ofGyrA in E.coli is probably harmful to the cell,
either as a result of loss of control of supercoiling, incorrect binding to other
targets in the cell or the formation of insoluble aggregates ofGyrA in inclusion
bodies.
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5 The Cellular Response to Quinolone Drugs
Although the quinolories have been shown to target DNA gyrase and poison
the enzyme through the formation of the "cleavable complex", the actual cellular
process of death has remained elusive. The experiments described in this chapter
attempted to explain some of the molecular aspects of quinolone-induced cell
death.
5.1 The effect of quinolone drugs on the viable
count of E.coli
E.coli TGI was investigated regarding its response to nalidixic acid and
ciprofloxacin. Various concentrations of nalidixic acid (Figure 5.1) or
ciprofloxacin (Figure 5.3) were added to a log phase culture of E.coli TGI and 2
hours later a sample withdrawn and the viable count calculated. The results
are displayed in Figures 5.1 and 5.3 below. From the graphs, the Optimum
Bactericidal Concentration (OBC) of nalidixic acid and ciprofloxacin were
estimated as being 90mg/l (Figure 5.1) and 0.15mg/l (Figure 5.3) respectively.
These values and the shapes of the graphs were identical to previous data
published for E.coli KL16 (Smith, 1986). As expected, the proportion ofbacteria
surviving treatment with a range of concentrations of quinolones followed a
biphasic responsewith concentrations less than andmore than the OBC resulting
in a decreased proportion ofbacterial death. The bacteriostatis at concentrations
greater than the OBC has been correlated with an increased inhibition of RNA
and thus protein synthesis. Therefore at quinolone concentrations higher than
the OBC, the proposed bactericidal event responsible for cell death after
treatmentwith nalidixic acid and partly responsible for cell death after treatment
with ciprofloxacin is prevented from taking place (Deitz,Cook and Goss, 1966).
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The experiment was then modified slightly by the addition of 170mg/l
chloramphenicol 1 hour prior to the addition of the OBC of quinolone drug to
inhibit protein synthesis. The viable counts are displayed in Figure 5.2 and
Figure 5.4. As shown in Figure 5.2, the addition of chloramphenicol resulted in
inhibition of cell death by nalidixic acid over the period of 3 hours tested.
Instead, bacteriostatis results which agreed with previous findings that de novo
protein synthesis is required for cell death after treatment with nalidixic acid
(Smith, 1984). In contrast, the bactericidal effect of ciprofloxacin was not found
to be as susceptible to antagonism by inhibition of protein synthesis as was
that of nalidixic acid as shown in Figure 5.4. This again agrees with previous
findings that there seem to be two mechanisms of cell death after treatment of
E.coli with ciprofloxacin: a bactericidal event which requires de novo protein
synthesis and a bactericidal event that does not (Smith, 1986).
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Figure 5.2 Viable count of E. coli TGI challenged with the Optimum Bactericidal
Concentration of nalidixic acid in the present of 170mg/l chloramphenicol over
3 hours
125




Figure 5.3: Viable count of E. coli TGI challenged with various concentrations
of ciprofloxacin
[Ciprofloxacin] mg/1
Figure 5.4 Viable count of E. coli TGI challenged with theOptimum Bactericidal
Concentration of ciprofloxacin in the presence or absence of 170mg/l
chloramphenicol over 3 hours
Time (minutes)
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5.2 The effect of quinolone drugs on the integrity
of chromosomal DNA
To investigate the mechanisms of E.coli cell death further, the effect of the
addition of quinolone drugs on the integrity of the bacterial chromosome was
then studied. As a result of cleavable complexes on the chromosome giving
rise to double-stranded DNA breaks which are potentially lethal, it was hoped
that studying the effects of the quinolone drugs on the chromosome would be
informative.
E.coli TGI was grown up to log phase, the culture split into various aliquots
which were then challenged with a specified amount of either nalidixic acid or
ciprofloxacin. The cultures were incubated for a further period of time. To
prepare the DNA for electrophoresis, different methods were employed as
described below.
(i) Gentle lysis of bacterial cells with SDS
The method of Walker et al (1993) was followed. Briefly an equal volume of 2%
(w/v) SDS was added to the bacterial culture. As well as causing cell lysis, any
ongoing endogenousDNA cleavagewould be suppressed and the chromosomal
DNA would be effectively "deproteinized". It was found that the addition of
50mg/ml RNase (60 minutes at 50°C) and 0.5mg/ml proteinase K (60 minutes
at 50°C), improved the appearance of the DNA. These lysates were loaded
onto a gel and subjected to conventional agarose gel electrophoresis.
As shown in Figure 5.5, the chromosomalDNA extracted from E.coli untreated
with ciprofloxacin remained intact and did not leave the wells of the agarose
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gel as a result of its high molecular weight (Figure 5.5, Lane 1). However with
increasing amounts of ciprofloxacin added to the bacterial culture (Figure 5.5,
Lanes 2-9), the DNA was observed to have left the wells and form a band just
above the top band of the XHindlll markers (23.1kb). This DNA is believed to
correspond to a size of 50-300kbp (Walker et al, 1993). The results show that
increasing the concentration of ciprofloxacin results in the cleavage of the
bacterial chromosome into smaller fragments of approximately 50-300kbp.
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Figure 5.5: The effect of various concentrations of ciprofloxacin on the integrity
of E. coli chromosomal DNA. Displayed below is a photograph of the
conventional agarose gel on which the fragments of DNA were resolved.
Cells were challenged with various concentrations of ciprofloxacin and an
aliquot of cells removed after 10 minutes to assess DNA damage. Lane 1, no
ciprofloxacin; Lane 2,0.004mg/l ciprofloxacin; Lane 3,0.008mg/l ciprofloxacin;
Lane 4, 0.016mg/l ciprofloxacin; Lane 5, 0.032mg/l ciprofloxacin; Lane 6,
0.064mg/l ciprofloxacin; Lane 7, 0.128mg/l ciprofloxacin; Lane 8, 0.256 mg/1
ciprofloxacin; Lane 9, 0.512mg/l ciprofloxacin; Lane 10, A, Hzndlll markers.
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(ii) Lysis of cells in agarose plugs
As before, a logarithmic culture of E.coli TGI was challenged with different
concentrations of ciprofloxacin (Figure 5.6) or nalidixic acid (Figure 5.7),
incubated for a further 60 minutes and the cells embedded in agarose plugs.
Pulsed field gel electrophoresis was then used to separate the DNA fragments.
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Figure 5.6: The effect of various concentrations of ciprofloxacin on the integrity
of E. coli chromosomal DNA. Displayed below is a photograph of the pulsed
field gel on which the larger fragments of DNA were resolved.
1 234 56 78 M
Cells were challenged with various concentrations of ciprofloxacin and an
aliquot of cells removed after 60 minutes to assess DNA damage. Lane 1, no
ciprofloxacin; Lane 2,0.001mg/l ciprofloxacin; Lane 3,0.004mg/l ciprofloxacin;
Lane 4, 0.016mg/l ciprofloxacin; Lane 5, 0.064mg/l ciprofloxacin; Lane 6,
0.15mg/l ciprofloxacin; Lane 7, 0.5mg/l ciprofloxacin; Lane 8, 5 mg/1
ciprofloxacin ; Lane M, X concatemer markers.
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On analysing the DNAby pulsed field electrophoresis, it appeared that at low
ciprofloxacin concentrations (O.OOlmg/1, Figure 5.6, Lane 2), the chromosomal
DNA remained intact. However it seemed that the addition of increasing
amounts of ciprofloxacin up to the minimum inhibitory concentration (MIC)
(0.004mg/l, Figure 5.6, Lane 3), the chromosomal DNA became increasingly
damaged. The addition of a higher concentration of ciprofloxacin than the
MIC caused the damage of the chromosomalDNA into even smaller fragments
as shown in Figure 5.6, Lane 4 and even more so in Lane 5. In Lanes 6 to 8, a
faint chromosomal DNA band could be seen, however the remainder of the
DNA seemed to be on average much smaller. Compared to the DNA in the
previous lane (Figure 5.6, Lane 5 [ciprofloxacin]=0.064mg/l), the DNA in Lane
6 [ciprofloxacin]=0.15mg/l seemed to lack the very high molecular weight
fragments with the majority of DNA fragments appearing as being less than
48.5kb (bottom band of X concatemer markers). At a concentration of
ciprofloxacin above the OBC (0.5mg/l, Figure 5.6, Lane 7), even less DNA in
the highmolecularweight range was observed with some of theDNA appearing
again to be of size less than 48.5kb. However on challenge with the highest
tested amount of ciprofloxacin (Figure 5.6, Lane 8, [ciprofloxacin]=5mg/l), it
appeared that there was not so much DNA damage at this concentration
compared to the last two lower concentrations.
Therefore from these data alone, it seemed that themost ciprofloxacin-induced
damage to the bacterial chromosome occurs around the OBC but at ciprofloxacin
concentrations above and below this value, the bacterial chromosome is less
degraded. The characteristics of the DNA at the various concentrations of
ciprofloxacin used seemed to follow the pattern of the viable count of the culture
at various concentrations of the drug (Figure 5.3).
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Figure 5.7: The effect of various concentrations of nalidixic acid on the integrity
of E. coli chromosomal DNA. Displayed below is a photograph of the pulsed
field gel on which the larger fragments of DNAwere resolved.
123456 7 8 9 M
18.5kb
Cells were challenged with various concentrations of nalidixic acid and an
aliquot of cells removed after 60 minutes to assess DNA damage. Lane 1, no
nalidixic acid; Lane 2, lmg/1 nalidixic acid; Lane 3,5mg/l nalidixic acid; Lane
4,10mg/l nalidixic acid; Lane 5,50mg/l nalidixic acid; Lane 6,90mg/l nalidixic
acid; Lane 7, 200mg/l nalidixic acid; Lane 8, 500mg/l nalidixic acid; Lane 9,
1000mg/l nalidixic acid; Lane M, X concatemer markers.
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As can be seen in Figure 5.7, minimal, if any, damage to the chromosomalDNA
occurs at low nalidixic acid concentrations (Figure 5.7, Lanes 2 to 4, representing
[nalidixic acid] lmg/1 to 10mg/l) compared to the drug-free control (Figure
5.7, Lane 1). Even around the MIC of nalidixic acid (3mg/l), minimal double
stranded DNA breaks are observed. However on addition of 50mg/l nalidixic
acid (Figure 5.7, Lane 5) to the bacterial culture, the chromosomalDNA appears
much more damaged. At the concentration of nalidixic acid corresponding to
the OBC of nalidixic acid, 90mg/l, (Figure 5.7, Lane 6) and at concentrations
above (Lanes 7 to 8), the chromosomal DNA seems increasingly damaged,
suggesting that the more nalidixic acid that is added to the culture, the more
DNA damage by double-stranded breaks. This is in contrast with the effect of
ciprofloxacin on chromosomal DNA (Figure 5.6) since at higher ciprofloxacin
concentrations (Figure 5.6, Lane 9), there appeared to be less double-stranded
DNA breaks. The other difference between the action of ciprofloxacin and
nalidixic acid on the bacterial chromosome was that while with nalidixic acid,
the chromosome always seemed to remain comparatively intact despite
extensive double stranded DNA breaks, at certain concentrations of
ciprofloxacin, the bacterial chromosome appeared less intact and the majority
of the DNA seemed to be of much smaller size.
Since these preliminary experiments suggested that the mode of action of
ciprofloxacin was different to that of nalidixic acid with regards to the formation
of double stranded DNA breaks and smaller DNA fragments at high antibiotic
concentrations, it was decided to carry out a more detailed study.
135
Investigating the extent of DNA damage at different
concentrations of ciprofloxacin at different time points
Different amounts of ciprofloxacin, ranging from 0 to 100mg/l were added to a
log phase culture and incubated for either 0, 5, 15, 30, 60, 90, 120, 180 or 360
minutes. The cells were treated as described in (ii) above and the DNA fragments
separated by pulsed field gel electrophoresis. A small section of the agarose
plug was cut off and run in a conventional agarose gel to ascertain the effect of
the drugs on the chromosome as regards to the smaller fragments. It was
found that this method of preparing DNA for conventional gel electrophoresis
was better than that used previously since loading the SDS-treated lysate directly
into the wells resulted in the mixture escaping from the wells. Both pulsed
field gels and conventional agarose gels showing the effects of different
concentrations of ciprofloxacin over different time points are displayed in the
following Figures 5.8 to 5.19 along with a graph plotting the viable counts of
the different cultures at the specified time points.
136
Figure 5.8: The effect of 0.001mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.8A), a photograph of the pulsed field
gel onwhich the large fragments ofDNAwere resolved (5.8B) and a photograph
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Cells were challenged with 0.001mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (in minutes) to assessDNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane
7,t=120; Lane 8, t=180; Lane 9, t=360; Lane M, 'k concatemer/ A,Hindlllmarkers.
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As shown in Figure 5.8B, the addition of 0.001mg/l ciprofloxacin causesminimal
degradation of chromosomal DNA. At all the time points tested from t=0 to
t=360, the chromosomal DNA appears intact and free from double stranded
DNAbreaks. The lower molecularweightDNA range is shown in Figure 5.8C.
As expected, the DNA resolves as 50kb to 300kb fragments, compared to the A.
Hindlll markers. It appears that at this ciprofloxacin concentration, minimal
DNA damage occurs to the chromosome and correspondingly, the viable count
of the ciprofloxacin-challenged culture, over the time points tested, despite an
initial lag on addition of ciprofloxacin, showed the kinetics expected of a healthy
dividing culture (Figure 5.8A).
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Figure 5.9: The effect of 0.004mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.9A), a photograph of the pulsed field
gel onwhich the large fragments ofDNAwere resolved (5.9B) and a photograph
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Cells were challenged with 0.004mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (in minutes) to assessDNA damage: Lane
l,t=0; Lane2,t=5; Lane 3, t=15; Lane4,t=30; Lane5, t=60; Lane 6, t=90; Lane
7, t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer / XHindlll markers.
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As shown in Figure 5.9B, the addition of 0.004mg/l ciprofloxacin (the MIC)
causesminimal degradation of chromosomalDNA. At all the time points tested
from t=0 to t=360 minutes, the chromosomal DNA appears intact and only
containsminimal double stranded DNAbreaks. The extent of the double strand
DNAbreaks actually appears to increase with time up until 60 minutes (Figure
5.9B, Lane 4) and then remain constant up to 360 minutes (Figure 5.9B, Lane 9)
and the smallest fragments resolved by the pulsed field gel seem to be slightly
smaller than the bottom band of the X concatamers (48.5kb). To resolve such
small fragments, a conventional agarose gel was used as shown in Figure 5.9C.
As expected, the DNA resolves as 50kb to 300kb fragments, compared to the X
Hindlll markers. On addition of 0.004mg/l of ciprofloxacin to the bacterial
culture, the viable count was found to decrease slowly to 90% of the original
population at 30 minutes, stabilise at this level up until 180 minutes and then
increase to 120% of the population at 360 minutes. This suggests that the cells
cannot divide for 180 minutes after the addition of the MIC of ciprofloxacin as
a result of DNA damage, however once the necessary repairs had been made,
cell division can resume once again.
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Figure 5.10: The effect of 0.016mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.10A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.1OB) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challenged with 0.016mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (in minutes) to assessDNA damage: Lane
l,t=0; Lane2, t=5; Lane 3, t=15; Lane4, t=30; Lane5,t=60; Lane 6, t=90; Lane
7, t=120; Lane 8, t=180; Lane 9, t=360; LaneM, X concatemer /X Hindlll markers.
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As shown in Figure 5.10B, the addition of more than the MIC of ciprofloxacin
(0.016mg/l) causes increasing double stranded DNAbreaks. The formation of
these double stranded DNAbreaks is evident even after 5 minutes (Figure 5.1 OB,
Lane 2) and after 30 minutes (Figure 5.10B, Lane 4) there appears to be increasing
amounts of smaller fragments of DNA. Interestingly after 90 minutes, the
amount of smaller fragments of DNA seemed to decrease (Figure 5.10B, Lane
6) and this trend continued up until 360 minutes (Figure 5.1OB, Lane 9). At the
later time points, even though there appeared to be less smaller DNA fragments,
there appeared to be less evidence of extensive double stranded DNA breaks
with a persisting population of DNA fragments of size approximately 48.5kb.
Despite the extensive double stranded breakage, at this concentration of
ciprofloxacin, the bacterial chromosome appeared largely intact.
These observations correlate with the results of resolving the smaller fragments
on a conventional gel. As shown in Figure 5.10C, the majority of the DNA
extracted from the cells at the early time points (t=5 minutes, t=15 minutes,
Figure 5.10C, Lanes 2 and 3) is resolved at a position on the gel corresponding
to amolecular size of 50kb to 300kb. However incubating the cells for 30 minutes
after challenge with 0.016mg/l ciprofloxacin seemed to reveal the production
of smaller fragments of sizes as small as 4kb (compared to the XHindlll markers,
Lane M). The amount of lower molecular weight DNA appeared to decrease
after 60 minutes and from this time point onwards, the DNA again appeared to
be 50kb to 300kb. Correspondingly, the viable count of culture decreased after
15 minutes and even more so after 30,60 and 120 minutes (Figure 5.10A). The
viable count of the culture then stabilised for one hour between 120 minutes
and 180 minutes during which time DNA repair was probably being carried
out. However, after this time point, an increase in cell viability was observed.
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These results suggest either the action of DNA repair enzymes in the cell after
120 minutes or that the cells with heavily damaged DNA die and are perhaps
removed from the population by cell lysis.
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Figure 5.11: The effect of 0.064mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.11A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.11B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Figure 5.11C
Cells were challenged with 0.064mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (in minutes) to assessDNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane
7, t=120; Lane8,t=180; Lane9,t=360; Lane M, X concatemer/ XHindlllmarkers.
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As shown in Figure 5.11B, the addition of 0.064mg/l ciprofloxacin causes even
more extensive double stranded DNA damage. Again, the formation of these
double stranded DNA breaks is evident even after 5 minutes (Figure 5.11B,
Lane 2) and after this time point there seems to be evidence of more smaller
fragments ofDNA. With increasing time, there appears to bemoreDNA double
stranded breaks, however despite this, at least some chromosomalDNA remains
intact. Therefore these results differ from these discussed previously (Figure
5.10B, [ciprofloxacin]=0.016mg/l) in that at this concentration of ciprofloxacin
(0.064mg/l) there appears to be no active DNA repair reducing the appearance
of theDNA double stranded breaks over time. Bearing this inmind, it is unlikely
that the explanation for less lower molecular weight DNA at increasing time
points in the previous figure (Figure 5.10) is as a result of bacterial lysis removing
the heavily damaged cell from the population. If this were the case, the effect
would be much more pronounced in Figure 5.11 as four times more
ciprofloxacin was added to the cell. However it is still possible that cell lysis
only occurs at lower ciprofloxacin concentrations but this is unlikely. Therefore
it appears that, at lower ciprofloxacin concentrations, a more pronounced DNA
repair process is responsible for the presence of less smaller DNA fragments at
the highest time points. It is likely that at a concentration of 0.064mg/l
ciprofloxacin, the DNA repair process is saturated with double stranded DNA
breaks and at this concentration, DNA repair is inefficient.
These conclusions correlate with the results of the conventional agarose gel
used to separate the lower molecular weight DNA fragments shown in Figure
5.11C. After 15 minutes of ciprofloxacin challenge, the chromosomalDNAwas
seen to become degraded into smaller fragments, some of which appeared to
be less than 4.3kb (compared to XHindlU, Lane M). It is interesting that at the
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highest time points (180minutes and 360 minutes, Lanes 8 and 9), there seemed
to be a decrease in the amount of lower molecular weight DNA so an active
repair process does indeed seem plausible.
The results of the viable count demonstrated that there is a decreased viability
of the bacterial culture after 15 minutes which becomes more pronounced after
30 and 60 minutes. However, cell viability does seem to increase after 120
minutes, perhaps because the cell has had more of a time to be able to repair its
DNA and cells that have escaped death by the addition of the drug can
commence cell division.
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Figure 5.12: The effect of 0.15mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.12A) and a photograph of the pulsed
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Cells were challenged with 0.15mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (inminutes) to assess DNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane
7, t=150; Lane 8, t=180; Lane 9, t=240; Lane 10, t=300.
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The effect of the OBC of ciprofloxacin on the production of smaller fragments
ofDNA was then studied as before. A log culture of E.coli TGI was grown up,
challengedwith 0.15mg/l ciprofloxacin and samples withdrawn at various time
points. The DNA extracted from these samples was electrophoresed on a
conventional agarose gel as shown in Figure 5.13. This was directly compared
with a culture challenged with the OBC of nalidixic acid in order to investigate
any differences in the sizes ofDNA fragments generated by the addition of the
two antibiotics.
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Figure 5.13: The effect of 0.15mg/l ciprofloxacin or 90mg/l nalidixic acid on
the integrity of E. coli chromosomal DNA. Displayed below is a photograph of
the conventional agarose gel on which the smaller fragments of DNA were
resolved.
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Cells were challenged with 0.15mg/l ciprofloxacin or 90mg/l nalidixic acid
and an aliquot of cells removed at the following time points (in minutes) to
assess DNA damage: Lane M, X Hind III markers; Lane 1, Antibiotic-free
culture t=0; Lane 2, ciprofloxacin treated culture t=5; Lane 3, nalidixic acid
treated culture t=5; Lane 4, ciprofloxacin treated culture t=15; Lane 5, nalidixic
acid treated culture t=15; Lane 6, ciprofloxacin treated culture t=30; Lane 7,
nalidixic acid treated culture t=30; Lane 8, ciprofloxacin treated culture t=60;
Lane 9, nalidixic acid treated culture t=60; Lane 10, ciprofloxacin treated culture
t=120; Lane 11, nalidixic acid treated culture t=120; Lane 12, ciprofloxacin treated
culture t=180; Lane 13, nalidixic acid treated culture t=180; Lane 14, ciprofloxacin
treated culture t=270; Lane 15, nalidixic acid treated culture t=270; Lane 16,
nalidixic acid treated culture t=360; Lane 17, ciprofloxacin treated culture t=360.
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On the addition of the OBC of ciprofloxacin (0.15mg/l), it appeared that rapid
DNA degradation occurred, even after 5 minutes (Figure 5.12B, Lane 2). With
increasing time, a definite trend was seen to emerge which showed that
increasing DNA double stranded breaks were evident and the intact
chromosomal band always seen at the top of the gel had disappeared. This
suggested that the DNA inside the cells was most damaged after 60 minutes
(Figure 5.12B, Lane 5). After this point, the DNA appeared to become less
damaged and the band at the top of the gel corresponding to intact chromosomal
DNA seemed to reappear. Again, the reason for this is unclear, either the DNA
becomes more repaired because the antibiotic becomes less active, the DNA is
repaired by the action ofDNA repair enzymes or the cells badly affected by the
antibiotic die and burst and are therefore removed from the population, leaving
the cells that have survived.
The results of analysing the lower molecular weight fragments by conventional
gel electrophoresis (Figure 5.13) confirms these ideas. DNA degradation was
seen to occur as soon as 15 minutes after the addition of ciprofloxacin and
increased over time (Figure 5.13, Lane 4). Extensive DNA damage releasing
DNA fragments as small as 4kb was observed on this gel. The results of the
viable count showed that there was rapid death as a result of ciprofloxacin
addition and even after 15 minutes, only 50% viability was seen. After 30
minutes just over 90% of the bacterial population had died and after one hour,
more than 99.9% were non-viable. Further decreases in the viability of the
culture was observed; however after 180minutes, it appeared that a very small
percentage of the culture was viable and could divide. This agreed with the
idea of an active repair process suggested by the results of the pulsed field gel
(Figure 5.12B).
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Figure 5.14: The effect of 0.5mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.14A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.14B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challenged with 0.5mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (inminutes) to assessDNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane
7, t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer/ XHindlllmarkers.
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As shown in Figure 5.14B, the addition of 0.5mg/l ciprofloxacin results in a
response following the same pattern as that seen in Figure 5.12. Briefly, the
formation of double stranded DNAbreaks was evident after 5 minutes as before
and after 30 minutes more smaller DNA fragments were observed (Figure
5.14, Lane 4). At this stage, a definite reduction in the proportion of larger
DNA fragments was seen although a small trace of the intact chromosomal
DNA was evident. With increasing time, more larger DNA fragments were
observed, again suggesting the presence of a DNA repair mechanism. After
360 minutes (Figure 5.14, Lane 9), chromosomal DNA appeared to contain
approximately the same extent of double stranded DNA breaks as at after 15
minutes (Figure 5.14, Lane 3). The presence of some sort of DNA repair
mechanism is reaffirmed by the results displayed in Figure 5.14C. The amount
of DNA in the lower molecular weight range (compared to XHindlll markers,
Figure 5.14C, LaneM), can be seen to increase to an optimum occurring around
60 minutes (Figure 5.14C, Lane 5) after which the average molecular weight of
DNA fragments seems to increase (Figure 5.14, Lanes 6 to 9). This correlates
with the results of the pulsed field gel, already discussed above.
The viable count carried out on the culture demonstrated that there was again
a rapid decrease in viability even after 5 minutes and more so after 15 minutes
and 30minutes (Figure 5.14A). The optimum amount of cell death was observed
to occur at 180 minutes, after which the viable count started to increase up until
360 minutes. This data correlates to the pulsed field and conventional gels,
reaffirming the view that there is an active DNA repair mechanism.
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Figure 5.15: The effect of lmg/1 ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.15A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.15B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challenged with lmg/1 ciprofloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer / X HindlTL markers.
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Strengthening the conclusions drawn before, the results from a similar
experiment but this timewith lmg/1 ciprofloxacin (Figure 5.15) again suggested
the presence of a DNA repair mechanism. As before, the DNA was shown to
incur double stranded breaks after 5 minutes (Figure 5.15, Lane 2) and the most
damage was observed at 60 minutes (Figure 5.15B, Lane 5). After this point,
the DNA appears more intact and a definite decrease in the amount of lower
molecular weight fragments was evident (Figure 5.15B, Lanes 6 to 9). These
results were again confirmed by the pattern of DNA damage observed by
conventional electrophoresis where an increase in the averagemolecularweight
of the DNA fragments was seen to occur with time (Figure 5.15C, Lanes 7 to 9)
after 60minutes (Figure 5.15C, Lane 5) and the results of the viable count (Figure
5.15A) which showed that the bacterial culture increased in size by a factor of
one hundred after 180 minutes.
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Figure 5.16: The effect of 5mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.16A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.16B) and a
photograph of the conventional agarose gel on which the smaller fragments of





1 23456 7 8 9 M
Cells were challenged with 5mg/l ciprofloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer/ X HindlR markers.
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The result of challenging the cells with 5mg/l ciprofloxacin followed the same
pattern as before, the only difference being that at time points that had before
correlated with extensive DNA damage and lack of high molecular weight
fragments, that is at 60 minutes (Lane 5, Figures 5.12B and 5.14B) did not
appear to give rise to somuch DNA damage at this ciprofloxacin concentration.
Evidence of at least some larger chromosomal DNA fragments was always
present and the average size of fragments seemed to increase gradually after
60 minutes incubation (Figure 5.16B, Lanes 5 to 9). This observation is confirmed
by the results of the conventional gel electrophoresis of the smaller DNA
fragments where double stranded breaks were seen to become slightly more
prominent from 5 minutes incubation to 60 minutes incubation (Figure 5.16C,
Lanes 2 to 5) but then became less obvious after 60 minutes (Figure 5.16C, Lanes
6 to 9). Flowever even at the time points atwhichDNA double stranded breaks
were seen, the fragments produced were not as small as seen previously at
lower ciprofloxacin concentrations. The results of the viable counts followed
the same pattern as before, however, a significant increase in the number of
viable colonies from 60 minutes to 360 minutes was observed (Figure 5.16A).
At this higher concentration of ciprofloxacin, it seemed that although double
stranded DNA breaks were present as before, the DNA seemed not to be
degraded into smaller molecular weight fragments. It even appeared that the
proposed DNA repair mechanism was more efficient at higher ciprofloxacin
concentrations. Almost identical patterns were seen to occur at even higher
concentrations of ciprofloxacin tested as shown in the following three figures:
Figure 5.17 corresponding to 10mg/l ciprofloxacin, Figure 5.18 corresponding
to 50mg/l ciprofloxacin and Figure 5.19 corresponding to 100mg/l.
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Figure 5.17: The effect of 10mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.17A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.17B) and a
photograph of the conventional agarose gel on which the smaller fragments of












Cellswere challenged with 10mg/l ciprofloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, A concatemer / AHindlll markers.
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Figure 5.18: The effect of 50mg/l ciprofloxacin on the integrity of E. coll
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.18A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.18B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Figure 5.18C
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Cells were challenged with 50mg/l ciprofloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer/ X Hindlll markers.
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Figure 5.19: The effect of 100mg/l ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.19A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.19B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challenged with 100mg/l ciprofloxacin and an aliquot of cells
removed at the following time points (in minutes) to assessDNA damage: Lane
l,t=0; Lane 2, t=5; Lane3, t=15; Lane4/t=30; Lane5,t=60; Lane6,t=90; Lane
7, t=120; Lane 8, t=180; Lane 9, t=360; LaneM, X concatemer / XHindJll markers.
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The effect of ciprofloxacin on a different strain of E.coli other than E.coli TGI
was then studied. E.coli strain CIP223 (described in 3.7) has a MIC of
ciprofloxacin of ciprofloxacin of 2mg/l and thus requires higher levels of
ciprofloxacin to cause bacterial cell death. A culture of E.coli CIP223 was
challenged with various concentrations of ciprofloxacin, allowed to grow for
one hour and its DNA analysed by pulsed field electrophoresis as before. The
results are displayed in Figure 5.20.
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Figure 5.20: The effect of various concentrations of ciprofloxacin on the integrity
of E. coli CIP223 chromosomal DNA. Displayed below is a photograph of the
pulsed field gel on which the large fragments of DNA were resolved.
1 2 3456 7 89M
Cells were challenged with various concentrations of ciprofloxacin and an
aliquot of cells removed after one hour to assess DNA damage: Lane 1, no
ciprofloxacin; Lane 2, 0.00025mg/l ciprofloxacin; Lane 3, 0.001mg/l
ciprofloxacin; Lane 4,0.004mg/l ciprofloxacin; Lane 5,0.016mg/l ciprofloxacin;
Lane 6, 0.064mg/l ciprofloxacin; Lane 7, blank well; Lane 8, 0.5mg/l
ciprofloxacin; Lane 9, 5mg/l ciprofloxacin; Lane M, X concatemer markers.
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The results establish that E.coli CIP223 shows the same production of double
stranded breaks and DNA degradation as E.coli TGI. The difference is that
only minimal double stranded breaks are detected at concentrations of
ciprofloxacin up until 0.064mg/l (Figure 5.20, Lane 6), after which DNA
degradation is apparent after the addition of 5mg/l ciprofloxacin (Figure 5.20,
Lane 9). Therefore the addition of ciprofloxacin has the same effect on the
chromosomal DNA in E.coli CIP223 as E.coli TGI, however the pattern ofDNA
degradation and double strand break formation in E.coli CIP223 occurs at a
higher ciprofloxacin concentration.
173
Since challenge of E.coli TGI with ciprofloxacin seemed to culminate in a
different response to nalidixic acid with regards to degradation of DNA at the
OBC, further experiments were carried out to investigate this. As mentioned
before, microbiological experiments carried out previously demonstrated that
the fluoroquinolones ciprofloxacin and ofloxacin possess an additional
mechanism of bactericidal action (Mechanism B) compared to the basic
quinolone response, shown to occur with nalidixic acid (Mechanism A). The
results achieved from the experiments described in this chapter suggested that
the additional bactericidal mechanism of action of ciprofloxacin but not of
nalidixic acid, was the degradation of DNA into small fragments at the OBC
(compare Figure 5.6, Lane 6 to Figure 5.7, Lane 6). After incubating the cells for
360 minutes at the OBC of ciprofloxacin, DNA fragments as small as 4kb are
released but at the optimum bactericidal concentration of nalidixic acid, these
small fragments are not visible (Figure 5.13).
This destruction of the bacterial chromosome into small fragments is reminiscent
of apoptosis in eukaryotic cells. Apoptosis is the name given to the changes
through which a cell passes when, for example, it is damaged to such an extent
that it is past the point of being repairable. Apoptosis, or physiological cell
death occurs when a cell within an organism dies by a mechanism orchestrated
by proteins encoded by the host's genome. In this way unwanted cells are
killed which is important, for example, in ageing, in development and in
defence. It is very interesting that topoisomerase II-inhibiting drugs such as
VM26 and VP16 which have an identical mode of action to the quinolone drugs
actually elicit apoptosis in thymocyte and lymphocyte cells (Walker et al, 1991).
Themechanismby which these drugs function, that is formation of the "cleavable
complex" and formation of double stranded DNAbreaks, results inDNAwhich
is considered by the cell as being too damaged to repair. In eukaryotic cells, the
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nucleus shrinks, the nuclear membrane breaks down, the chromatin collapses
and nucleases pass from the cytoplasm to the nucleus and destroy the DNA. It
has been shown that the interaction with the eukaryotic antineoplastic drugs
VM26 and VP16 has two components, firstly the interaction of the drug with
topoisomerase II and secondly the activation of endonucleolytic activities
associated with apoptosis. Enzymes which have been discussed previously as
having a role in this process are endo-exonucleases. For example in human
leukemic CEM cells an endo-exonuclease has been connected with the chromatin
DNA fragmentation that accompanies apoptosis (Fraser, 1994). Parallels have
been drawn between these eukaryotic enzymes which processively degrade
regions of DNA in cells that have become too damaged to be repaired and the
RecBCD enzyme of E.coli (Fraser, 1994). As discussed in 1.6.6, RecBCD has
both endonuclease and exonuclease activities and is normally involved in repair
of double stranded DNA breaks. However, if the bacterial cell becomes damaged
beyond repair, the RecBCD enzyme becomes reckless and degrades the
chromosomal DNA to acid-soluble nucleotides (Smith, 1988).
Unlike many enzymes that have been previously discussed to be involved in
the response of the cell to quinolones, RecBCD is not part of the SOS regulation,
nor is it inducible. Therefore, in order to show that it was indeed RecBCD that
was involved in this "apoptosis"-like DNA degradation effect, the presence of
DNA degradation in the presence of a protein synthesis inhibitor would have
to be shown.
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5.3 Is the "apoptosis"-like DNA degradation de¬
pendent on protein synthesis?
In the light of the ideas described above, experiments were then carried out to
investigate whether the "apoptosis"-like response observed to occur on
challenge with ciprofloxacin occurred in the absence of ongoing protein
synthesis. If the "apoptosis" -like response was still seen to occur, the production
of a DNA damage-inducible nuclease could be ruled out and the DNA damage
could be attributed to a constitutive nuclease such as RecBCD.
A logarithmic culture of E.coli TGI was challenged as before with various
concentrations of ciprofloxacin, however, one hour prior to the addition of
ciprofloxacin, 170mg/l chloramphenicol was added to inhibit all ongoing
protein synthesis. Samples of the cultures after one hour were embedded in
agarose as before and electrophoresed on pulsed field gels.
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Figure 5.21A: The effect of the inhibition of protein synthesis prior to the addition
of various concentrations of ciprofloxacin on the integrity of E.coli chromosomal
DNA. Displayed below is a photograph of the pulsed field gel on which the
large fragments of DNA were resolved.
1 23456 7 8 9 M
48.5kb
Protein synthesis was inhibited by the addition of 170mg/l chloramphenicol
one hour prior to the addition of various concentrations of ciprofloxacin and
an aliquot of cells removed after one hour to assess DNA damage: Lane 1, no
ciprofloxacin; Lane 2, 0.00025mg/l ciprofloxacin; Lane 3, 0.001mg/l
ciprofloxacin; Lane 4,0.004mg/l ciprofloxacin; Lane 5,0.016mg/l ciprofloxacin;
Lane 6,0.064mg/l ciprofloxacin; Lane 7,0.15mg/l ciprofloxacin; Lane 8,0.5mg/
1 ciprofloxacin; Lane 9, 5mg/l ciprofloxacin; Lane M, X concatemer markers.
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It was found that at the lowest concentration of ciprofloxacin (Figure 5.21A,
Lane 2), or even in the absence of ciprofloxacin (Figure 5.21A, Lane 1), DNA
double stranded breaks were seen to occur routinely. This is possibly as a result
of protein synthesis inhibition affecting the cellular manufacture ofDNA repair
enymes which would normally repair any DNA nicks. Although it has been
hypothesised that RecBCD, the predominant DNA repair enzyme is
constitutively expressed and is responsible for the DNA degradation, it is
possible that on addition of chloramphenicol to the cell, the inhibition of other
accessory repair enzymes results in more persistent DNA double stranded
breaks (Figure 5.21A, Lanes 1 to 5). As shown in Figure 5.21A, Lane 6, on
addition of 0.064mg/l ciprofloxacin, DNA degradation starts to proceed, and
is increasingly predominant with higher ciprofloxacin concentrations (Figure
5.21A, Lane 9). At the OBC and high ciprofloxacin concentrations, smallerDNA
fragments were detected, as had been found to occur also in the presence of
ongoing protein synthesis. Therefore it was concluded that the "apoptosis"-
like DNA degradation found to occur with ciprofloxacin also proceeded in the
absence of protein synthesis. The results of inhibiting protein synthesis on
nalidixic acid-induced cell death are shown in Figure 5.21B.
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Figure 5.21B: The effect of the inhibition ofprotein synthesis prior to the addition
of various concentrations of nalidixic acid on the integrity of E. coli chromosomal
DNA. Displayed below is a photograph of the pulsed field gel on which the
large fragments of DNA were resolved.
12 34 56 7 8 9 M
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Protein synthesis was inhibited by the addition of 170mg/l chloramphenicol
one hour prior to the addition of various concentrations of nalidixic acid and
an aliquot of cells removed after one hour to assess DNA damage: Lane 1, no
nalidixic acid; Lane 2, lmg/1 nalidixic acid; Lane 3,5mg/l nalidixic acid; Lane
4,10mg/l nalidixic acid; Lane 5,50mg/l nalidixic acid; Lane 6,90mg/l nalidixic
acid; Lane 7, 200mg/l nalidixic acid; Lane 8, 500mg/l nalidixic acid ; Lane 9,
1000mg/l nalidixic acid ; Lane M, X concatemer markers.
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Even when no nalidixic acid was added to the bacterial culture, more DNA
damage was observed compared to the addition of nalidixic acid in the absence
of chloramphenicol (Figure 5.7). The inhibition of protein synthesis by
chloramphenicol is believed to affect the repair of "routine" DNA damage in
the cell. Even at high nalidixic acid concentrations, there was still found to be
evidence of intact bacterial chromsomal DNA. In conclusion, nalidixic acid,
although resulting in double stranded breaks at high concentrations, does not
cause degradation of the chromosomal DNA.
It was interesting that the addition of ciprofloxacin in the absence of protein
synthesis (Figure 5.21A) resulted inwhat appeared to be incomplete degradation
of the bacterial chromsome. Comparing the effect of various concentrations of
ciprofloxacin in the presence and absence of protein synthesis (Figure 5.6 and
Figure 5.21A respectively), it is apparent that a band on the pulsed field gel
corresponding to intact chromosomal DNA is present with the latter but not
the former. Although the addition of chloramphenicol and ciprofloxacin
together do show an "apoptosis"-like degradation of DNA and the bulk of the
larger DNA fragments seem to be degraded into smaller fragments (Figure
5.21A, Lanes 6 to 9), the bacterial chromosome remains intact to some degree.
This can possibly be explained by the fact that the mode of action of
chloramphenicol has been shown to cause loops of DNA to migrate from the
cytoplasm to the nucleoid mass, thus the bacterial chromosome may become
less accessible to the quinolone drugs and the enzymes responsible for the
degradation (see later).
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5.4 Is the "apoptosis'Mike DNA degradation de¬
pendent on RNA synthesis?
In the same way, the RNA synthesis dependence of the "apoptosis"-like DNA
degradation was investigated. By adding rifampicin to the bacterial culture
one hour prior to the addition of various concentrations of ciprofloxacin, the
effect of the inhibition of RNA synthesis on this "apoptosis"-like effect was
studied. As shown in Figure 5.22, the inhibition of RNA synthesis did not
affect the "apoptosis"-like DNA degradation. This reconfirmed that the nuclease
responsible for degrading the chromosomal DNAwas constitutively expressed.
Itwas found that at the lowest concentration of ciprofloxacin (Figure 5.22, Lane
2), or even in the absence of ciprofloxacin (Figure 5.22, Lane 1), DNA double
stranded breaks were seen to occur routinely. This is possibly as a result of
RNA synthesis inhibition affecting the cellular manufacture of DNA repair
enzymes whichwould normally be around tomend anyDNAnicks. Although
it has been hypothesised that RecBCD, the predominant DNA repair enzyme is
constitutively expressed and is responsible for the DNA degradation, it is
possible that on addition of rifampicin to the cell, the inhibition of other
accessory repair enzymes results in more persistent DNA double stranded
breaks (Figure 5.22, Lanes 1 to 5). As shown in Figure 5.22B, Lane 6, on addition
of 0.064mg/l ciprofloxacin, DNA degradation starts, and is increasingly
predominant with higher ciprofloxacin concentrations (Figure 5.22, Lane 9).
At the OBC and high ciprofloxacin concentrations, theDNAwas found to be in
the lower molecular weight range, as had been found to occur also in the
presence of ongoing RNA synthesis.
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Figure 5.22: The effect of 160mg/l rifampicin added one hour prior to the
addition of various concentrations of ciprofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below is a photograph of the pulsed field gel
on which the large fragments of DNA were resolved.
1 23 4567 8 9M
RNA synthesis was inhibited by the addition of 160mg/l rifampicin one hour
prior to the addition of various concentrations of ciprofloxacin and an aliquot
of cells removed after one hour to assessDNA damage: Lane 1, no ciprofloxacin;
Lane 2, 0.00025mg/l ciprofloxacin; Lane 3, 0.001mg/l ciprofloxacin; Lane 4,
0.004mg/l ciprofloxacin; Lane 5, 0.016mg/l ciprofloxacin; Lane 6, 0.064mg/l
ciprofloxacin; Lane 7, 0.15mg/l ciprofloxacin; Lane 8, 0.5mg/l ciprofloxacin;
Lane 9,5mg/l ciprofloxacin; Lane M, A. concatemer markers.
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In order to show that the concentrations of chloramphenicol and rifampicin
added did not affect the production of double stranded DNA breaks, different
concentrations of chloramphenicol (Figure 5.23) or rifampicin (Figure 5.24) were
added to a logarithmic culture of E.coli TGI as before.
As shown in Figures 5.23B, 5.23C, 5.24B and 5.24C the same amount of DNA
damage was found to be constant throughout different concentrations of
chloramphenicol and rifampicin and the viable count was not seen to differ
significantly.
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Figure 5.23: The effect of various concentrations of chloramphenicol added on
the integrity of E. coli chromosomalDNA. Displayed below are a graph plotting
the viable counts of the culture at the specified time points (5.23A), a photograph
of the pulsed field gel on which the large fragments of DNA were resolved
(5.23B) and a photograph of the conventional agarose gel on which the smaller
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Cells were challenged by the addition of various concentrations of
chloramphenicol and an aliquot of cells removed after 60 minutes to assess
DNA damage: Lane 1, no chloramphenicol; Lane 2, 20mg/l chloramphenicol;
Lane 3, 40mg/l chloramphenicol; Lane 4, 80mg/l chloramphenicol; Lane 5,
120mg/l chloramphenicol; Lane 6,170mg/l chloramphenicol; Lane 7,200mg/
1 chloramphenicol; Lane 8, 240mg/l chloramphenicol; Lane 9, 300mg/l
chloramphenicol; Lane M, X concatemer/ X Hindlll markers.
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Figure 5.24: The effect of various concentrations of rifampicin added on the
integrity of E. coli chromosomal DNA. Displayed below are a graph plotting
the viable counts of the culture at the specified time points (5.24A), a photograph
of the pulsed field gel on which the large fragments of DNA were resolved
(5.24B) and a photograph of the conventional agarose gel on which the smaller
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Cells were challenged by the addition of various concentrations of rifampicin
and an aliquot of cells removed after 60 minutes to assess DNA damage: Lane
1, no rifampicin ; Lane 2, 20mg/l rifampicin; Lane 3, 40mg/l rifampicin; Lane
4,80mg/l rifampicin; Lane 5,120mg/l rifampicin; Lane 6,160mg/l rifampicin;
Lane 7, 200mg/l rifampicin; Lane 8, 240mg/l rifampicin; Lane 9, 300mg/l
rifampicin; Lane M, X concatemer / X Hindlll markers.
187
5.5 Is the "apoptosis"-like DNA degradation
occurring after ciprofloxacin challenge Mechanism
B?
As mentioned before, the bactericidal activities of nalidixic acid and
ciprofloxacin have been differentiated into Mechanism A and Mechanism B
(Smith, 1986). Mechanism A is common to all quinolones and is abolished by
the inhibition of RNA synthesis. Mechanism B is unique to ofloxacin and
ciprofloxacin and does not require RNA or protein synthesis. The results above
suggested that the "apoptosis"-like effect was possibly what had been referred
to as Mechanism B since it was found to be unique to ciprofloxacin, does not
require RNA or protein synthesis and causes rapid cell death. As shown in
Figure 5.7, the addition of the OBC of nalidixic acid did not cause this
"apoptosis"-like effect, and the addition of chloramphenicol to inhibit protein
synthesis did not change the pattern of DNA degradation (Figure 5.21B).
The inhibition of protein synthesis increased the viable count of the nalidixic
acid-challenged bacterial culture as shown in Figure 5.2, despite the formation
of double stranded DNA breaks which are in this case non-lethal. If this
"apoptosis" -like effect was indeed Mechanism B, then as well as occurring in
response to ciprofloxacin-challenge, it would also be expected to occur in
response to ofloxacin challenge. On the other hand, it would not be expected
to occur in response to norfloxacin and oxolinic acid which have been shown
only to elicit Mechanism A in the same way as nalidixic acid. This was
investigated as described in 5.6 to 5.7.
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5.6 Does ofloxacin elicit the "apoptosis"-like
response?
In the same way as before, a logarithmic culture of E.coli TGI was challenged
with the OBC of ofloxacin (Figure 5.25). Aliquots of the culture were extracted
at different time points and embedded in agarose plugs. Photographs of the
gels after pulsed field and conventional electrophoresis are displayed below in
Figure 5.25.
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Figure 5.25: The effect of 0.9mg/l ofloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.25A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.25B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Figure 5.25C
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Cells were challenged with 0.9mg/l ofloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane8,t=180; Lane9, t=360; Lane M, A, concatemer / TiHindlll markers.
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Addition of ofloxacin at the OBC to a logarithmic culture of E.coli TGI suggested
that this antibiotic did elicit the "apoptosis"-like response. Even after 5 minutes,
a decrease in the viable count of the culture was observed (Figure 5.25A),
corresponding with degradation of the chromosomal DNA and loss of high
molecular weight fragments (Figure 5.25B). It appeared that an active repair
mechanism was again present as the DNA seemed to become more intact with
time. However the extent of the "apoptosis"-like response was much less
pronounced with ofloxacin than it was with ciprofloxacin (Figure 5.12B).
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5.7 Do norfloxacin and oxolinic acid elicit the
MapoptosisM-like response?
In the same way as before, a logarithmic culture of E.coli TGI was challenged
with either the OBC of norfloxacin or oxolinic acid (Figures 5.26 and 5.27).
Aliquots of the culture were extracted at different time points and embedded
in agarose plugs. Photographs of the gels after pulsed field and conventional
electrophoresis are displayed below in Figures 5.26 and 5.27.
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Figure 5.26: The effect of 1.5mg/l norfloxacin on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.26A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.26B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challengedwith 1.5mg/l norfloxacin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7, t=120;
Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer / X Hindlll markers.
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Figure 5.27: The effect of 9mg/l oxolinic acid on the integrity of E. coli
chromosomal DNA. Displayed below are a graph plotting the viable counts of
the culture at the specified time points (5.27A), a photograph of the pulsed
field gel on which the large fragments of DNA were resolved (5.27B) and a
photograph of the conventional agarose gel on which the smaller fragments of
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Cells were challenged with 9mg/l oxolinic acid and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; LaneM, X concatemer / A,Hindlll markers.
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The "apoptosis"-like response did not seem to occur with oxolinic acid (Figure
5.27). Instead, extensive double stranded breaks were observed but no small
DNA fragments (Figure 5.27C). However some loss of the chromosomal DNA
was detected five and fifteen minutes after addition of the OBC of norfloxacin
to the bacterial culture (Figure 5.26B). This suggested that the "apoptosis"-like
effect might be a characteristic of norfloxacin-mediated as well as ofloxacin-
and ciprofloxacin-mediated cell death.
It also seemed that the formation of double stranded DNA breaks was lethal in
the case of fluoroquinolones such as ciprofloxacin, ofloxacin and norfloxacin
but non-lethal in the case of quinolones such as nalidixic acid and oxolinic acid.
To confirmwhether the formation of double stranded DNAbreaks could indeed
be the lethal event, two further experiments were carried out.
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5.8 Is double stranded break formation the lethal
event in fluoroquinolone challenged cells?
The formation of double stranded DNA breaks in fluoroquinolone challenged
cells was mimicked by two separate experiments in order to ascertain that it
was the formation of double stranded breaks by the fluoroquinolones that was
the lethal event and not another property of the antibiotics. Two different
plasmids were used to introduce double stranded DNA breaks into the
chromosome and the effect on the integrity of the DNA and on the viability of
the cells was investigated.
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5.8.1 Use of a ccdB-carrying plasmid tomimick quinolone double
stranded DNA breakage
As mentioned before, the CcdB toxin targets the GyrA subunit of DNA gyrase
and poisons it in the same way as do the quinolones (Bernard et al, 1993). By
doing so, double stranded breaks are formed in the chromosome and the cell
dies. It has previously been shown by comparing the viscosity of total DNA
extracted from CcdACcdB bacteria and from CcdA+ CcdB+ bacteria that CcdB
fragments the genomic DNA (Bernard and Couturier, 1992). However the
appearance of the genomic DNA on a pulsed field gel was not ascertained.
A plasmid carrying the ccdB gene under an inducible promoter pKIL119 was
transformed into E.coli TGI. A logarithmic culture of the resulting strain E.coli
TGlpKIL119 was grown up and production of CcdB induced by the addition
of 0.5mM IPTG. Aliquots of the culture were extracted at specified time points
and treated as before.
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Figure 5.28: The effect of ccdB expression on the integrity of E. coli chromosomal
DNA. Displayed below is a photograph of the pulsed field gel on which the
large fragments of DNA were resolved (5.28A) and a photograph of the
conventional agarose gel onwhich the smaller fragments ofDNAwere resolved
(5.28B).
Figure 5.28A
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Figure 5.28B
Cells carrying pKIL119 were induced with 0.5mM IPTG and an aliquot of cells
removed at the following time points (in minutes) to assess DNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer/ X Hindlll markers.
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The results of inducing expression of CcdB in E.coli revealed that this
topoisomerase poison did not culminate in the same effect as did ciprofloxacin.
At all the time points investigated, intact chromosomal DNA was always
detected. However a faint band was seen corresponding to a 48.5kb DNA
fragment. This band was also detected on the conventional agarose gel (Figure
5.28B). The identity of this band is discussed later. However by no means the
cellular response to CcdB appeared as destructive as that to ciprofloxacin. The
results of the viable count experiments revealed that a rapid loss of viability
occurred on induction of ccdB by the addition of IPTG (data not shown).
Therefore even the minimal double stranded breaks detected on the gels
corresponded to cell death.
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5.8.2 Use of aNofl-carrying plasmid tomimick quinolone-induced
double stranded DNA breakage
The Notl restriction endonuclease is known to cleave the E.coli chromosome at
22 sites (Condemine and Smith, 1990), releasing fragments of size 20kb to lOOkb.
Therefore this rare-cutting endonuclease was used tomimick quinolone-induced
double stranded breaks.
A plasmid carrying the Nofl-encoding gene under an inducible promoter was
transformed into E.coli TGI. A logarithmic culture of the resulting strain E.coli
TGlpNotI was grown up and production of Notl induced by the addition of
0.5mM IPTG. Aliquots of the culture were extracted at specified time points
and treated as before.
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Figure 5.29: The effect of Notl expression on the integrity of E. coli chromosomal
DNA. Displayed below are a photograph of the pulsed field gel on which the
large fragments of DNA were resolved (5.29A) and a photograph of the
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Cells carrying pNotl were induced with 0.5mM IPTG and an aliquot of cells
removed at the following time points (inminutes) to assess DNA damage: Lane
1, t=0; Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, A concatemer / A,Hindlll markers.
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The induction of Notl in E.coli resulted in the production of a smear of
chromosomal DNA fragments on the pulsed field gel (Figure 5.29A).
Surprisingly, this effect was also seen prior to the addition of IPTG (Figure
5.29A, Lane 1). It can possibly be concluded that the expression ofNotl is "leaky"
and occurs even when the promoter is not stimulated. The extent of DSBs
actually seemed to increase with time (compare Figure 5.29A Lane 2 to Lane 9)
and the presence of a band corresponding to a DNA fragment of size 48.5kb
(compared to the bottom band of X concatemers) was detected. This is shown
more clearly in Figure 5.29B. The identity of this band is discussed further
later. Again, The results of the viable count experiments revealed that a rapid
loss of viability occurred on induction of Notl by the addition of IPTG (data
not shown). Therefore even the minimal double stranded breaks detected on
the gels corresponded to cell death.
205
5.9 Is this "apoptosisM-like effect involved in the
bactericidal mechanisms of other antibiotics than
the fluoroquinolones?
Having related a bacterial "apoptosis"-like effect to ofloxacin and ciprofloxacin
mediated cell death and possibly to norfloxacin mediated cell death, the
occurrence of this cell deathmechanism in response to other unrelated antibiotics
was investigated. The effect of growth-inhibiting concentrations of three
antibiotics from three separate classes on the integrity of chromosomal DNA
was studied: ampicillin (an inhibitor of cell division), trimethoprim (an inhibitor
of dihydrofolate reductase) and streptomycin (an inhibitor of protein synthesis).
The results are displayed in the following Figures 5.30 to 5.32.
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Figure 5.30: The effect of lmg/1 ampicillin on the integrity of E. coli chromosomal
DNA. Displayed below are a photograph of the pulsed field gel on which the
large fragments of DNA were resolved (5.30A) and a photograph of the
conventional agarose gel onwhich the smaller fragments ofDNAwere resolved
(5.30B).
Figure 5.30A
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Figure 5.30B
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Cells were challenged with lmg/1 ampicillin and an aliquot of cells removed at
the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7, t=120;
Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer / X Hindlll markers.
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Figure 5.31: The effect lmg/1 trimethoprim on the integrity of E. coli
chromosomal DNA. Displayed below are a photograph of the pulsed field gel
on which the large fragments ofDNAwere resolved (5.31A) and a photograph
of the conventional agarose gel on which the smaller fragments of DNA were
resolved (5.31B).
Figure 5.31A
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Figure 5.31B




Cells were challenged with lmg/1 trimethoprim and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7,
t=120; Lane 8, t=180; Lane 9, t=360; Lane M, X concatemer / XHindlll markers.
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Figure 5.32: The effect of 25mg/l streptomycin on the integrity of E. coli
chromosomal DNA. Displayed below are a photograph of the pulsed field gel
on which the large fragments of DNAwere resolved (5.32A) and a photograph
of the conventional agarose gel on which the smaller fragments of DNA were
resolved (5.32B).
Figure 5.32A
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Figure 5.32B
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Cells were challenged with 25mg/l streptomycin and an aliquot of cells removed
at the following time points (in minutes) to assess DNA damage: Lane 1, t=0;
Lane 2, t=5; Lane 3, t=15; Lane 4, t=30; Lane 5, t=60; Lane 6, t=90; Lane 7, t=120;
Lane 8, t=180; Lane 9, t=360; Lane M, A concatemer / A Hindlll markers.
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The results in Figures 5.30 to 5.32 display some interesting results. While
ampicillin and trimethoprim do not appear to affect the integrity of the DNA,
the addition of streptomycin was found to induce DSBs in a manner very similar
to that of nalidixic acid. The reason for this may be a result of streptomycin's
mode of action as an antibiotic affecting the accuracy of protein manufacture.
As will be discussed in more detail later, streptomycin results in misreading of
the mRNA at the ribosome and subsequently mutant proteins are formed. It
can be imagined how such proteins could damage the cell in various ways as
well as prevent the correct repair of DNA. Therefore as a result, any DNA
nicks that arise in the cell cannot be repaired, as seen in Figure 5.32A.
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5.10 What is Mechanism A?
Having investigated the molecular aspects of Mechanism B of the quinolone
drugs, attention was turned to the bactericidal pathway named Mechanism A.
MechanismA as described before, was the name given to the cell death occurring
with all quinolones which was dependent on protein and RNAsynthesis (Smith,
1986). The cause of this bactericidal mechanism has been the source of much
debate with suggestions that the production of a toxic protein might be the
key event (Courtright et al, 1988). These results suggested that it was RNA and
protein synthesis per se that were lethal to the cell after quinolone challenge. In
considering the roles of rifampicin and chloramphenicol in the inhibition of
RNA and protein synthesis, it is vital to realise at which point in transcription
and translation these compounds function. Rifampicin and chloramphenicol
are both bacteriostatic antibiotics, rifampicin works by binding to the [3 subunit
of RNA polymerase and prevents the initiation of transcription, whereas
chloramphenicol prevents the initiation of protein synthesis by binding to the
50S ribosomal subunit.
This information, coupled with the findings of Willmott et al (1994) which
showed that the complex of quinolone, gyrase and DNA in vitro results in the
production of truncated transcripts by RNA polymerase was the basis for the
next set of experiments. Truncated transcripts were believed to be produced
since the quinolone-gyrase-DNA poisoned complex acted as a barrier to the
movement of RNA polymerase which fell off the template 10 to 20bp before
the quinolone-gyrase complex on the DNA, releasing a shortened mRNA. If
this also happened in vivo, one could expect that the production of truncated
mRNAs and hence truncated polypeptides would result in a complete de¬
regulation of the cell.
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By adding either rifampicin or chloramphenicol to inhibit either RNAor protein
synthesis respectively, it can be understood how this quinolone-induced lethal
event could be avoided. Although a cell deficient in RNA and/or protein
synthesis would not be able to grow and divide, once the effect of the RNA
and/or protein synthesis inhibitor and the quinolone wore off, the cell would
again be functional.
To investigate this quinolone-induced RNA polymerase block that occurred in
vitro also occurred in vivo, a logarithmic culture of E.coli TGI was challenged
with the OBC of nalidixic acid for specified amounts of time and RNA extracted.
After electrophoresis, the RNA was blotted and the membrane probed with a
probe specific to gyrA. AgyrA oligo probe labelled with fluorescein was initially
used to detect the prematurely truncated transcripts. However this non¬
radioactive system was found not to be sensitive enough, considering that it
was aimed to detect single-copy gyrA mRNAs of varying length. The use was
then made of a 32P-dCTP labelled gyrA probe which was hoped to be much
more sensitive.
Preliminary results show that a "smear" of gyrA mRNA of varying length was
detected, correlating with the in vitro results as shown in Figure 5.33. The
addition of lower concentrations of ciprofloxacin and nalidixic acid correlates
with much truncation of gyrA (Figure 5.33, Lanes 4,5,10,13 and 14) whereas
higher concentrations of ciprofloxacin and nalidixic acid correlate with no
detectable gyrA transcripts, confirming the theory that at high quinolone
concentrations, transcription is inhibited.
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Figure 5.33: Northern blot of ciprofloxacin- and nalidixic acid-treated cultures
of E.coli TGI probed with a gyrA-specific probe. E.coli TGI was grown up to
log phase, challenged with various concentrations of ciprofloxacin or nalidixic
acid and RNA extracted after 10 minutes. After electrophoresis the gel was
blotted and the membrane hybridised to a gyrA-specific probe.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Lane 1, 0.15mg/l ciprofloxacin; Lane 2, 0.5mg/l ciprofloxacin; Lane 3, lmg/1
ciprofloxacin; Lane 4,0.004mg/l ciprofloxacin; Lane 5,0.008mg/l ciprofloxacin;
Lane 6,5mg/l ciprofloxacin; Lane 7,0.002mg/l ciprofloxacin; Lane 8,0.OOlmg/
1 ciprofloxacin; Lane 9, no ciprofloxacin; Lane 10,3mg/l nalidixic acid; Lane 11,
no nalidixic acid; Lane 12, 100mg/l nalidixic acid; Lane 13, 5mg/l nalidixic
acid; Lane 14,10mg/l nalidixic acid.
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5.11 The Contribution of SOS Mutagenesis to
Quinolone-Induced Cell Death
Although the two major pathways of quinolone-iriduced cell death have been
elucidated by this work, it is also likely that some minor cellular pathways
contribute. For example, quinolone drugs have previously been shown to cause
a loss of membrane integrity and leakage of intracellular material (Dougherty
and Saukkonen, 1985). Another cellular response to quinolone drugs is the
SOS response, although there has been much debate whether or not the SOS
response increases cell viability after quinolone challenge (Lewin et al, 1989;
Walters et al, 1989; Piddock and Wise, 1987). Proteins produced in the response
to DNA damage such as RecA, UmuD, UmuC and SulA although offering a
protective role to the cell, do not actually seem to affect cell viability. The reason
for this could be that so many cellular repair functions rely on the nicking-
resealing activity of DNA gyrase. One of the SOS functions induced by
quinolone drugs was investigated in the course of this work. SOSmutagenesis
in E.coli is carried out by RecA, DNA polymerase III, UmuD, UmuD' and UmuC
(Murli and Walker, 1993; Peat et al, 1996) and the result is that error-prone DNA
replication occurs although the mutation rate is unknown. A correlation
between umuC induction and a Salmonella mutagenicity assay for quinolone
antimicrobials has previously been ascertained (Power and Phillips, 1993). To
study how errors in DNA replication might affect the viability of the cell,
0.002mg/l ciprofloxacin (a level below the MIC so the cells could still divide)
was added to a logarithmic culture of E.coli, the culture allowed to continue to
grow and a chromosomal preparation of DNA carried out. Taking gyrA as a
representative gene, a part of the gyrA gene was sequenced but no mutations
were found. This probably suggests that the DNA replication mutations only
occurred at a low frequency, the mutations were detrimental and the cell died
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or that they were later repaired by the DNA repair machinery.
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5.12 Discussion
By relating the viable count of a quinolone challenged E.coli culture to double
stranded DNAbreaks (DSBs) andDNA degradation, the molecular mechanisms
involved in quinolone cell death have been investigated. The previously
unexplained mechanism "Mechanism B" has been thoroughly studied at a
molecular level and shown to correlate with the microbiological observations.
Preliminary findings showed that the molecular mechanism of Mechanism A
correlates with the in vitro investigations (Willmott et al, 1994).
5.12.1 The Molecular Basis of Mechanism B
Mechanism B had previously been described as a bactericidal response of the
cell as a result of challenge with quinolone drugs which could not be inhibited
by RNA synthesis- and protein synthesis-inhibitors. This bactericidal
mechanism had been found only to be possessed by ciprofloxacin (Smith and
Lewin, 1988), DR-3355 (Lewin andAmyes, 1989), fleroxacin (Lewin and Amyes,
1990), tomefloxacin (Lewin et al, 1989b), ofloxacin (Smith and Lewin, 1988) and
perfloxacin (Lewin and Amyes, 1990). BothDNA damage and the inhibition of
any further DNA replication have been previously discussed in relation to
quinolone binding to an actively replicating gyrase-DNA complex and the
occurrence of a potentially cytotoxic event (Crumplin and Smith, 1976). Maxwell
(1992) speculated that Mechanism B was the result of the formation of a stable
ternary complex of quinolone, gyrase and DNA which then forms a barrier to
the passage of DNA and RNA polymerases. The lesion that resulted was
proposed to be the basis for cell death. Howard et al (1993) proposed that
Mechanism B resulted from SOS processing of quinolone-damaged DNA and
that the GyrA subunit is the site of action of Mechanism B. All these previous
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observations were found to fit in with the model proposed by this work.
Differences in the state of the bacterial genomic DNA were observed by
electrophoresis depending whether the antibiotic used elicited Mechanism B
as well as Mechanism A. Those tested which had been shown before to exhibit
Mechanism B, that is ciprofloxacin and ofloxacin, were shown to give rise to
DNA degradation after 60minutes which was likened to the apoptosis induced
by eukaryotic topoisomerase targeting drugs (Walker et al, 1991). The quinolone
antibiotics only possessing Mechanism A that were tested (nalidixic acid and
oxolinic acid) did not show this "apoptosis"-like effect even although extensive
DSBs were observed. Norfloxacin, which had previously been shown not to
elicit Mechanism B, showed a very similar response to that of ofloxacin during
the course of this work, suggesting that the action of norfloxacin is somewhat
similar to ciprofloxacin and ofloxacin.
5.12.2 The formation of "cleavable complexes"
The similarity of mode of action between the quinolone antibacterials and some
anti-cancer drugs on DNA gyrase and topoisomerase II respectively prompted
parallels to be drawn as concerns the mechanism of cell death (Maxwell, 1992;
Liu, 1989; Hsiang, Libou and Lou, 1989). Topoisomerase Il-targeting drugs
also form "cleavable complexes" with topoisomerase II and DNA in which the
enzyme becomes covalently but reversibly linked to the broken ends of DNA.
Three possible outcomes then exist for the cleavable complex:
1. The cleavable complex could be converted to a permanent enzyme-linked
strand break by random thermalmotion (although this is probably a rare event).
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2. The cleavable complex could be dissociated into functional enzyme and intact
DNA.
3. The cleavable complex could be processed by either the DNA replication
machinery, the transcriptional machinery or the DNA repair machinery into a
form of DNA damage that is irreversible.
It is such damage resulting from the breakage of the cleavable complexes that
is thought to be cytotoxic. However, the reversible nature of cleavable complexes
means that cytotoxicity results from the small fraction that become irreversible.
Since DSBs are in fact routinely repaired, only a certain number of DSBs will
become cleavable complexes ofwhich only somewill accumulate in irreversible
DNA damage. Another similarity between cleavable complex formation in
prokaryotes and eukaryotes is that the lethal effects of topoisomerase II-targeting
drugs also appear to involve the action of the nucleic acid synthesis machinery
in the conversion of topoisomerase II cleavable complexes to lethal lesions. It
has been found in eukaryotes that the addition of DNA or RNA synthesis
inhibitors reduce the lethality of the topoisomerase II drugs (D'Arpa et al, 1990;
Kaufman et al, 1991) presumably by reducing the number of potentially lethal
collisions between the nucleic acid synthesis machinery and the cleavable
complexes. However a basal level of cell death was detected in the lack of
nucleic acid synthesis suggesting either that a small level of DNA synthesis is
ongoing or that there is another pathway creating DSBs. In E.coli, the inhibition
of RNA synthesis has also been shown to lessen the bactericidal effect of
quinolone drugs although this may also be explained by a different theory (see
later).
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5.12.3 Parallels with eukaryotic cells
In eukaryotes, the existence of repairmechanisms for cleavable complex-induced
damage is indicated by the hypersensitivity ofDNA repairmutants to the lethal
effects of topoisomerase-targeting drugs, for example the RAD52 mutants of
Saccharomyces cerevisiae. These RAD52 mutations are extremely sensitive to the
topoisomerase targeting drugsm-AMSA and camptothecin which induce high
levels of both gene conversion and reciprocal exchange consistentwith the type
of damage repaired by the RAD52 pathway (Nitiss andWang, 1988). The RAD52
gene product has been implicated in DSB repair and it is interesting that X-ray
sensitive CHO cells defective in DSB repair are also sensitive to topoisomerase
II-targeting drugs (Caldecott et al, 1990).
5.12.4 The Involvement of an Endo-exonuclease
In E.coli, it has been previously found thatDNA repair mutants such as recB' or
recC cells are hypersensitive to the lethal effects of quinolone drugs (Lewin et
al, 1989). Strengthening the evidence that RecBCD was the endo-exonuclease
responsible for this DNA degradation is the fact that parallels have previously
been drawn between RecBCD in E.coli and RAD52 in S.cerevisiae (Fraser, 1994).
From this it was concluded that possibly the same type of pathway was
responsible for the cytotoxicity of the quinolone drugs in E.coli as the cytotoxicity
of the topoisomerase II-targeting drugs in eukaryotes. Indeed, the fact that
nalidixic acid-treated cells of E.coli (Cook et al,1966a; Grigg, 1970; Hill and
Fangman, 1973) and B.subtilis (Cook et al, 1966b) have been already shown to
degrade their DNA suggested that DNA degradation may be associated with
cell death. Smith (1984) proposed that nicked DNA formed by the action of
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quinolone-inhibited DNA gyrase acts as a substrate for exonucleases which
degrade the DNA. The identity of the nuclease responsible for degrading the
chromosomal DNA in eukaryotes is unclear. However, evidence of a DNase I-
like enzyme in rat thymocytes (Peitsch et al, 1993), a Ca2+-dependent DNase I-
like endonuclease in virally transformed murine fibroblasts (Ucker et al, 1992)
and an inducible lymphocyte nuclear endonuclease associated with apoptosis
(Khodarev and Ashwell, 1996) have been published. It has been found that the
human leukemic CEM cell endo-exonuclease plays a role in the apoptotic cell
death induced in response to cytotoxic doses of various DNA damaging agents.
The degradative activity of this eukaryotic endo-exonuclease involved in
apoptosis has been likened to RecBCD of E.coli (Fraser, 1994). Also the RAD52
mutation in S.cerevisiae has been shown to result in a loss of nuclear endo-
exonuclease and a deficiency in recombination and recombinational DSB repair.
This observation provides a strong parallel between the functions of the
eukaryotic and prokaryotic endo-exonucleases. As discussed in 1.6.6, RecBCD
has both endonuclease and exonuclease activities and is normally involved in
the repair of DSBs and the repair of collapsed replication forks (Kuzminov,
1995a,b). However if the bacterial cell becomes damaged beyond repair, the
RecBCD enzyme becomes "reckless" and degrades the chromosomal DNA to
acid-soluble nucleotides (Smith, 1988). It has also been proposed that the
presence of lesions in templateDNAor a protein-mediated block to the progress
of replisomes results in the breakage of arrested replication forks, albeit an
apparently self-destructive behaviour of the cell (Kuzminov, 1995a,b).
Experiments have suggested that replication forks that are broken as a result of
treatment with nalidixic acid are repaired by the RecBCD recombinational
pathway (Kuzminov, 1995a,b). However the very nature of RecBCD repair
suggests that if the DNA was badly damaged, DNA degradation rather than
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DNA repairwould be the prominent activity. The results of experiments carried
out by Lewin and Smith (1990) suggested that RecBCD may be the enzyme
responsible for the DNA breakdown that was observed in bacteria challenged
with quinolones. Indeed pulse-chase experiments carried out on quinolone-
challenged B.subtilis indicated that the DNA degradation started from the
replication fork and continued sequentially along the chromosome from the
"new" to the"old" DNA (Ramareddy and Reiter, 1969). Although Lewin and
Smith (1990) found that DNA breakdown did occurwith quinolone-challenged
cells, they could not correlate it with the bactericidal effect of the drug. If, for
example, they had studied the DNA fragment sizes on pulsed field and
conventional gels, as described in this chapter, they would have possibly arrived
at a correlation. Themultiplemutagen sensitivities of recB' and recC cells reflects
a deficiency in post-replication repair processes, especially recombinational DSB
repair which attempt to rid the cell of DNA damage not excised by various
specific excision-repair enzymes before replication. Therefore as a result of the
parallels previously drawnbetween RecBCD and enzymes involved in apoptosis
in eukaryotes, and the fact that recB' and recC cells were hypersensitive to the
quinolones, it would be interesting to investigate the possible role of RecBCD
in the apparent "apoptosis"-like effect that had been observed after treatment
of E.coli cells with ciprofloxacin. The breakage of stalled replication forks has
been found to be followed by the RecBCD-dependent degradation of the newly
synthesised DNA (Kuzminov, 1995a,b). Interestingly, this degradation has been
found not to occur in a recB' cell (Buttin and Wright, 1968). By repeating the
ciprofloxacin-challenge experiments in a recB' or recC E.coli strain and studying
the DNA on a pulsed field gel, the presence or absence of an "apoptosis"-like
effect would confirm participation of this enzyme. The single-strand specificity
of RecBCD-mediated DNA degradation is reflected by the observation that if
the degradation is allowed to proceed to completion, only half of the newly
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incorporation label ismade acid-soluble (Buttin andWright, 1968; Veomert and
Kuempel, 1973).
Unlike many enzymes that have been previously discussed to be involved in
the response of the cell to quinolones, RecBCD is not part of the SOS regulon,
nor is it inducible. Therefore, in order to show that it was indeed RecBCD that
was involved in the "apoptosis"-like DNA degradation effect, the presence of
DNA degradation in the presence of a protein synthesis inhibitor had to be
shown. To investigate this, an amount of chloramphenicol sufficient to inhibit
protein synthesis was added one hour prior to the addition of various
concentrations of ciprofloxacin. The degradation of chromosomal DNA and
the apparent loss of the larger fragments ofDNA (Figure 5.21A) suggested that
this "apoptosis"-like degradation was protein synthesis independent.
5.12.5 Factors determining the lethality of DSBs
Although DSBs were observed in the chromosomal DNA of the cultures
challengedwith 0.001mg/l to 0.064mg/l ciprofloxacin, no "apoptosis"-like effect
was seen. Also in the nalidixic acid and oxolinic acid challenged cultures,
addition of these two antibiotics at their OBCs did not result in the same extent
of DNA degradation that was seen with ofloxacin and ciprofloxacin at their
OBCs. Even when the bactericidal effect of nalidixic acid was inhibited by the
addition of chloramphenicol (Figure 5.21B), DSBs were observed to be present
in the chromosomal DNA. This suggested that DSB formation was sometimes
non-lethal and possibly reversible. These observations agreed with those of
Lewin and Smith (1990) who detected degradation ofDNA in bacteria exposed
to nalidixic acid even when chloramphenicol or rifampicin was also present,
that is when nalidixic acid was not bactericidal. However on the other hand
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evidence has previously suggested that DSBs are a type ofDNA damage that is
highly lethal as it has been shown that repairable single stranded breaks may
be converted into DSBs (Boothman and Pardee, 1989). Indeed, single-stranded
breaks in the bacterial chromosome (Hill and Fangman, 1973) enlarging to
double stranded gaps (Fenwick and Curtis, 1973) have been observed in bacteria
treated with nalidixic acid. This suggested that it was the extent of DSB
formation that dictated the lethality on the bactericidal cell. Such a scenario
can easily be imagined since a cell with only a few DSBs in its chromosomal
DNAwould possibly have the repair proficiency to mend the breaks whereas a
cell with an abundance ofDSBs would possibly be unable to carry out sufficient
DNA repair and subsequently die. Therefore the binding affinity of a particular
quinolone for the gyrase-DNA complex probably determines the likelihood of
irreversible DSB formation since a drug that binds tightly to the gyrase-DNA
complex and forms a irreversible cleavable complex would be more likely to
result in lethality that a drug which bound less tightly and formed a more
reversible cleavable complex. This is illustrated in Figure 5.34.
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Figure 5.34:
Table 5.1: Potencies of quinolone drugs for cleavage ofDNA and inhibition of
supercoiling by DNA gyrase
Drug Gyrase Gyrase 50% Antibacterial Mechanism B?
cleavage inhibition activity Yes/No
pg/ml fig/ml M-g/ml
Nalidixic acid 50 >100 6.3 No
Oxolinic acid 10 25 0.2 No
Norfloxacin 1 5.5 0.1 No/ Yes
Ofloxacin 5 6.3 0.1 Yes
Ciprofloxacin 0.5 5.3 0.025 Yes
Data taken from Domagala et al (1986)
From these data, it seemed that the higher the affinity of the quinolone drug
for the DNA gyrase cleavage reaction, the more DNA degradation leading to a
potential "apoptosis"-like effect occurred. Drugs binding tightly to the gyrase-
DNA complex and readily causing DNA cleavage were possibly more likely to
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form an irreversible cleavable complex and therefore stimulate the endo-
exonuclease function of RecBCD. Although less norfloxacin was required to
elicit cleavage of DNA than ofloxacin, it is possible that ofloxacin perhaps has
a more marked effect which affects cell death in a different way.
5.12.6 The Relationship between Cell Death and Transcription/
Replication
In all the experiments carried out involving the addition of ciprofloxacin to the
bacterial culture, an optimum in DNA degradation was observed to occur at
around 60minutes after which theDNA seemed to becomemore intact. This is
likely to be as a result of DNA repair enzymes which start to function again
after the antibiotic begins to become less active. From the viable count
experiments, it was found that on addition of a concentration of ciprofloxacin
less than or equal to the MIC (Figures 5.8A and 5.9A), the bacterial culture
stopped dividing for some time but then reinitiated cell division and resumed
normal growth kinetics. At concentrations of ciprofloxacin exceeding the MIC,
the culture rapidly died withminimum viability after 15 to 60minutes but then
seemed to start division once again. It was found that at higher ciprofloxacin
concentrations (5mg/l, 10mg/l, 50mg/1,100mg/l- Figures 5.16A, 5.17A, 5.18A,
5.19A), the extent of cell death was not as severe as with lower ciprofloxacin
concentrations (0.15mg/l, 0.5mg/l- Figures 5.12A and 5.14A). At the higher
ciprofloxacin concentrations, recovery seemed to be quicker also. The conclusion
from this set of viable counts was that at higher ciprofloxacin concentrations,
there was greater viability of the culture. This could possibly be attributed to
the fact that at high ciprofloxacin concentrations, no transcription or replication
forkmovement can occur as a result ofwidespread cleavable complex formation.
Since in this case the cleavable complexes will not be broken apart, the rapid
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death observed to occur with the lower ciprofloxacin concentrations did not
occur. This would explain why on the pulsed field gel there is always evidence
of intact chromosomal DNA at higher ciprofloxacin concentrations and the
chromosome is not as degraded as seen with the OBC of ciprofloxacin for
example. This scenario reflects the effect of topoisomerase II-targeting drugs
on topoisomerase II in the presence of nucleic acid synthesis inhibitors. As
mentioned previously, low levels of killing occur in quiescent eukaryotic cells
suggesting that active DNA replication and transcription contributes to cell
death (D'Arpa and Liu, 1989).
Therefore it appeared that an //apoptosis"-like effect was occurring with
ofloxacin and ciprofloxacin however the effect of these antibiotics differed from
the effect of eukaryotic topoisomerase Il-targeting drugs in that the bacterial
"apoptosis" seemed to be reversible to some extent whereas apoptosis in
eukaryotic cells certainly is not.
5.12.7 The preponderance of DNA migrating as a 50kb fragment
By running both pulsed field and conventional agarose gels, both highmolecular
weight and lowmolecularweight fragments can be detected. Only ciprofloxacin
(Figure 5.12B and 5.13) and ofloxacin (Figure 5.25B) were expected to be
associatedwithDNA degradation resulting in the production ofDNA fragments
as small as 4kb (Figure 5.13). However addition of norfloxacin to the bacterial
culture yielded surprising results: norfloxacin also showed this "apoptosis"-
like effect. On studying the pattern ofDNA degradation after ciprofloxacin or
ofloxacin challenge by pulsed field gel electrophoresis, it was apparent that
there was a preponderance of DNA fragments in the 50kb size region. The
production of DNA fragments in the 50kb size range was also seen to some
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extent to happenwith nalidixic acid, oxolinic acid and norfloxacin (Figures 5.7,
5.27 and 5.26) and has been reported also to occur with enoxacin (Courtright et
al, 1988). This can be explained by the action of RecBCD and the spacing of the
replication/ transcription complexes. The binding of RecBCD to the free ends
of DNA after the collapse of replication forks for example, has already been
discussed. The double stranded DNA is then unwound and degraded until a
Chi sequence is reached. At this point, the affinity of the RecD subunit for the
RecBC heterodimer is weakened and the resulting protein, RecBC loses its
exonuclease activity. The enzyme then becomes proficient as a recombinogenic
helicase. The binding of RecA to the single-stranded DNA, as well as protecting
it from further nuclease degradation and stimulating recombination, induces
the SOS response. In badly damaged cells, it is likely that single-stranded DNA
of variable lengthwill be released which maymigrate as a 50kb fragment when
electrophoresed. Although it has been estimated that there are 5kb between
Chi sequences in E.coli (Myers and Stahl, 1994), it is unlikely that all the Chi
sequences would be involved at once as this would result in very large scale
degradation of the chromosome. Another explanation is that if the replication/
transcription complexes were 50kb apart on the bacterial chromosome, stalling
of two by gyrase poisoningwould result in degradation ofDNA, leaving single-
stranded fragments plus a 50kb double-stranded DNA fragment.
If the average fragment size after DNA degradation is around 50kb then it can
be estimated that there are about 90 cuts per E.coli chromosome. The number
of DNA gyrase binding sites on the bacterial chromosome has been a matter of
contention, with one estimate of one gyrase binding site per domain giving 45
DNAbreaks in the chromosome after oxolinic acid treatment (Snyder and Drlica,
1979), another estimate of as many as 10,000 (Franco and Drlica, 1988),
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suggesting that gyrase probably can accessmost of the chromosome as required
for the enzyme to concentrate around replication forks (Drlica et al, 1980) and
downstream of active promoters (Kato et al, 1990). It is the replication-fork
associated DNA gyrase molecules (Drlica et al, 1980) and the transcription
complexes associated DNA gyrase molecules that are rapidly inhibited by the
addition of quinolone. E.coli growing in a rich medium divides once every 25
minutes; however the time required to duplicate is less than that needed for
chromosomal DNA replication which takes about 40 minutes. As a result,
multiple replication bubbles in the bacterial chromosome are present. In
estimating the numbers of potential cleavable complexes that could be formed
after quinolone challenge, the large number of transcriptional complexes on
the bacterial chromosome also has to be taken into account. Although DNA
degradation occurs at both replication forks, the selectivity shown means that
only one of the two strands of newly synthesised DNA is degraded (Veomert
and Kuempel, 1973). The preponderance of 50kb fragments may well reflect
the spacing of DNA replication forks and transcriptional machinery on the
bacterial chromosome.
5.12.8 Is this really bacterial "apoptosis"?
By referring to the DNA degradation observed with ofloxacin and ciprofloxacin
as "apoptosis", it must be clarified what exactly is meant by "apoptosis". As
mentioned previously, apoptosis is a name given to the cellular processes
associated with programmed cell death (PCD) that occur mainly during
development of eukaryotes (Vaux and Strasser, 1996). Similar patterns of high
molecular weight DNA fragmentation to those observed by this work have
been shown to occur in many cell types stimulated to undergo apoptosis
(Oberhammer et al, 1993). Although the concepts of DNA degradation carried
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out by endo-exonucleases in response to heavy DNA damage appear identical
in E.coli and eukaryotic organisms and the effect of such agents on bacterial
DNA has been likened to apoptosis (Fraser, 1994), an actual PCD mechanism
would not seem to be a well-evolved process in single-celled organisms.
However evidence of PCD-like responses on E.coli have been reported. Firstly,
some bacterial plasmids can program the death of plasmid-free segregants so
that no plasmid-free cells (which would overgrow the plasmid carriers) can
survive. An example of this is the previously described CcdB/ CcdA system of
E.coli (Bernard et al, 1993). Secondly some type IImethylases and their cognate
methylases are plasmid-encoded and work as toxin-antidote pairswith theDNA
methylase protecting the chromosomal DNA from endonucleolytic attack by
the restriction enzyme. These restriction enzymes cleave chromosomal DNA
directly whereas CcdB acts by converting gyrase into a DNA-damaging agent
through the formation of DSBs.
The difference between the PCD-like responses described above and the
RecBCD-mediatedDNA degradation response found to occur after ciprofloxacin
and ofloxacin challenge is that while both the CcdB/ CcdA and restriction
enzyme /methylase systems are plasmid-mediated and have evolved as a result
of the selfishness of the plasmid, RecBCD is chromosomally encoded and any
evolution of this enzyme to become selfish would be antagonistic to the
evolution of the whole organism. PCD responses have however been reported
to occur in E.coli, for example if the bacteria has a "feast or famine" way of life
in which self-sacrifice is common (Yarmolinsky, 1995). Yarmolinsky (1995)
proposed that for bacteria to profit from the death of their own kind, theymust
be heterogeneous. In a clonal population of bacteria, temporal and positional
variation seems to be quite normal. A variety of colonial forms exist as the
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result of changes in cell density, nutrient supply, substratum surface, plasmid
burden, incident variation, viral infection or the passage of time. In amoribund
subpopulation it seems that starvation induces E.coli to become hypermutable
(Rosenberg et al, 1994). These hypermutable individuals may go unnoticed as
they may not be colony-formers. Since bacteria grow as clones, it has been
suggested that a virally infected cell committing suicide for example is a pacifist
strategy as by doing this, the other cells would escape infection (Shub, 1994).
Therefore, although it is tempting to speculate that bacteria with DNA so badly
damaged might kill themselves in a bid to protect the rest of the population,
considering the intrinsic selfishness and competitiveness of bacteria, this
proposal is unlikely.
5.12.9 The Molecular Implications of Mechanism A
Mechanism A had previously been identified as the bactericidal pathway
common to all quinolone drugs which was somehow associated with RNA
and protein synthesis. Although there had been speculation of production of a
SOS-encoded toxic proteinwhich killed the cells (Smith, 1984; Dietz et al, 1966),
with the in vitro evidence that the quinolone-gyrase-DNA complex led to the
formation of a barrier to RNA polymerase resulting in truncated transcripts
(Willmott et al, 1994) it seemed more likely that it was the general act of RNA
and protein synthesis that was bactericidal. Rifampicin, which inhibits RNA
synthesis, and chloramphenicol, which inhibits protein synthesis, have both
found to completely block the bactericidal effect of nalidixic acid. The
importance of this information is the realisation of where exactly rifampicin
and chloramphenicol target their effect. Rifampicin acts on the P subunit of
bacterial RNA polymerase by preventing completion of the initiation phase
while chloramphenicol binds to the 50S subunit of the bacterial ribosome.
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However, inhibiting protein synthesis with streptomycin for example which
binds to sites on the 30S subunit of the bacterial ribosome causing an alteration
in codon: anticodon recognition, was not found to inhibit the bactericidal effect
(Lewin and Smith, 1989). Therefore itwas concluded that it was the interruption
of RNA synthesis and protein synthesis per se that was toxic to the cell. To
verify that the truncation of RNA transcripts also occurred in vivo as in vitro,
various concentrations of nalidixic acid and ciprofloxacin were added to a
logarithmic culture,RNA extracted after 10 minutes, blotted and hybridisation
of the blot carried out with a gyrA probe. It was hoped that with increasing
quinolone concentration, truncated mRNAswould bemore apparent as shown
by a smear on the Northern blot. However, after the addition of 90mg/l nalidixic
acid and above, it was hoped that no mRNAwould be detected, presumably
as a result of high quinolone concentrations inhibiting all the transcriptional
machinery. SinceDNA gyrase is present in front of the transcriptionalmachinery
as well as at the gyrase binding sites, inhibition of the RNA polymerase-
associated DNA gyrase at high quinolone concentrationswould cause a drastic
inhibition of RNA synthesis. However, constraints of time meant that this
technique could not be optimised and only a preliminary Northern blot is shown
(Figure 5.33). Use of the ECL kit to detect truncated mRNAswas an unfortunate
choice as the kit is not sensitive enough to detect single copy mRNAs. By the
time that this was realised and a 32P-labelling procedure attempted, this
experiment had to be put on hold.
The implications of this are severe for the cell as an abundance of prematurely
terminated mRNAs will be translated into incorrectly folded proteins (since
transcription and translation in bacteria are tightly coupled). The result would
be expected to be a complete deregulation of cellular functions. By inhibiting
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RNA synthesis and protein synthesis prior to quinolone challenge, it is apparent
how under these conditions, the quinolones only elicit a bacteriostatic effect.
Other important mRNAs that would also be expected to be prematurely
terminated are those encoding the messages for SOS-associated and repair
proteins. After quinolone challenge, the induction of the SOS response is a
major event, resulting in the production of proteins such as UmuC, SulA,UvrA,
UvrB, RecA and LexA (Gottesman, 1984). For example, the level ofSulA in the
cell increases significantly. Therefore in the presence of quinolone drug, itwould
be expected that some of the sulA mRNA transcripts would be truncated
especially if there is a gyrase binding site in the sulA gene. If this was the case,
this would explain the morphology of E.coli cells at different concentrations of
quinolone (Figure 5.35).
Figure 5.35:Morphology of E.coli cells at different concentrations of quinolones
At the MIC of the quinolone drug, extensive filamentation is seen with cells
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appearing many times their normal length (Diver and Wise, 1986). After this
point, the cells seem to be less filamented and at the OBC, amore mixed culture
of some filamented cells and some not so filamented cells is apparent.
Filamentation is brought about by the SulA proteinwhich inhibits the initiation
of cell division by FtsZ at the septum (Dai et al, 1994). The importance of SulA
being SOS-induced is that when cells undergo damage, they are inhibited by
SulA to divide until the damage has been repaired by the SOS response. At the
OBC of quinolone drug, if some of the sulA mRNAs were truncated, less active
SulA would be expected to be produced. Perhaps incorrectly folded SulA
interfereswith another protein other than FtsZ and thus causes deregulation of
the cell. It is also possible that not as much SulA is produced at the OBC than
at the MIC because RNA synthesis is blocked by the transcription-associated
gyrase being poisoned. However since cell death at the OBC is an active process
seeming to be dependent on at least some transcription and translation, the
first explanation is possibly more likely.
It is unknown whether mRNA truncation occurs at certain sites, for example
the gyrase binding sites (Willmott et al, 1994) or randomly throughout the
genome depending on the position of the replication fork. It is possible that
some proteins will tend to be truncated more than others depending where
they are on the chromosome. Changes in the protein profiles of quinolone-
challenged E.coli cells have previously been reported (Guan et al, 1992), however
it is unclear whether the appearance of a quinolone-induced protein band on a
SDS-PAGE gel relates to a SOS-induced protein or a constitutively expressed
protein which is truncated. Since the production of truncated proteins is
probably quite a random event, depending on the position of the cleavable
complex, it is possibly rather difficult to detect truncated proteins on a
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conventional SDS-PAGE gel. However, electrophoresis of proteins on a native
gel would probably more accurately show if the proteins were correctly folded
or not.
It is interesting that the proposed molecular basis of Mechanism A appears
similar to the molecular basis of the action of the aminoglycoside group of
antibiotics. Aminoglycosides such as gentamicin, streptomycin, amikacin,
kanamycin, tobramycin and neomycin elicit their antibacterial effect by binding
to sites on the 30S subunit of the bacterial ribosome, causing an alteration in
codon: anticodon recognition. This results in misreading of the mRNA and
hence in the production of defective bacterial proteins which is bactericidal.
Previous experiments carried out investigating the effect of streptomycin on
quinolone-mediated cell death (Lewin and Smith, 1989) led to the conclusions
that it was the action of streptomycin on the bacterial membrane that resulted
in the synergistic effect of these two antibiotics. However, the effect of
streptomycin on the bacterial membrane is actuallymediated by the formation
of membrane channels by misread proteins (Davis et al, 1986). Although it is
possible that the synergistic effect of quinolones and streptomycin results from
streptomycin damaging the membrane rather than the continuation of protein
synthesis in general, it is also tempting to speculate that the damage induced
by the quinolones (especially nalidixic acid) on the bacterial membrane
(Dougherty et al, 1985) is also as a result of misformed proteins.
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12.10 The Synergistic Effect of Mechanism A and Mechanism B
on the Bacterial Cell
Antibiotics which elicit both Mechanism A and Mechanism B on E.coli have
been observed to result in quicker killing of the cell. For example, the addition
of ofloxacin or ciprofloxacin (which work byboth MechanismA and Mechanism
B) at the OBC has been found to result in a 90% loss of viability in 19 minutes,
compared to 52 minuteswith the OBC of norfloxacin, 58 minuteswith the OBC
of oxolinic acid and 62 minutes with nalidixic acid (Smith, 1984; Smith, 1988).
The viability studies carried out during the course of the presently described
research suggested that E.coli TGI was killed even quicker with cells appearing
non-viable even after 5 minutes. Since nalidixic acid and oxolinic acid have
been shown to result in degradation to a small degree (Lewin and Smith, 1990),
it is proposed that all the quinolone antibacterials can elicit cell death by both
Mechanism A and Mechanism B, however, depending on their ability to cleave
and bind to DNA, one mechanism of death is probably overshadowed by the
other. Addition of nalidixic acid to the cell possibly results in truncatedmRNAs,
misfolded proteins and deregulation of the cell by pathways previously
discussed such as insertion of faulty proteins into the cell membrane. Although
nalidixic acid forms a cleavable complex with gyrase and DNA, its binding to
DNA can probably be repaired eventually if the cell does not die before by
faulty protein deregulation. On the other hand, ciprofloxacin which is much
more adept at DNA cleavage (see Table 5.1) possibly forms a much tighter
cleavable complex which cannot be repaired easily, thus enzymes such as
RecBCD are stimulated and result in wide scale DNA degradation. Although
the formation of truncated mRNAs has been shown to occur with quinolones
such as ciprofloxacin and ofloxacin (Willmott et al, 1994), this is probably just a
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minor mechanism of cell death as the cell will die before from the production
of DSBs as shown by the "apoptosis"-like response.
5.12.11 Another recently proposed model for quinolone-induced
cell death
The basis for quinolone-induced cell death in E.coli proposed in this thesis fits
in with previous observations and ideas as discussed. However another
explanation for quinolone-induced cell death has recently been proposed (Chen
et al, 1996). Although the results of the experiments performed by Chen et al
(1996) add weight to the ideas raised by this thesis, the role of topoisomerase
IV as a drug target is more strongly considered. In agreement with the results
presented in this thesis, Chen et al (1996) propose that the inhibition of DNA
synthesis is notby itself the cause of the bactericidal effect of oxolinic acid (which
was used as the standard quinolone drug). Also these authors concluded that
formation of the quinolone-gyrase-DNA complex as detected by SDS-dependent
DNA fragmentation is not alone sufficient to kill cells as even at high
concentrations, the nucleoids maintained most of their integrity. However at
higher quinolone concentrations, the nucleoid structure was found to change
to some degree. All of these observations are compatible with the proposals of
this thesis. The formation of cleavable complexes was detected even when
chloramphenicol had been added to the culture to inhibit protein synthesis
(Chen et al, 1996). The lethal effect of oxolinic acid was suggested to result from
the intracellular release ofDNA ends and not simply the formation of quinolone-
gyrase-DNA complexes. Chen et al (1996) found that treating the cells with
chloramphenicol blocked the release of the free ends associated with the addition
of oxolinic acid. These ideas are in keeping with the results of this thesis in that
lack of protein synthesis reduces cell death to some extent with quinolones
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such as oxolinic acid and nalidixic acid possibly by decreasing the number of
potential lethal collisions between a cleavable complex and moving replication
forks/ transcriptional machinery. Chen et al (1996) do not consider this option
and instead propose that a repair factor, independent of the SOS response is
responsible for dissociating the quinolone-gyrase-DNA complex and forming
a DSB. The speculated repair factor would however have to turn over very
rapidly as chloramphenicol inhibits nalidixic acid-induced lethality evenwhen
added 2 to 3 hours after the quinolone (Deitz et al, 1966). Such a factor has yet
to be identified. Chen et al (1996) acknowledge the existence of Mechanism B
and suggest that this chloramphenicol-insensitive cell death mechanism in E.coli
results from the dissociation of gyrase. It is perhaps more likely that instead of
the DNA gyrase enzyme dissociating, it is broken apart by the movement of
DNA replication machinery and/or transcriptional machinery as suggested in
this thesis. In agreement with these ideas, Chen et al (1996) postulate that
ciprofloxacin at low concentrations behaves much like oxolinic acid at high
concentrations since chloramphenicol can inhibit the bactericidal action of
ciprofloxacin at low concentrations. These authors concluded that the potency
or concentration of a quinolone appears to shift its mode of action from a
mechanism requiring protein synthesis (Mechanism A) to one that does not
(Mechanism B). Chen et al (1996) propose that chloramphenicol blocks the lethal
effects associated with topoisomerase IV-ciprofloxacin interactions and one or
more components of the SOS response eliminate the gap of time between
addition of ciprofloxacin and topoisomerase IV-mediated cell death.
A difference between the size of DNA fragments generated by ciprofloxacin
treatment and oxolinic acid treatment was observed (Chen et al, 1996) in
agreement with this thesis. However, Chen et al (1996) conclude that this is a
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result of ciprofloxacin trapping both gyrase and topoisomerase IV on the
chromosome. As discussed previously, topoisomerase IV is thought to occupy
different domains of the chromosome than does gyrase. Unlike gyrase, it is not
present in front of the replication fork or transcriptional machinery and instead
it has been localised to the bacterial membrane and the region of the chromosome
opposite the origin of replication. In light of these ideas, it is unlikely that
cleavable complexes are formed between topoisomerase IV, quinolone and
DNA and instead the reason for the existence of the smaller DNA fragments
detected after ciprofloxacin challenge possibly results from ciprofloxacin
forming a tighter and therefore more lethal cleavable complex. Topoisomerase
IV is believed to be a secondary target for quinolone drugs in E.coli, however
its inhibition is bacteriostatic rather than bactericidal (Khodursky et al, 1995).
5.12.12 Conclusions
In conclusion, this work has revealed that an "apoptosis"-like response seems
to correlatewithMechanism B after challenge of E.coli TGI with concentrations
of ciprofloxacin and ofloxacin at and above the OBC. This result is interesting
as it confirms that the mechanism of action of prokaryotic and eukaryotic
topoisomerase II-poisoning drugs is very similar. Addition of eukaryotic
topoisomerase II-poisoning drugs such as VP16 and VM26 to eukaryotic cells
results in the cell dying and the cell death is indicative of that typified by
apoptosis. In E.coli as well as eukaryotes, DSBs have been demonstrated to
correlate with cell death. The enzyme primarily responsible for this "apoptosis"-
like effect in E.coli is believed to be RecBCD, however other enzymes could
play a minor role. The "apoptosis"-like effectwas found not to occurwith three
differently acting antibiotics: ampicillin, trimethoprim and streptomycin,
suggesting that the "apoptosis"-like effect is related to the formation of the
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gyrase-DNA-quinolone cleavable complex and furthermore, the strength of
quinolone-binding to the complex. It was also shown that the quinolone
antibacterials result in premature transcription termination in vivo in agreement
with the in vitro results (Willmott et al, 1994) and it is proposed that this formation
of truncated mRNA in vivo corresponds to Mechanism A. Other minor
mechanisms possibly also contribute to quinolone-mediated cell death. Changes
in membrane permeability, induction of SOS mutagenesis and death by lethal




Various molecular interactions between DNA gyrase and the quinolone
antibacterials have been investigated and described in this thesis. Decreased
susceptibilities of clinical Salmonella strains have been shown to correlate to
point mutations in the quinolone resistance determining region such as serine-
83 to leucine, serine-83 to phenylalanine, aspartate-87 to tyrosine, aspartate-87
to asparagine and aspartate-87 to glycine when compared to thegyrA sequence
of a standard NCTC Salmonella control. The results suggest a general trend
towards quinolone resistance in clinical strains, particularly those isolated in
India.
Experiments showed that expression ofGyrAwas toxic at a high copy number,
possibly by disturbing the supercoiling status quo of the bacterial cell. By
correlating expression of gyrA mRNA to cell viability, high expression of gyrA
mRNAwas shown to result in reduced cell numbers. This observation explained
the failure of cloning gyrA into a high copy number vector such as pBluescript
but not a medium copy number vector such as pBR322.
The effect of various quinolone antibacterials on the bacterial cell was studied
at a molecular level. By examining the cellular DNA on pulsed field gels, all
the quinolone drugs tested produced double stranded breaks which did not
necessarily correlate to loss of viability. Potent fluroquinolones such as
ciprofloxacin and ofloxacin resulted in the production of severe double stranded
breaks which lead to further degradation of the DNA to fragments which were
as small as 4kb. The pattern of degradation on a pulsed field gel was likened to
that observed during eukaryotic apoptosis. The similarities and differences of
eukaryotic apoptosis and quinolone-induced bacterial cell death were discussed
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in depth including the involvement of DNA repair enzymes. However
physiologically eukaryotic apoptosis differs from quinolone-induced cell death
in that the former is a controlled processwith the aim of destroying the cell and
removing it from the populataion, for example during development. Quinolone-
induced cell death, on the other hand, is the result of an antibiotic acting on the
cell culminating in cell death through double stranded break formation. The
formation of severe double stranded breaks, as seen with ciprofloxacin and
ofloxacin, was correlated to Mecahnism B and is a result of the high affinity of
these antibiotics with DNA gyrase and DNA. The formation of truncated
mRNAs and therefore truncated misfolded proteins was correlated to
Mechansism A and almost definitely occurs with all quinolone drugs.
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